FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Takeuchi, F
   Ikeda, S
   Tsukamoto, Y
   Iwasawa, Y
   Chen, QH
   Otakaki, Y
   Ryota, O
   Yao, WL
   Narita, R
   Makoto, H
   Watashi, K
   Wakita, T
   Takeuchi, K
   Chayama, K
   Kogure, A
   Kato, H
   Fujita, T
AF Takeuchi, Fumihiko
   Ikeda, Sotaro
   Tsukamoto, Yuta
   Iwasawa, Yoshikazu
   Chen Qihao
   Otakaki, Yukie
   Ryota, Ouda
   Yao, Wan-Ling
   Narita, Ryo
   Makoto, Hijikata
   Watashi, Koichi
   Wakita, Takaji
   Takeuchi, Koh
   Chayama, Kazuaki
   Kogure, Amane
   Kato, Hiroki
   Fujita, Takashi
TI Screening for inhibitor of episomal DNA identified dicumarol as a
   hepatitis B virus inhibitor
SO PLOS ONE
LA English
DT Article
ID CLOSED CIRCULAR DNA; HBV; ANTIGEN; REPLICATION; EXPRESSION; PREVENTION;
   THERAPY; ANALOGS; CCCDNA; CELLS
AB Currently, there is no available therapy to eradicate hepatitis B virus (HBV) in chronically infected individuals. This is due to the difficulty in eliminating viral covalently closed circular (ccc) DNA, which is central to the gene expression and replication of HBV. We developed an assay system for nuclear circular DNA using an integration-deficient lentiviral vector. This vector produced non-integrated circular DNA in nuclei of infected cells. We engineered this vector to encode firefly luciferase to monitor the lentiviral episome DNA. We screened 3,840 chemicals by this assay for luciferase-reducing activity and identified dicumarol, which is known to have anticoagulation activity. We confirmed that dicumarol reduced lentiviral episome DNA. Furthermore, dicumarol inhibited HBV replication in cell culture using NTCP-expressing HepG2 and primary human hepatocytes. Dicumarol reduced intracellular HBV RNA, DNA, supernatant HBV antigens and DNA. We also found that dicumarol reduced the cccDNA level in HBV infected cells, but did not affect HBV adsorption/entry. This is a novel assay system for screening inhibitors targeting nuclear cccDNA and is useful for finding new antiviral substances for HBV.
C1 [Takeuchi, Fumihiko; Ikeda, Sotaro; Iwasawa, Yoshikazu; Chen Qihao; Otakaki, Yukie; Yao, Wan-Ling; Makoto, Hijikata; Kato, Hiroki; Fujita, Takashi] Kyoto Univ, Grad Sch Biostudies, Kyoto, Japan.
   [Takeuchi, Fumihiko; Ikeda, Sotaro; Tsukamoto, Yuta; Iwasawa, Yoshikazu; Chen Qihao; Otakaki, Yukie; Ryota, Ouda; Yao, Wan-Ling; Narita, Ryo; Makoto, Hijikata; Kogure, Amane; Kato, Hiroki; Fujita, Takashi] Kyoto Univ, Inst Frontier Life & Med Sci, Dept Virus Res, Kyoto, Japan.
   [Tsukamoto, Yuta; Kato, Hiroki] Univ Hosp Bonn, Inst Cardiovasc Immunol, Bonn, Germany.
   [Ryota, Ouda] Hokkaido Univ, Fac Med, Dept Immunol, Sapporo, Hokkaido, Japan.
   [Ryota, Ouda] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.
   [Narita, Ryo] Aarhus Univ, Dept Mol Biol & Genet, Ctr Struct Biol, Aarhus, Denmark.
   [Watashi, Koichi; Wakita, Takaji] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan.
   [Watashi, Koichi] Tokyo Univ Sci, Dept Appl Biol Sci, Noda, Chiba, Japan.
   [Watashi, Koichi] Japan Sci & Technol Agcy JST, CREST, Saitama, Japan.
   [Takeuchi, Koh] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery, Tokyo, Japan.
   [Chayama, Kazuaki] Hiroshima Univ, Liver Res Project Ctr, Hiroshima, Japan.
RP Fujita, T (reprint author), Kyoto Univ, Grad Sch Biostudies, Kyoto, Japan.; Fujita, T (reprint author), Kyoto Univ, Inst Frontier Life & Med Sci, Dept Virus Res, Kyoto, Japan.
EM tfujita@infront.kyoto-u.ac.jp
RI Ouda, Ryota/P-9681-2019
OI TSUKAMOTO, Yuta/0000-0002-0773-7190
FU Ministry of Health, Labour and Welfare/Japan Agency for Medical Research
   and Development (AMED) for Program on the Innovative Development and the
   Application of New Drugs for Hepatitis B [JP18fk0310107h0002,
   JP18fk0310109h0002]
FX The work was supported by The Ministry of Health, Labour and
   Welfare/Japan Agency for Medical Research and Development (AMED) for
   Program on the Innovative Development and the Application of New Drugs
   for Hepatitis B, Grant number: JP18fk0310107h0002 to TF and
   JP18fk0310109h0002 to KC and HK (URL: https://www.amed.go.jp/).The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Baran B, 2015, WORLD J HEPATOL, V7, P1742, DOI 10.4254/wjh.v7.i13.1742
   BEASLEY RP, 1983, LANCET, V2, P1099
   BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X
   BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601
   Cai DW, 2012, ANTIMICROB AGENTS CH, V56, P4277, DOI 10.1128/AAC.00473-12
   DANE DS, 1970, LANCET, V1, P695
   Durantel D, 2016, J HEPATOL, V64, pS117, DOI 10.1016/j.jhep.2016.02.016
   Faure-Dupuy S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050095
   Guo H, 2017, METHODS MOL BIOL, V1540, P1, DOI 10.1007/978-1-4939-6700-1
   HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5
   Honda M, 2016, J INFECT DIS, V213, P1096, DOI 10.1093/infdis/jiv572
   Ishida Y, 2015, AM J PATHOL, V185, P1275, DOI 10.1016/j.ajpath.2015.01.028
   Kramvis A, 2008, J MED VIROL, V80, P27, DOI 10.1002/jmv.21049
   Kumar R, 2016, LIVER INT, V36, P72, DOI 10.1111/liv.13001
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   Levrero M, 2016, CURR OPIN VIROL, V18, P135, DOI 10.1016/j.coviro.2016.06.003
   Lucifora J, 2016, J HEPATOL, V64, pS41, DOI 10.1016/j.jhep.2016.02.009
   Lucifora J, 2014, SCIENCE, V343, P1221, DOI 10.1126/science.1243462
   Madari H, 2003, CANCER RES, V63, P1214
   Norder H, 2004, INTERVIROLOGY, V47, P289, DOI 10.1159/000080872
   Ogura N, 2014, BIOCHEM BIOPH RES CO, V452, P315, DOI 10.1016/j.bbrc.2014.08.029
   Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000
   Tie JK, 2011, BLOOD, V117, P2967, DOI 10.1182/blood-2010-08-304303
   Tsukamoto Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197664
   Urban S, 2014, GASTROENTEROLOGY, V147, P48, DOI 10.1053/j.gastro.2014.04.030
   Watashi K, 2014, INT J MOL SCI, V15, P2892, DOI 10.3390/ijms15022892
   WHO, 2015, HEP B
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yao WL, 2017, INT IMMUNOL, V29, P109, DOI 10.1093/intimm/dxx012
   Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4
   Zhang EJ, 2015, ANTIVIR RES, V123, P193, DOI 10.1016/j.antiviral.2015.10.009
   Zhou TL, 2006, ANTIVIR RES, V72, P116, DOI 10.1016/j.antiviral.2006.05.006
   Zoulim F, 2004, ANTIVIR RES, V64, P1, DOI 10.1016/j.antiviral.2004.07.003
NR 34
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 19
PY 2019
VL 14
IS 2
AR e0212233
DI 10.1371/journal.pone.0212233
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HL9KY
UT WOS:000459062900036
PM 30779774
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Muller, SF
   Konig, A
   Doring, B
   Glebe, D
   Geyer, J
AF Mueller, Simon F.
   Koenig, Alexander
   Doering, Barbara
   Glebe, Dieter
   Geyer, Joachim
TI Characterisation of the hepatitis B virus cross-species transmission
   pattern via Na+/taurocholate co-transporting polypeptides from 11 New
   World and Old World primate species
SO PLOS ONE
LA English
DT Article
ID TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; TUPAIA HEPATOCYTES; WOOLLY
   MONKEY; ENTRY; INFECTION; ACID; NTCP; RECEPTOR
AB The hepatic Na+/taurocholate co-transporting polypeptide (NTCP in man, Ntcp in animals) is the high-affinity receptor for the hepatitis B (HBV) and hepatitis D (HDV) viruses. Species barriers for human HBV/HDV within the order Primates were previously attributed to Ntcp sequence variations that disable virus-receptor interaction. However, only a limited number of primate Ntcps have been analysed so far. In the present study, a total of 11 Ntcps from apes, Old and New World monkeys were cloned and expressed in vitro to characterise their interaction with HBV and HDV. All Ntcps showed intact bile salt transport. Human NTCP as well as the Ntcps from the great apes chimpanzee and orangutan showed transport-competing binding of HBV derived myr-preS1-peptides. In contrast, all six Ntcps from the group of Old World monkeys were insensitive to HBV myr-preS1-peptide binding and HBV/HDV infection. This is basically predetermined by the amino acid arginine at position 158 of all studied Old World monkey Ntcps. An exchange from arginine to glycine (as present in humans and great apes) at this position (R158G) alone was sufficient to achieve full transport-competing HBV myr-preS1-peptide binding and susceptibility for HBV/HDV infection. New World monkey Ntcps showed higher sequence heterogeneity, but in two cases with 158G showed transport-competing HBV myr-preS1-peptide binding, and in one case (Saimiri sciureus) even susceptibility for HBV/HDV infection. In conclusion, amino acid position 158 of NTCP/Ntcp is sufficient to discriminate between the HBV/HDV susceptible group of humans and great apes (158G) and the non-susceptible group of Old World monkeys (158R). In the case of the phylogenetically more distant New World monkey Ntcps amino acid 158 plays a significant, but not exclusive role.
C1 [Mueller, Simon F.; Doering, Barbara; Geyer, Joachim] Justus Liebig Univ Giessen, Inst Pharmacol & Toxicol, Biomed Res Ctr Seltersberg, Giessen, Germany.
   [Koenig, Alexander; Glebe, Dieter] Justus Liebig Univ Giessen, Inst Med Virol, Biomed Res Ctr Seltersberg, Giessen, Germany.
RP Geyer, J (reprint author), Justus Liebig Univ Giessen, Inst Pharmacol & Toxicol, Biomed Res Ctr Seltersberg, Giessen, Germany.
EM Joachim.M.Geyer@vetmed.uni-giessen.de
OI Geyer, Joachim/0000-0003-2663-1858
FU Deutsche Forschungsgemeinschaft DFG [Sonderforschungsbereich SFB1021/2]
FX The study was supported in part by funding from the Deutsche
   Forschungsgemeinschaft DFG (http://www.dfg.de), Sonderforschungsbereich
   SFB1021/2 "RNA viruses: RNA metabolism, host response and pathogenesis",
   project B08 to JG and DG. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.; The authors thank Anita Neubauer, Klaus Schuh, Regina
   Leidolf, and Sigrun Broehl for technical help. The study was supported
   in part by funding from the Deutsche Forschungsgemeinschaft (DFG),
   Sonderforschungsbereich SFB1021/2 "RNA viruses: RNA metabolism, host
   response and pathogenesis", project B08 to JG and DG.
CR Barrera A, 2004, J VIROL, V78, P5233, DOI 10.1128/JVI.78.10.5233-5243.2004
   Blank A, 2016, J HEPATOL, V65, P483, DOI 10.1016/j.jhep.2016.04.013
   Bonvicino CR, 2014, WORLD J GASTROENTERO, V20, P7665, DOI 10.3748/wjg.v20.i24.7665
   Burwitz BJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01953-y
   Doring B, 2012, CURR TOP MEMBR, V70, P105, DOI 10.1016/B978-0-12-394316-3.00004-1
   Dupinay T, 2013, HEPATOLOGY, V58, P1610, DOI 10.1002/hep.26428
   Fu LR, 2017, VIROLOGY, V505, P1, DOI 10.1016/j.virol.2017.02.006
   Geyer J, 2006, N-S ARCH PHARMACOL, V372, P413, DOI 10.1007/s00210-006-0043-8
   Geyer J, 2007, J BIOL CHEM, V282, P19728, DOI 10.1074/jbc.M702663200
   Glebe D, 2005, GASTROENTEROLOGY, V129, P234, DOI 10.1053/j.gastro.2005.03.090
   Glebe D, 2013, SEMIN LIVER DIS, V33, P103, DOI 10.1055/s-0033-1345717
   Konig A, 2014, J HEPATOL, V61, P867, DOI 10.1016/j.jhep.2014.05.018
   Lanford RE, 1998, P NATL ACAD SCI USA, V95, P5757, DOI 10.1073/pnas.95.10.5757
   Lempp FA, 2017, HEPATOLOGY, V66, P703, DOI 10.1002/hep.29112
   Li WH, 2016, J HEPATOL, V64, pS32, DOI 10.1016/j.jhep.2016.02.011
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Nkongolo S, 2014, J HEPATOL, V60, P723, DOI 10.1016/j.jhep.2013.11.022
   Petzinger E, 1999, HEPATOLOGY, V30, P1257, DOI 10.1002/hep.510300529
   Shimura S, 2017, J HEPATOL, V66, P685, DOI [10.1016/j.jhep.2016.11.009a, 10.1016/j.jhep.2016.11.009]
   Souza BFDD, 2018, J HEPATOL, V68, P1114, DOI 10.1016/j.jhep.2018.01.029
   Sureau C, 2016, J HEPATOL, V64, pS102, DOI 10.1016/j.jhep.2016.02.013
   World Health Organization, 2017, GLOB HEP REP 2017
   Yan H, 2013, J VIROL, V87, P7977, DOI 10.1128/JVI.03540-12
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zhong GC, 2013, J VIROL, V87, P7176, DOI 10.1128/JVI.03533-12
   Zhou XM, 2014, NATURE, V505, P569, DOI 10.1038/nature12811
NR 26
TC 4
Z9 4
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 18
PY 2018
VL 13
IS 6
AR e0199200
DI 10.1371/journal.pone.0199200
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GJ6XV
UT WOS:000435528600087
PM 29912972
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Kitamura, K
   Que, LS
   Shimadu, M
   Koura, M
   Ishihara, Y
   Wakae, K
   Nakamura, T
   Watashi, K
   Wakita, T
   Muramatsu, M
AF Kitamura, Kouichi
   Que, Lusheng
   Shimadu, Miyuki
   Koura, Miki
   Ishihara, Yuuki
   Wakae, Kousho
   Nakamura, Takashi
   Watashi, Koichi
   Wakita, Takaji
   Muramatsu, Masamichi
TI Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B
   virus
SO PLOS PATHOGENS
LA English
DT Article
ID CLOSED CIRCULAR DNA; SUBSTRATE-BINDING; EXCISION-REPAIR; INFECTION;
   CELLS; IDENTIFICATION; INHIBITORS; REPLICATION; EXPRESSION; STABILITY
AB Hepatitis B virus (HBV) is one of the major etiological pathogens for liver cirrhosis and hepatocellular carcinoma. Chronic HBV infection is a key factor in these severe liver diseases. During infection, HBV forms a nuclear viral episome in the form of covalently closed circular DNA (cccDNA). Current therapies are not able to efficiently eliminate cccDNA from infected hepatocytes. cccDNA is a master template for viral replication that is formed by the conversion of its precursor, relaxed circular DNA (rcDNA). However, the host factors critical for cccDNA formation remain to be determined. Here, we assessed whether one potential host factor, flap structure-specific endonuclease 1 (FEN1), is involved in cleavage of the flap-like structure in rcDNA. In a cell culture HBV model (Hep38.7-Tet), expression and activity of FEN1 were reduced by siRNA, shRNA, CRISPR/Cas9-mediated genome editing, and a FEN1 inhibitor. These reductions in FEN1 expression and activity did not affect nucleocapsid DNA (NC-DNA) production, but did reduce cccDNA levels in Hep38.7-Tet cells. Exogenous overexpression of wild-type FEN1 rescued the reduced cccDNA production in FEN1-depleted Hep38.7-Tet cells. Anti-FEN1 immunoprecipitation revealed the binding of FEN1 to HBV DNA. An in vitro FEN activity assay demonstrated cleavage of 50-flap from a synthesized HBV DNA substrate. Furthermore, cccDNA was generated in vitro when purified rcDNA was incubated with recombinant FEN1, DNA polymerase, and DNA ligase. Importantly, FEN1 was required for the in vitro cccDNA formation assay. These results demonstrate that FEN1 is involved in HBV cccDNA formation in cell culture system, and that FEN1, DNA polymerase, and ligase activities are sufficient to convert rcDNA into cccDNA in vitro.
C1 [Kitamura, Kouichi; Que, Lusheng; Shimadu, Miyuki; Koura, Miki; Ishihara, Yuuki; Wakae, Kousho; Muramatsu, Masamichi] Kanazawa Univ, Grad Sch Med Sci, Dept Mol Genet, Kanazawa, Ishikawa, Japan.
   [Nakamura, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Radiol & Canc Biol, Nagasaki, Japan.
   [Watashi, Koichi; Wakita, Takaji; Muramatsu, Masamichi] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan.
RP Muramatsu, M (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Mol Genet, Kanazawa, Ishikawa, Japan.; Muramatsu, M (reprint author), Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan.
EM muramatsu@nih.go.jp
RI Kitamura, Kouichi/L-3654-2015
OI Kitamura, Kouichi/0000-0001-9692-8724; Que, Lusheng/0000-0001-8509-9473
FU Funding Program for Next Generation World-Leading Researchers [LS051];
   Japan Society for the Promotion of Science [26293103, 26460993];
   Ministry of Health, Labour and Welfare of Japan [H26-kanen
   jitsuyouka-wakate008]; Japan Agency for Medical Research and
   Development, AMED [JP18fk0310119h0002]; Takeda Science Foundation;
   Association for Research on Lactic Acid Bacteria; GSK Japan Research
   Grant
FX This study was supported by the Funding Program for Next Generation
   World-Leading Researchers (LS051 to MM)
   http://www.jsps.go.jp/english/e-jisedai/index.html; a Grant-in-Aid for
   Scientific Research B (26293103 to MM) and C (26460993 to KK) from the
   Japan Society for the Promotion of Science
   http://www.jsps.go.jp/english/e-grants/index.html; the Ministry of
   Health, Labour and Welfare of Japan (H26-kanen jitsuyouka-wakate008 to
   KK) http://www.mhlw.go.jp/english/; Program on the Innovative
   Development and the Application of New Drugs for Hepatitis B from Japan
   Agency for Medical Research and Development, AMED (JP18fk0310119h0002 to
   KK) http://www.amed.go.jp/en/;the Takeda Science Foundation (to MM and
   KK) http://www.takeda-sci.or.jp/index.html; and the Association for
   Research on Lactic Acid Bacteria (to MM)
   https://institute.yakult.co.jp/en/; the GSK Japan Research Grant 2016
   (to KK) https://jp.gsk.com/jp/. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahasan MM, 2015, BIOCHEM BIOPH RES CO, V457, P295, DOI 10.1016/j.bbrc.2014.12.103
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cui XJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128401
   Dorjsuren D, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1082
   Gao WF, 2007, J VIROL, V81, P6164, DOI 10.1128/JVI.02721-06
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   Guo JT, 2015, ANTIVIR RES, V122, P91, DOI 10.1016/j.antiviral.2015.08.005
   HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344
   Henneke G, 2003, TRENDS BIOCHEM SCI, V28, P384, DOI 10.1016/S0968-0004(03)00138-5
   Ishida Y, 2015, AM J PATHOL, V185, P1275, DOI 10.1016/j.ajpath.2015.01.028
   Iwamoto M, 2014, BIOCHEM BIOPH RES CO, V443, P808, DOI 10.1016/j.bbrc.2013.12.052
   Kitamura K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003361
   Kock J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001082
   Koniger C, 2014, P NATL ACAD SCI USA, V111, pE4244, DOI 10.1073/pnas.1409986111
   Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Levrero M, 2009, J HEPATOL, V51, P581, DOI 10.1016/j.jhep.2009.05.022
   Liang GX, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004780
   Liu Y, 2012, TRENDS BIOCHEM SCI, V37, P162, DOI 10.1016/j.tibs.2011.12.002
   Long QX, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006784
   Margeridon S, 2008, ANTIMICROB AGENTS CH, V52, P3068, DOI 10.1128/AAC.01318-07
   Mason AL, 1998, HEPATOLOGY, V27, P1736, DOI 10.1002/hep.510270638
   Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809
   Ogura N, 2014, BIOCHEM BIOPH RES CO, V452, P315, DOI 10.1016/j.bbrc.2014.08.029
   Saharia A, 2008, CURR BIOL, V18, P496, DOI 10.1016/j.cub.2008.02.071
   Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031
   Sharma S, 2005, NUCLEIC ACIDS RES, V33, P6769, DOI 10.1093/nar/gki1002
   Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173
   Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200
   Sohn JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008093
   Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200
   Sun XM, 2003, DNA REPAIR, V2, P925, DOI 10.1016/S1568-7864(03)00093-4
   Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487
   Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8
   Tumey LN, 2005, BIOORG MED CHEM LETT, V15, P277, DOI 10.1016/j.bmcl.2004.10.086
   Wanrooij PH, 2015, DNA REPAIR, V32, P17, DOI 10.1016/j.dnarep.2015.04.009
   Watashi Koichi, 2013, J Biol Chem, V288, P31715, DOI 10.1074/jbc.M113.501122
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599
   Zheng L, 2007, MOL CELL BIOL, V27, P3176, DOI 10.1128/MCB.01652-06
   Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884
   Zhou TL, 2006, ANTIVIR RES, V72, P116, DOI 10.1016/j.antiviral.2006.05.006
NR 42
TC 11
Z9 11
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUN
PY 2018
VL 14
IS 6
AR e1007124
DI 10.1371/journal.ppat.1007124
PG 20
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA GL7UG
UT WOS:000437410000026
PM 29928064
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Guo, F
   Zhao, Q
   Sheraz, M
   Cheng, JJ
   Qi, YH
   Su, Q
   Cuconati, A
   Wei, L
   Du, YM
   Li, WH
   Chang, JH
   Guo, JT
AF Guo, Fang
   Zhao, Qiong
   Sheraz, Muhammad
   Cheng, Junjun
   Qi, Yonghe
   Su, Qing
   Cuconati, Andrea
   Wei, Lai
   Du, Yanming
   Li, Wenhui
   Chang, Jinhong
   Guo, Ju-Tao
TI HBV core protein allosteric modulators differentially alter cccDNA
   biosynthesis from de novo infection and intracellular amplification
   pathways
SO PLOS PATHOGENS
LA English
DT Article
ID HEPATITIS-B-VIRUS; CLOSED CIRCULAR DNA; INNATE IMMUNE-RESPONSE;
   HETEROARYLDIHYDROPYRIMIDINE HAP; PRECLINICAL CHARACTERIZATION;
   VIRAL-DNA; REPLICATION; INTERFERON; INHIBITOR; SUPERINFECTION
AB Hepatitis B virus (HBV) core protein assembles viral pre-genomic (pg) RNA and DNA polymerase into nucleocapsids for reverse transcriptional DNA replication to take place. Several chemotypes of small molecules, including heteroaryldihydropyrimidines (HAPs) and sulfamoylbenzamides (SBAs), have been discovered to allosterically modulate core protein structure and consequentially alter the kinetics and pathway of core protein assembly, resulting in formation of irregularly-shaped core protein aggregates or "empty" capsids devoid of pre-genomic RNA and viral DNA polymerase. Interestingly, in addition to inhibiting nucleocapsid assembly and subsequent viral genome replication, we have now demonstrated that HAPs and SBAs differentially modulate the biosynthesis of covalently closed circular (ccc) DNA from de novo infection and intracellular amplification pathways by inducing disassembly of nucleocapsids derived from virions as well as double-stranded DNA-containing progeny nucleocapsids in the cytoplasm. Specifically, the mistimed cuing of nucleocapsid uncoating prevents cccDNA formation during de novo infection of hepatocytes, while transiently accelerating cccDNA synthesis from cytoplasmic progeny nucleocapsids. Our studies indicate that elongation of positive-stranded DNA induces structural changes of nucleocapsids, which confers ability of mature nucleocapsids to bind CpAMs and triggers its disassembly. Understanding the molecular mechanism underlying the dual effects of the core protein allosteric modulators on nucleocapsid assembly and disassembly will facilitate the discovery of novel core protein-targeting antiviral agents that can more efficiently suppress cccDNA synthesis and cure chronic hepatitis B.
C1 [Guo, Fang; Zhao, Qiong; Cheng, Junjun; Su, Qing; Du, Yanming; Chang, Jinhong; Guo, Ju-Tao] Baruch S Blumberg Inst, Doylestown, PA USA.
   [Sheraz, Muhammad] Drexel Univ, Coll Med, Microbiol & Immunol Grad Program, Philadelphia, PA 19104 USA.
   [Qi, Yonghe; Li, Wenhui] Natl Inst Biol Sci, Beijing, Peoples R China.
   [Cuconati, Andrea] Arbutus Biopharma Inc, Doylestown, PA USA.
   [Wei, Lai] Peking Univ, Peoples Hosp, Inst Hepatol, Beijing, Peoples R China.
RP Chang, JH; Guo, JT (reprint author), Baruch S Blumberg Inst, Doylestown, PA USA.
EM jinhong.chang@bblumberg.org; ju-tao.gua@bblumberg.org
FU National Institutes of Health, USA [AI113267]; Arbutus Biopharma Inc.
FX This work was supported by grants from the National Institutes of
   Health, USA (AI113267) to JTG and Arbutus Biopharma Inc. to JTG and JiC.
   The funder and sponsor had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Belloni L, 2012, J CLIN INVEST, V122, P529, DOI 10.1172/JCI58847
   Berke JM, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00560-17, 10.1128/aac.00560-17]
   Bock CT, 2001, J MOL BIOL, V307, P183, DOI 10.1006/jmbi.2001.4481
   Bourne C, 2008, J VIROL, V82, P10262, DOI 10.1128/JVI.01360-08
   Byrd CM, 2013, ANTIMICROB AGENTS CH, V57, P15, DOI 10.1128/AAC.01429-12
   Campagna MR, 2013, J VIROL, V87, P6931, DOI 10.1128/JVI.00582-13
   Ceres P, 2002, BIOCHEMISTRY-US, V41, P11525, DOI 10.1021/bi0261645
   Chang JH, 2014, ACTA PHARM SIN B, V4, P248, DOI 10.1016/j.apsb.2014.05.002
   Chang JH, 2012, ANTIVIR RES, V96, P405, DOI 10.1016/j.antiviral.2012.10.001
   Cheng X, 2017, HEPATOLOGY
   Cui XJ, 2016, J VIROL, V90, P486, DOI 10.1128/JVI.01263-15
   Cui XJ, 2015, J VIROL, V89, P9021, DOI 10.1128/JVI.01261-15
   Cui XJ, 2015, J VIROL, V89, P10064, DOI 10.1128/JVI.01481-15
   Cui X, 2013, J VIROL, V87, P11494, DOI 10.1128/JVI.01912-13
   Dansako H, 2016, FEBS J, V283, P144, DOI 10.1111/febs.13563
   Dhason MS, 2012, VIROLOGY, V430, P20, DOI 10.1016/j.virol.2012.04.012
   Ganser-Pornillos BK, 2008, CURR OPIN STRUC BIOL, V18, P203, DOI 10.1016/j.sbi.2008.02.001
   Gao WF, 2007, J VIROL, V81, P6164, DOI 10.1128/JVI.02721-06
   Gudima S, 2007, J VIROL, V81, P3608, DOI 10.1128/JVI.02277-06
   Guo F, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00771-17
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   Guo HT, 2010, J VIROL, V84, P387, DOI 10.1128/JVI.01921-09
   Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001
   Guo JT, 2003, J VIROL, V77, P1885, DOI 10.1128/JVI.77.3.1885-1893.2003
   Guo JT, 2015, ANTIVIR RES, V122, P91, DOI 10.1016/j.antiviral.2015.08.005
   Hasan M, 2013, NAT IMMUNOL, V14, P61, DOI 10.1038/ni.2475
   He J, 2016, J GEN VIROL, V97, P3368, DOI 10.1099/jgv.0.000647
   Hu JM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9030056
   Katen SP, 2013, STRUCTURE, V21, P1406, DOI 10.1016/j.str.2013.06.013
   Klumpp K, 2015, P NATL ACAD SCI USA, V112, P15196, DOI 10.1073/pnas.1513803112
   Klumpp K, 2014, CURR OPIN VIROL, V5, P63, DOI 10.1016/j.coviro.2014.02.002
   Kock J, 1998, J VIROL, V72, P9116
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Liang TJ, 2015, HEPATOLOGY, V62, P1893, DOI 10.1002/hep.28025
   Liu F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003613
   Liu SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169701
   Lucifora J, 2014, SCIENCE, V343, P1221, DOI 10.1126/science.1243462
   Mason WS, 2009, J VIROL, V83, P1778, DOI 10.1128/JVI.01587-08
   Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Ning XJ, 2017, J VIROL, V91, DOI 10.1128/JVI.00092-17
   Ning XJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002255
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Petersen J, 2008, NAT BIOTECHNOL, V26, P335, DOI 10.1038/nbt1389
   Qi YH, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005893
   Qiu ZX, 2017, J MED CHEM, V60, P3352, DOI 10.1021/acs.jmedchem.7b00083
   Rabe B, 2003, P NATL ACAD SCI USA, V100, P9849, DOI 10.1073/pnas.1730940100
   Rodrigues L, 2015, J VIROL, V89, P384, DOI 10.1128/JVI.02361-14
   Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031
   Selzer L, 2015, J BIOL CHEM, V290, P28584, DOI 10.1074/jbc.M115.678441
   Stray SJ, 2005, P NATL ACAD SCI USA, V102, P8138, DOI 10.1073/pnas.0409732102
   SUMMERS J, 1990, J VIROL, V64, P2819
   SUSSMAN NL, 1992, HEPATOLOGY, V16, P60, DOI 10.1002/hep.1840160112
   Tang LD, 2017, EXPERT OPIN DRUG DIS, V12, P5, DOI 10.1080/17460441.2017.1255195
   Thomsen MK, 2016, HEPATOLOGY, V64, P746, DOI 10.1002/hep.28685
   TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1
   Venkatakrishnan B, 2016, J VIROL, V90, P3994, DOI 10.1128/JVI.03058-15
   Walters KA, 2004, J VIROL, V78, P7925, DOI 10.1128/JVI.78.15.7925-7937.2004
   Wu GY, 2013, ANTIMICROB AGENTS CH, V57, P5344, DOI 10.1128/AAC.01091-13
   Wu S, 2017, J VIROL, V91, DOI 10.1128/JVI.00519-17
   WU TT, 1990, VIROLOGY, V175, P255, DOI 10.1016/0042-6822(90)90206-7
   Xia YC, 2016, GASTROENTEROLOGY, V150, P194, DOI 10.1053/j.gastro.2015.09.026
   Xu CX, 2010, J VIROL, V84, P9332, DOI 10.1128/JVI.00918-10
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zhao XS, 2014, P NATL ACAD SCI USA, V111, P6756, DOI 10.1073/pnas.1320856111
   Zhou TL, 2006, ANTIVIR RES, V72, P116, DOI 10.1016/j.antiviral.2006.05.006
   Zhou Z, 2017, SCI REP-UK, V7, DOI 10.1038/srep42374
   Zlotnick A, 2015, ANTIVIR RES, V121, P82, DOI 10.1016/j.antiviral.2015.06.020
NR 68
TC 19
Z9 19
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2017
VL 13
IS 9
AR e1006658
DI 10.1371/journal.ppat.1006658
PG 24
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA FI4TG
UT WOS:000411968300055
PM 28945802
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Cheng, ST
   Tang, H
   Ren, JH
   Chen, X
   Huang, AL
   Chen, J
AF Cheng, Sheng-Tao
   Tang, Hua
   Ren, Ji-Hua
   Chen, Xiang
   Huang, Ai-Long
   Chen, Juan
TI Interleukin-34 inhibits hepatitis B virus replication in vitro and in
   vivo
SO PLOS ONE
LA English
DT Article
ID X PROTEIN; IL-34; INFECTION; TRANSCRIPTION; MACROPHAGES; CSF-1; CELLS
AB Background
   The hepatitis B virus (HBV) infection could activate the immune system and induce extensive inflammatory response. As the most important inflammatory factor, interleukins are critical for anti-viral immunity. Here we investigated whether interleukin-34 (IL-34) play a role in HBV infection.
   Methodology/Principal findings
   In this study, we first found that both serum IL-34 and IL-34 mRNA in PBMCs in chronic HBV patients was significantly decreased compared to the healthy controls. Furthermore, both IL-34 protein and mRNA levels were declined hepatoma cells expressing HBV. In addition, the clinical parameters analysis found that serum IL-34 was significantly associated with HBV DNA (P = 0.0066), ALT (P = 0.0327), AST (P = 0.0435), TB (P = 0.0406), DB (P = 0.0368) and AFP (P = 0.0225). Correlation analysis also found that serum IL-34 negatively correlated with HBV DNA copies, ALT and AST. In vitro studies found that IL-34 treatment in HepAD38 and HepG2.2.15 cells markedly inhibited HBV DNA, total RNA, 3.5kb mRNA and HBc protein. In vivo studies further demonstrated IL-34 treatment in HBV transgenic mice exhibited greater inhibition on HBV DNA, total RNA, 3.5kb mRNA and HBc protein, suggesting the effect to IL-34 on HBV is likely due to host innate or adaptive immune response.
   Conclusions/Significance
   Our study identified a novel interleukin, IL-34, which has anti-viral activity in HBV replication in hepatocytes in vitro and in vivo. These data suggest a rationale for the use of IL-34 in the HBV treatment.
C1 [Cheng, Sheng-Tao; Tang, Hua; Ren, Ji-Hua; Huang, Ai-Long; Chen, Juan] Chongqing Med Univ, Inst Viral Hepatitis, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis,Minist Educ,Dept Infe, Chongqing, Peoples R China.
   [Chen, Xiang] Zhuzhou Cent Hosp, Dept Clin Lab, Zhuzhou, Peoples R China.
   [Huang, Ai-Long] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
RP Huang, AL; Chen, J (reprint author), Chongqing Med Univ, Inst Viral Hepatitis, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis,Minist Educ,Dept Infe, Chongqing, Peoples R China.; Huang, AL (reprint author), Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
EM ahuang1964@163.com; yixin_xinyuan@163.com
FU National Natural Science Foundation of China [81672012]; Chongqing
   Natural Science Foundation [cstc2016jcyjA0183]
FX This study was supported by the National Natural Science Foundation of
   China (81672012, JC) and Chongqing Natural Science Foundation
   (cstc2016jcyjA0183, JC). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adoro S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8562
   Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033
   Bao S, 2016, CLIN RES HEPATOLOGY
   Belloni L, 2009, P NATL ACAD SCI USA, V106, P19975, DOI 10.1073/pnas.0908365106
   Braum O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070281
   Busca A, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-22
   Chen L, 2016, ANN RHEUMATIC DIS
   Chen RD, 2017, SCI REP-UK, V7, DOI 10.1038/srep40783
   Chen Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018689
   Dandri M, 2016, CLIN INFECT DIS, V62, pS281, DOI 10.1093/cid/ciw023
   Darrieutort-Laffite C., 2014, MEDIAT INFLAMM, V2014
   Edwards Jessica K, 2015, Nat Rev Nephrol, V11, P504, DOI 10.1038/nrneph.2015.116
   Fan Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep39324
   Garceau V, 2010, J LEUKOCYTE BIOL, V87, P753, DOI 10.1189/jlb.0909624
   Gerngross L, 2015, J NEUROVIROL, V21, P249, DOI 10.1007/s13365-014-0270-6
   Ivanov S, 2013, J VIROL, V87, P6911, DOI 10.1128/JVI.02943-12
   Lin CL, 2016, LIVER INT, V36, P85, DOI 10.1111/liv.13003
   Locarnini S, 2004, SEMIN LIVER DIS, V24, P3, DOI 10.1055/s-2004-828672
   Lucifora J, 2011, J HEPATOL, V55, P996, DOI 10.1016/j.jhep.2011.02.015
   Neuveut C, 2010, J HEPATOL, V52, P594, DOI 10.1016/j.jhep.2009.10.033
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Peng YZ, 2016, DIAGN MICR INFEC DIS, V85, P154, DOI 10.1016/j.diagmicrobio.2015.09.017
   Pham Edward A, 2016, Curr Hepatol Rep, V15, P237, DOI 10.1007/s11901-016-0315-9
   Pollicino T, 2015, WORLD J HEPATOL, V7, P819, DOI 10.4254/wjh.v7.i6.819
   Preisser L, 2014, HEPATOLOGY, V60, P1879, DOI 10.1002/hep.27328
   Ren JH, 2014, J VIROL, V88, P2442, DOI 10.1128/JVI.02861-13
   Roh EY, 2017, ANN HEPATOL, V16, P63, DOI 10.5604/16652681.1226816
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   van de Klundert MAA, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100281
   Wang YF, 2012, NATURE, V491, P51, DOI 10.1038/nature11564
   Wei SW, 2010, J LEUKOCYTE BIOL, V88, P495, DOI 10.1189/jlb.1209822
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yu GZ, 2015, AM J MED SCI, V349, P145, DOI 10.1097/MAJ.0000000000000373
   Zepp JA, 2011, J IMMUNOL, V186, P4110, DOI 10.4049/jimmunol.1000081
   Zhou SL, 2016, HEPATOLOGY, V63, P1560, DOI 10.1002/hep.28445
   Zwicker S, 2015, CLIN SCI, V129, P281, DOI 10.1042/CS20150176
NR 36
TC 4
Z9 4
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 14
PY 2017
VL 12
IS 6
AR e0179605
DI 10.1371/journal.pone.0179605
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EX5KN
UT WOS:000403280900065
PM 28614380
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Liu, YJ
   Nie, H
   Mao, RC
   Mitra, B
   Cai, DW
   Yan, R
   Guo, JT
   Block, TM
   Mechti, N
   Guo, HT
AF Liu, Yuanjie
   Nie, Hui
   Mao, Richeng
   Mitra, Bidisha
   Cai, Dawei
   Yan, Ran
   Guo, Ju-Tao
   Block, Timothy M.
   Mechti, Nadir
   Guo, Haitao
TI Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus
   replication through directly binding to the epsilon stem-loop structure
   of viral RNA
SO PLOS PATHOGENS
LA English
DT Article
ID HUMAN HEPATOMA-CELLS; SINGLE-STRANDED RNA; IN-VITRO; REVERSE
   TRANSCRIPTION; EPIGENETIC REGULATION; GENE-EXPRESSION; PROTEIN;
   INFECTION; ALPHA; IDENTIFICATION
AB Hepatitis B virus (HBV) replicates its DNA genome through reverse transcription of a viral RNA pregenome. We report herein that the interferon (IFN) stimulated exoribonuclease gene of 20 KD (ISG20) inhibits HBV replication through degradation of HBV RNA. ISG20 expression was observed at basal level and was highly upregulated upon IFN treatment in hepatocytes, and knock down of ISG20 resulted in elevation of HBV replication and attenuation of IFN-mediated antiviral effect. The sequence element conferring the susceptibility of HBV RNA to ISG20-mediated RNA degradation was mapped at the HBV RNA terminal redundant region containing epsilon (epsilon) stem-loop. Furthermore, ISG20-induced HBV RNA degradation relies on its ribonuclease activity, as the enzymatic inactive form ISG20(D94G) was unable to promote HBV RNA decay. Interestingly, ISG20(D94G) retained antiviral activity against HBV DNA replication by preventing pgRNA encapsidation, resulting from a consequence of ISG20-epsilon interaction. This interaction was further characterized by in vitro electrophoretic mobility shift assay (EMSA) and ISG20 was able to bind HBV epsilon directly in absence of any other cellular proteins, indicating a direct e RNA binding capability of ISG20; however, cofactor(s) may be required for ISG20 to efficiently degrade epsilon. In addition, the lower stem portion of epsilon is the major ISG20 binding site, and the removal of 4 base pairs from the bottom portion of epsilon abrogated the sensitivity of HBV RNA to ISG20, suggesting that the specificity of ISG20-epsilon interaction relies on both RNA structure and sequence. Furthermore, the C-terminal Exonuclease III (ExoIII) domain of ISG20 was determined to be responsible for interacting with epsilon, as the deletion of ExoIII abolished in vitro ISG20-epsilon binding and intracellular HBV RNA degradation. Taken together, our study sheds light on the underlying mechanisms of IFN-mediated HBV inhibition and the antiviral mechanism of ISG20 in general.
C1 [Liu, Yuanjie; Mao, Richeng; Mitra, Bidisha; Cai, Dawei; Yan, Ran; Guo, Haitao] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
   [Nie, Hui] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA.
   [Guo, Ju-Tao; Block, Timothy M.] Baruch S Blumberg Inst, Doylestown, PA USA.
   [Mechti, Nadir] Univ Montpellier 2, CNRS, UMR5235, DIMNP, Montpellier, France.
RP Guo, HT (reprint author), Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
EM haitguo@iupui.edu
FU National Institutes of Health of United States [R21AI103838,
   R01AI094474, R01AI110762]
FX This study was supported by National Institutes of Health of United
   States (www.nih.gov) grants R21AI103838 (HG), R01AI094474 (HG), and
   R01AI110762 (HG). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR BEAMES B, 1993, VIROLOGY, V194, P597, DOI 10.1006/viro.1993.1299
   Belloni L, 2012, J CLIN INVEST, V122, P529, DOI 10.1172/JCI58847
   Block Timothy M, 2007, Clin Liver Dis, V11, P685, DOI 10.1016/j.cld.2007.08.002
   Cai DW, 2016, ANTIVIR RES, V132, P26, DOI 10.1016/j.antiviral.2016.05.005
   Cai Dawei, 2013, Methods Mol Biol, V1030, P151, DOI 10.1007/978-1-62703-484-5_13
   Chakrabarti A, 2011, J INTERF CYTOK RES, V31, P49, DOI 10.1089/jir.2010.0120
   Chisari FV, 2010, PATHOL BIOL, V58, P258, DOI 10.1016/j.patbio.2009.11.001
   Cuchillo CM, 2011, BIOCHEMISTRY-US, V50, P7835, DOI 10.1021/bi201075b
   Degols G, 2007, BIOCHIMIE, V89, P831, DOI 10.1016/j.biochi.2007.03.006
   Ding SW, 2010, NAT REV IMMUNOL, V10, P632, DOI 10.1038/nri2824
   Ehlers I, 2004, J BIOL CHEM, V279, P43437, DOI 10.1074/jbc.M402227200
   Espert L, 2005, J GEN VIROL, V86, P2221, DOI 10.1099/vir.0.81074-0
   Espert L, 2003, J BIOL CHEM, V278, P16151, DOI 10.1074/jbc.M209628200
   Espert L, 2006, J CELL BIOCHEM, V98, P1320, DOI 10.1002/jcb.20869
   GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0
   Gao B, 2009, HEPATOLOGY, V50, P424, DOI 10.1002/hep.23011
   Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333
   Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457
   Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   Guo HT, 2007, J VIROL, V81, P10072, DOI 10.1128/JVI.00541-07
   Guo H, 2009, J VIROL, V83, P847, DOI 10.1128/JVI.02008-08
   Hong R, 2013, J VIROL, V87, P6615, DOI 10.1128/JVI.03328-12
   Horio T, 2004, FEBS LETT, V577, P111, DOI 10.1016/j.febslet.2004.09.074
   Hu JM, 2009, FRONT BIOSCI-LANDMRK, V14, P1606, DOI 10.2741/3328
   Hu JM, 2006, J VIROL, V80, P2141, DOI 10.1128/JVI.80.5.2141-2150.2006
   Hu JM, 2004, J VIROL, V78, P13122, DOI 10.1128/JVI.78.23.13122-13131.2004
   Jiang D, 2008, J VIROL, V82, P1665, DOI 10.1128/JVI.02113-07
   Jones SA, 2012, J VIROL, V86, P5134, DOI 10.1128/JVI.07137-11
   Keskinen P, 1999, VIROLOGY, V263, P364, DOI 10.1006/viro.1999.9983
   Kim S, 2009, J VIROL, V83, P8032, DOI 10.1128/JVI.00332-09
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Ko C, 2014, J VIROL, V88, P13689, DOI 10.1128/JVI.02035-14
   Leong CR, 2016, ONCOTARGET, V7, P68179, DOI 10.18632/oncotarget.11907
   Li JH, 2010, J VIROL, V84, P6387, DOI 10.1128/JVI.00236-10
   Liang TJ, 2015, HEPATOLOGY, V62, P1893, DOI 10.1002/hep.28025
   Lu X, 2013, J MED VIROL, V85, P1506, DOI 10.1002/jmv.23610
   Mao RC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003494
   Mao RC, 2011, J VIROL, V85, P1048, DOI 10.1128/JVI.01998-10
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   Nassal M, 2008, VIRUS RES, V134, P235, DOI 10.1016/j.virusres.2007.12.024
   Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t
   Ning XJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002255
   POLLACK JR, 1993, J VIROL, V67, P3254
   Qu HR, 2016, VIRUS GENES, V52, P759, DOI 10.1007/s11262-016-1366-2
   Rang A, 1999, J HEPATOL, V31, P791, DOI 10.1016/S0168-8278(99)80279-7
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Sato S, 2015, IMMUNITY, V42, P123, DOI 10.1016/j.immuni.2014.12.016
   Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000
   Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031
   Uprichard SL, 2003, P NATL ACAD SCI USA, V100, P1310, DOI 10.1073/pnas.252773599
   Wieland S, 2004, P NATL ACAD SCI USA, V101, P6669, DOI 10.1073/pnas.0401771101
   Wieland SF, 2003, J VIROL, V77, P1227, DOI 10.1128/JVI.77.2.1227-1236.2003
   Wieland SF, 2004, P NATL ACAD SCI USA, V101, P2129, DOI 10.1073/pnas.0308478100
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yan R, 2015, J VIROL, V89, P9200, DOI 10.1128/JVI.00933-15
   Yan R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129889
   Zhang YG, 2007, J VIROL, V81, P11246, DOI 10.1128/JVI.01282-07
   Zhou Z, 2011, VIROLOGY, V409, P175, DOI 10.1016/j.virol.2010.10.008
   Zhu YP, 2008, RNA BIOL, V5, P65, DOI 10.4161/rna.5.2.6044
   Zoulim F, 2015, COLD SPRING HARB PER, V5
NR 61
TC 20
Z9 20
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2017
VL 13
IS 4
AR e1006296
DI 10.1371/journal.ppat.1006296
PG 35
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA EW5OL
UT WOS:000402555700014
PM 28399146
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU McFadden, VC
   Shalaby, RE
   Iram, S
   Oropeza, CE
   Landolfi, JA
   Lyubimov, AV
   Maienschein-Cline, M
   Green, SJ
   Kaestner, KH
   McLachlan, A
AF McFadden, Vanessa C.
   Shalaby, Rasha E.
   Iram, Saira
   Oropeza, Claudia E.
   Landolfi, Jennifer A.
   Lyubimov, Alexander V.
   Maienschein-Cline, Mark
   Green, Stefan J.
   Kaestner, Klaus H.
   McLachlan, Alan
TI Hepatic deficiency of the pioneer transcription factor FoxA restricts
   hepatitis B virus biosynthesis by the developmental regulation of viral
   DNA methylation
SO PLOS PATHOGENS
LA English
DT Article
ID HEPATOCYTE NUCLEAR FACTOR-3; CLOSED CIRCULAR DNA; PHOSPHOENOLPYRUVATE
   CARBOXYKINASE GENE; TISSUE-SPECIFIC ENHANCERS; SURFACE-ANTIGEN PROMOTER;
   EMBRYONIC STEM-CELLS; TRANSGENIC MICE; IN-VIVO; PEROXISOME
   PROLIFERATORS; NUCLEOCAPSID PROMOTER
AB The FoxA family of pioneer transcription factors regulates hepatitis B virus (HBV) transcription, and hence viral replication. Hepatocyte-specific FoxA-deficiency in the HBV transgenic mouse model of chronic infection prevents the transcription of the viral DNA genome as a result of the failure of the developmentally controlled conversion of 5-methylcytosine residues to cytosine during postnatal hepatic maturation. These observations suggest that pioneer transcription factors such as FoxA, which mark genes for expression at subsequent developmental steps in the cellular differentiation program, mediate their effects by reversing the DNA methylation status of their target genes to permit their ensuing expression when the appropriate tissue-specific transcription factor combinations arise during development. Furthermore, as the FoxA-deficient HBV transgenic mice are viable, the specific developmental timing, abundance and isoform type of pioneer factor expression must permit all essential liver gene expression to occur at a level sufficient to support adequate liver function. This implies that pioneer transcription factors can recognize and mark their target genes in distinct developmental manners dependent upon, at least in part, the concentration and affinity of FoxA for its binding sites within enhancer and promoter regulatory sequence elements. This selective marking of cellular genes for expression by the FoxA pioneer factor compared to HBV may offer the opportunity for the specific silencing of HBV gene expression and hence the resolution of chronic HBV infections which are responsible for approximately one million deaths worldwide annually due to liver cirrhosis and hepatocellular carcinoma.
C1 [McFadden, Vanessa C.; Shalaby, Rasha E.; Iram, Saira; Oropeza, Claudia E.; McLachlan, Alan] Univ Illinois, Coll Med, Dept Microbiol & Immunol, 909 South Wolcott Ave, Chicago, IL 60612 USA.
   [Landolfi, Jennifer A.; Lyubimov, Alexander V.] Univ Illinois, Coll Med, Dept Pharmacol, Toxicol Res Lab, Chicago, IL USA.
   [Maienschein-Cline, Mark; Green, Stefan J.] Univ Illinois, Coll Med, Res Resources Ctr, 835 South Wolcott Ave, Chicago, IL USA.
   [Kaestner, Klaus H.] Univ Penn, Dept Genet, Sch Med, Philadelphia, PA 19104 USA.
RP McLachlan, A (reprint author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, 909 South Wolcott Ave, Chicago, IL 60612 USA.
EM mclach@uic.edu
OI shalaby, rasha/0000-0001-7099-837X; Green, Stefan/0000-0003-2781-359X
FU National Institute of Allergy and Infectious Disease, National
   Institutes of Health [R01AI30070, R01AI125401, HHSN2662004000931];
   National Center for Advancing Translational Sciences, National
   Institutes of Health [UL1TR000050]
FX This work was supported by the National Institute of Allergy and
   Infectious Disease, National Institutes of Health under grants
   R01AI30070 (AM), R01AI125401 (AM), and contract HHSN2662004000931 (AVL),
   and the National Center for Advancing Translational Sciences, National
   Institutes of Health, under grant UL1TR000050 (MMC). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Addison WR, 2002, J VIROL, V76, P6356, DOI 10.1128/JVI.76.12.6356-6363.2002
   Anderson AL, 2005, J VIROL, V79, P11045, DOI 10.1128/JVI.79.17.11045-11052.2005
   Banks KE, 2002, J VIROL, V76, P12974, DOI 10.1128/JVI.76.24.12974-12980.2002
   BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x
   BENVENISTY N, 1985, P NATL ACAD SCI USA, V82, P267, DOI 10.1073/pnas.82.2.267
   Bestor TH, 2015, P NATL ACAD SCI USA, V112, P6796, DOI 10.1073/pnas.1415301111
   Bochkis IM, 2008, NAT MED, V14, P828, DOI 10.1038/nm.1853
   Bybee SM, 2011, GENOME BIOL EVOL, V3, P1312, DOI 10.1093/gbe/evr106
   CHEN M, 1994, VIROLOGY, V205, P127, DOI 10.1006/viro.1994.1627
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Dejardin J, 2015, TRENDS GENET, V31, P661, DOI 10.1016/j.tig.2015.09.003
   Dienstag JL, 2008, NEW ENGL J MED, V359, P1486, DOI 10.1056/NEJMra0801644
   GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0
   Gao N, 2008, GENE DEV, V22, P3435, DOI 10.1101/gad.1752608
   Green SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128122
   Grunberg S, 2013, TRENDS BIOCHEM SCI, V38, P603, DOI 10.1016/j.tibs.2013.09.002
   Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670
   GUIDOTTI LG, 1995, J VIROL, V69, P6158
   Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2
   Guidotti LG, 1999, J VIROL, V73, P10377
   Heard E, 2014, CELL, V157, P95, DOI 10.1016/j.cell.2014.02.045
   HIRSCH RC, 1991, J VIROL, V65, P3309
   Iwafuchi-Doi M, 2016, DEVELOPMENT, V143, P1833, DOI 10.1242/dev.133900
   Iwafuchi-Doi M, 2016, MOL CELL, V62, P79, DOI 10.1016/j.molcel.2016.03.001
   JOHNSON JL, 1995, VIROLOGY, V208, P147, DOI 10.1006/viro.1995.1138
   Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245
   KAMIMURA T, 1981, HEPATOLOGY, V1, P392, DOI 10.1002/hep.1840010504
   Kilbourne EJ, 1998, NUCLEIC ACIDS RES, V26, P1761, DOI 10.1093/nar/26.7.1761
   Kim JW, 2011, INTERVIROLOGY, V54, P316, DOI 10.1159/000321450
   Kosovsky MJ, 1998, HEPATITIS B VIRUS, P21
   KUNNATH L, 1983, EMBO J, V2, P317, DOI 10.1002/j.1460-2075.1983.tb01425.x
   Kyrmizi I, 2006, GENE DEV, V20, P2293, DOI 10.1101/gad.390906
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649
   Lee Heather J, 2014, CELL STEM CELL, V14, P710, DOI [10.1016/j.stem.2014.05.008, DOI 10.1016/J.STEM.2014.05.008]
   Lei H, 1996, DEVELOPMENT, V122, P3195
   Li L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005489
   Li L, 2009, J VIROL, V83, P1682, DOI 10.1128/JVI.02208-08
   Li ZY, 2009, J CLIN INVEST, V119, P1537, DOI 10.1172/JCI38201
   Liang P, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-231
   Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   ORI A, 1995, VIROLOGY, V207, P98, DOI 10.1006/viro.1995.1055
   Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426
   Plaschka C, 2016, J MOL BIOL, V428, P2569, DOI 10.1016/j.jmb.2016.01.028
   Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305
   RANEY AK, 1995, J VIROL, V69, P3265
   Raney AK, 2001, VIROLOGY, V289, P239, DOI 10.1006/viro.2001.1169
   Raney AK, 2001, J VIROL, V75, P2900, DOI 10.1128/JVI.75.6.2900-2911.2001
   Raney AK, 1997, J GEN VIROL, V78, P3029, DOI 10.1099/0022-1317-78-11-3029
   Raney AK, 1991, MOL BIOL HEPATITIS B, P1
   Reese V, 2011, INT J BIOCHEM CELL B, V43, P230, DOI 10.1016/j.biocel.2009.11.016
   Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192
   Schultz MD, 2015, NATURE, V523, P212, DOI 10.1038/nature14465
   Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031
   SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300
   Shen W, 2001, J BIOL CHEM, V276, P42812, DOI 10.1074/jbc.M106344200
   Song F, 2005, P NATL ACAD SCI USA, V102, P3336, DOI 10.1073/pnas.0408436102
   Straussman R, 2009, NAT STRUCT MOL BIOL, V16, P564, DOI 10.1038/nsmb.1594
   SUMMERS J, 1990, J VIROL, V64, P2819
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000
   Tang H, 2002, J VIROL, V76, P8572, DOI 10.1128/JVI.76.17.8572-8581.2002
   Tang H, 2001, P NATL ACAD SCI USA, V98, P1841, DOI 10.1073/pnas.041479698
   Tang H, 2001, DRUG NEWS PERSPECT, V14, P325
   Taube JH, 2010, J BIOL CHEM, V285, P16135, DOI 10.1074/jbc.M109.088096
   TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1
   Uprichard SL, 2003, P NATL ACAD SCI USA, V100, P1310, DOI 10.1073/pnas.252773599
   Vivekanandan P, 2010, J VIROL, V84, P4321, DOI 10.1128/JVI.02280-09
   Vivekanandan P, 2009, J INFECT DIS, V199, P1286, DOI 10.1086/597614
   Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604
   WEIMER T, 1987, J VIROL, V61, P3109
   Wieland SF, 2005, P NATL ACAD SCI USA, V102, P9913, DOI 10.1073/pnas.0504273102
   Wieland SF, 2000, J VIROL, V74, P4165, DOI 10.1128/JVI.74.9.4165-4173.2000
   Wieland SF, 2004, P NATL ACAD SCI USA, V101, P2129, DOI 10.1073/pnas.0308478100
   WILL H, 1987, J VIROL, V61, P904
   Xu J, 2007, P NATL ACAD SCI USA, V104, P12377, DOI 10.1073/pnas.0704579104
   Xu J, 2009, GENE DEV, V23, P2824, DOI 10.1101/gad.1861209
   YAMADA G, 1982, GASTROENTEROLOGY, V83, P348
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yang YQA, 2016, NUCLEIC ACIDS RES, V44, P8153, DOI 10.1093/nar/gkw498
   YEN TSB, 1993, SEMIN VIROL, V4, P33
   Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593
   Zhang LP, 2005, CELL METAB, V2, P141, DOI 10.1016/j.cmet.2005.07.002
   Zhang YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056711
   Zhang Y, 2016, NAT GENET, V48, P1003, DOI 10.1038/ng.3635
   Zhu Y, 2001, J VIROL, V75, P311, DOI 10.1128/JVI.75.1.311-322.2001
NR 89
TC 2
Z9 4
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD FEB
PY 2017
VL 13
IS 2
AR e1006239
DI 10.1371/journal.ppat.1006239
PG 34
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA EO0TL
UT WOS:000396410800017
PM 28235042
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Appelman, MD
   Chakraborty, A
   Protzer, U
   McKeating, JA
   van de Graaf, SFJ
AF Appelman, Monique D.
   Chakraborty, Anindita
   Protzer, Ulrike
   McKeating, Jane A.
   van de Graaf, Stan F. J.
TI N-Glycosylation of the Na plus - Taurocholate Cotransporting Polypeptide
   (NTCP) Determines Its Trafficking and Stability and Is Required for
   Hepatitis B Virus Infection
SO PLOS ONE
LA English
DT Article
ID CO-TRANSPORTING POLYPEPTIDE; BILE-ACID COTRANSPORTER; INHIBITOR
   MYRCLUDEX-B; PROTEASOMAL DEGRADATION; PROTEIN GLYCOSYLATION; LINKED
   GLYCOSYLATION; ENTRY; MEMBRANE; HEPATOCYTES; BINDING
AB The sodium/bile acid cotransporter NTCP was recently identified as a receptor for hepatitis B virus (HBV). NTCP is glycosylated and the role of glycans in protein trafficking or viral receptor activity is not known. NTCP contains two N-linked glycosylation sites and asparagine amino acid residues N5 and N11 were mutated to a glutamine to generate NTCP with a single glycan (NTCP- N5Q or NTCP- N11Q) or no glycans (NTCP- N5,11Q). HepG2 cells expressing NTCP with a single glycan supported HBV infection at a comparable level to NTCP-WT. The physiological function of NTCP, the uptake of bile acids, was also not affected in cells expressing these single glycosylation variants, consistent with their trafficking to the plasma membrane. However, glycosylation-deficient NTCP (NTCP- N5,11Q) failed to support HBV infection, showed minimal cellular expression and was degraded in the lysosome. This affected the physiological bile acid transporter function of NTCP- N5,11Q in a similar fashion. In conclusion, N-glycosylation is required for efficient NTCP localization at the plasma membrane and subsequent HBV infection and these characteristics are preserved in NTCP carrying a single carbohydrate moiety.
C1 [Appelman, Monique D.; van de Graaf, Stan F. J.] Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, Amsterdam, Netherlands.
   [Chakraborty, Anindita; Protzer, Ulrike] Tech Univ Munich, Inst Virol, Helmholtz Zentrum Munchen, Munich, Germany.
   [Chakraborty, Anindita; Protzer, Ulrike; McKeating, Jane A.] Tech Univ Munich, Inst Adv Study, Munich, Germany.
   [McKeating, Jane A.] Univ Birmingham, Ctr Human Virol, Birmingham, W Midlands, England.
   [van de Graaf, Stan F. J.] Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands.
RP van de Graaf, SFJ (reprint author), Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, Amsterdam, Netherlands.; van de Graaf, SFJ (reprint author), Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands.
EM k.f.vandegraaf@amc.uva.nl
RI Protzer, Ulrike/D-5915-2015
OI Protzer, Ulrike/0000-0002-9421-1911; van de Graaf,
   Stan/0000-0003-4238-4359
FU Netherlands Organization for Scientific Research [VIDI 91713319];
   European Research Council [337479]; MRC; EU; H2020 grant Hep-CAR; German
   research Foundation (DFG) [TRR179]; Institute for Advanced Study;
   Technische Universitat Munchen via the German Excellence Initiative; EU
   7th Framework Programme [291763]
FX SF JvdG is supported by the Netherlands Organization for Scientific
   Research (VIDI 91713319) and the European Research Council (Starting
   grant 337479). Research in the McKeating laboratory is funded by the
   MRC, EU FP7 PathCO and H2020 grant Hep-CAR. Research in the Protzer
   laboratory was funded by the H2020 grant Hep-CAR and by the German
   research Foundation (DFG; TRR179). AC and collaborative work between
   McKeating and Protrer laboratories is funded by the Institute for
   Advanced Study with the support of the Technische Universitat Munchen
   via the German Excellence Initiative and EU 7th Framework Programme
   under grant agreement number 291763.
CR Pereira IVA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117152
   Beers MF, 2013, AM J PHYSIOL-LUNG C, V305, pL970, DOI 10.1152/ajplung.00184.2013
   Bijsmans ITGW, 2012, BIOCHEM J, V441, P1007, DOI 10.1042/BJ20111234
   Blank A, 2016, J HEPATOL, V65, P483, DOI 10.1016/j.jhep.2016.04.013
   Christiansen MN, 2014, PROTEOMICS, V14, P525, DOI 10.1002/pmic.201300387
   Console L, 2015, BBA-MOL CELL RES, V1853, P1636, DOI 10.1016/j.bbamcr.2015.03.017
   Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157
   HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091
   Hallen S, 2002, BIOCHEMISTRY-US, V41, P7253, DOI 10.1021/bi012152s
   Jost S, 2007, J VIROL, V81, P10588, DOI 10.1128/JVI.02489-06
   Konig A, 2014, J HEPATOL, V61, P867, DOI 10.1016/j.jhep.2014.05.018
   LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x
   Meredith LW, 2016, J GEN VIROL, V97, P121, DOI 10.1099/jgv.0.000317
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Petersen J, 2008, NAT BIOTECHNOL, V26, P335, DOI 10.1038/nbt1389
   Protzer U, 2007, GASTROENTEROLOGY, V133, P1156, DOI 10.1053/j.gastro.2007.07.021
   Schulze A, 2007, HEPATOLOGY, V46, P1759, DOI 10.1002/hep.21896
   Slijepcevic D, 2015, HEPATOLOGY
   Stelzl T, 2016, AM J PHYSIOL-GASTR L, V310, pG128, DOI 10.1152/ajpgi.00350.2015
   Sun AQ, 2001, AM J PHYSIOL-GASTR L, V280, pG1305
   Urban S, 2014, GASTROENTEROLOGY, V147, P48, DOI 10.1053/j.gastro.2014.04.030
   Vaz FM, 2015, HEPATOLOGY, V61, P260, DOI 10.1002/hep.27240
   Verrier ER, 2016, HEPATOLOGY, V63, P35, DOI 10.1002/hep.28013
   Volz T, 2013, J HEPATOL, V58, P861, DOI 10.1016/j.jhep.2012.12.008
   Yan H, 2014, J VIROL, V88, P3273, DOI 10.1128/JVI.03478-13
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707
   Zhao NN, 2014, P NATL ACAD SCI USA, V111, P9175, DOI 10.1073/pnas.1405355111
NR 28
TC 12
Z9 12
U1 2
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 26
PY 2017
VL 12
IS 1
AR e0170419
DI 10.1371/journal.pone.0170419
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN7IT
UT WOS:000396176100110
PM 28125599
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Niu, CR
   Livingston, CM
   Li, L
   Beran, RK
   Daffis, S
   Ramakrishnan, D
   Burdette, D
   Peiser, L
   Salas, E
   Ramos, H
   Yu, M
   Cheng, GF
   Strubin, M
   Delaney, WE
   Fletcher, SP
AF Niu, Congrong
   Livingston, Christine M.
   Li, Li
   Beran, Rudolf K.
   Daffis, Stephane
   Ramakrishnan, Dhivya
   Burdette, Dara
   Peiser, Leanne
   Salas, Eduardo
   Ramos, Hilario
   Yu, Mei
   Cheng, Guofeng
   Strubin, Michel
   Delaney, William E.
   Fletcher, Simon P.
TI The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing
   an Innate Immune Response and Is Counteracted by the HBV X Protein
   Shortly after Infection
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-B-VIRUS; GENE-EXPRESSION; EPIGENETIC REGULATION;
   NUCLEAR-BODIES; HUMANIZED MICE; DNA; REPLICATION; BINDING; CELLS;
   COMPONENTS
AB The structural maintenance of chromosome 5/6 complex (Smc5/6) is a restriction factor that represses hepatitis B virus (HBV) transcription. HBV counters this restriction by expressing HBV X protein (HBx), which targets Smc5/6 for degradation. However, the mechanism by which Smc5/6 suppresses HBV transcription and how HBx is initially expressed is not known. In this study we characterized viral kinetics and the host response during HBV infection of primary human hepatocytes (PHH) to address these unresolved questions. We determined that Smc5/6 localizes with Nuclear Domain 10 (ND10) in PHH. Co-localization has functional implications since depletion of ND10 structural components alters the nuclear distribution of Smc6 and induces HBV gene expression in the absence of HBx. We also found that HBV infection and replication does not induce a prominent global host transcriptional response in PHH, either shortly after infection when Smc5/6 is present, or at later times post-infection when Smc5/6 has been degraded. Notably, HBV and an HBx-negative virus establish high level infection in PHH without inducing expression of interferon-stimulated genes or production of interferons or other cytokines. Our study also revealed that Smc5/6 is degraded in the majority of infected PHH by the time cccDNA transcription could be detected and that HBx RNA is present in cell culture-derived virus preparations as well as HBV patient plasma. Collectively, these data indicate that Smc5/6 is an intrinsic antiviral restriction factor that suppresses HBV transcription when localized to ND10 without inducing a detectable innate immune response. Our data also suggest that HBx protein may be initially expressed by delivery of extracellular HBx RNA into HBV-infected cells.
C1 [Niu, Congrong; Livingston, Christine M.; Li, Li; Beran, Rudolf K.; Daffis, Stephane; Ramakrishnan, Dhivya; Burdette, Dara; Peiser, Leanne; Salas, Eduardo; Ramos, Hilario; Yu, Mei; Cheng, Guofeng; Delaney, William E.; Fletcher, Simon P.] Gilead Sci, Foster City, CA 94404 USA.
   [Strubin, Michel] Univ Med Ctr, Dept Microbiol & Mol Med, Geneva, Switzerland.
RP Fletcher, SP (reprint author), Gilead Sci, Foster City, CA 94404 USA.
EM simon.fletcher@gilead.com
FU Helen Wills Neuroscience Institute [LSM880]
FX The authors gratefully acknowledge Ulrike Protzer for the HBVAX
   producing cell line; Hoa Truong for performing the MSD assay; Anna Celli
   and Jane Gordon (University of California, San Francisco) as well as
   Jen-Yi Lee and Holly Aaron (University of California, Berkeley Molecular
   Imaging Center) for technical assistance with confocal microscopy; Helen
   Wills Neuroscience Institute for supporting purchase of the Zeiss LSM880
   at the Berkeley Molecular Imaging Center; Vivian Barry, Rosanna Win and
   Rhyannon Spangler for helpful discussion and sectioning the uPA-SLID
   mouse liver tissue; Lindsay Gamelin for the identifying the patient
   plasma samples; Robert Jordan, Anuj Gaggar, Peng Yue, Sarah Gilmore,
   Tomas Cihlar and Frank Chisari for discussions and support.
CR Altinel K, 2016, J VIROL
   Ancey PB, 2015, ONCOTARGET, V6, P44877, DOI 10.18632/oncotarget.6270
   Belloni L, 2012, J CLIN INVEST, V122, P529, DOI 10.1172/JCI58847
   Belloni L, 2009, P NATL ACAD SCI USA, V106, P19975, DOI 10.1073/pnas.0908365106
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277
   Bertoletti A, 2012, GUT, V61, P1754, DOI 10.1136/gutjnl-2011-301073
   Bertoletti A, 2010, ANTIVIR THER, V15, P15, DOI 10.3851/IMP1620
   Boltjes A, 2015, J INFECT DIS, V211, P1268, DOI 10.1093/infdis/jiu599
   Cai Dawei, 2013, Methods Mol Biol, V1030, P151, DOI 10.1007/978-1-62703-484-5_13
   Carter SD, 2012, CRIT REV BIOCHEM MOL, V47, P1, DOI 10.3109/10409238.2011.614593
   CHEN HS, 1993, J VIROL, V67, P1218
   Chisari FV, 2010, PATHOL BIOL, V58, P258, DOI 10.1016/j.patbio.2009.11.001
   Chung YL, 2009, MOL CANCER RES, V7, P1672, DOI 10.1158/1541-7786.MCR-09-0112
   Decorsiere A, 2016, NATURE, V531, P386, DOI 10.1038/nature17170
   Diner BA, 2015, J BIOL CHEM, V290, P26412, DOI 10.1074/jbc.R115.652289
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dunn C, 2009, GASTROENTEROLOGY, V137, P1289, DOI 10.1053/j.gastro.2009.06.054
   Durantel D, 2009, HEPATOLOGY, V50, P1692, DOI 10.1002/hep.23361
   Everett RD, 2007, BIOCHIMIE, V89, P819, DOI 10.1016/j.biochi.2007.01.004
   Everett RD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003386
   Fletcher SP, 2013, HEPATOLOGY, V57, P13, DOI 10.1002/hep.25954
   Gallego-Paeza LM, 2014, MOL BIOL CELL, V25, P302, DOI 10.1091/mbc.E13-01-0020
   Giersch K, 2015, J HEPATOL, V63, P346, DOI 10.1016/j.jhep.2015.03.011
   Glass M, 2013, J VIROL, V87, P2174, DOI 10.1128/JVI.02950-12
   Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699
   Hosel M, 2009, HEPATOLOGY, V50, P1773, DOI 10.1002/hep.23226
   Jacome A, 2015, EMBO J, V34, P2604, DOI 10.15252/embj.201591829
   Ju LM, 2013, DNA REPAIR, V12, P356, DOI 10.1016/j.dnarep.2013.02.006
   Kanno T, 2015, CELL REP, V12, P1471, DOI 10.1016/j.celrep.2015.07.048
   Kegel A, 2010, Cold Spring Harb Symp Quant Biol, V75, P179, DOI 10.1101/sqb.2010.75.047
   Kwon H, 2011, NAT REV GASTRO HEPAT, V8, P275, DOI 10.1038/nrgastro.2011.33
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661
   Lamontagne J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005438
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Luangsay S, 2015, J HEPATOL, V63, P1314, DOI 10.1016/j.jhep.2015.07.014
   Lucifora J, 2011, J HEPATOL, V55, P996, DOI 10.1016/j.jhep.2011.02.015
   Martin-Lluesma S, 2008, HEPATOLOGY, V48, P1467, DOI 10.1002/hep.22542
   Menne S, 2015, J HEPATOL, V62, P1237, DOI 10.1016/j.jhep.2014.12.026
   Murphy CM, 2016, CELL REP, V16, P2846, DOI 10.1016/j.celrep.2016.08.026
   Oehler N, 2014, HEPATOLOGY, V60, P1483, DOI 10.1002/hep.27159
   Potts PR, 2007, NAT STRUCT MOL BIOL, V14, P581, DOI 10.1038/nsmb1259
   Ringelhan M, 2015, CURR OPIN VIROL, V14, P109, DOI 10.1016/j.coviro.2015.08.015
   Riviere L, 2015, J HEPATOL, V63, P1093, DOI 10.1016/j.jhep.2015.06.023
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sato S, 2015, IMMUNITY, V42, P123, DOI 10.1016/j.immuni.2014.12.016
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Shlomai A, 2014, P NATL ACAD SCI USA, V111, P12193, DOI 10.1073/pnas.1412631111
   Simon V, 2015, NAT IMMUNOL, V16, P546, DOI 10.1038/ni.3156
   Tavalai N, 2008, BBA-MOL CELL RES, V1783, P2207, DOI 10.1016/j.bbamcr.2008.08.004
   Tavalai N, 2008, J VIROL, V82, P126, DOI 10.1128/JVI.01685-07
   Thomsen MK, 2016, HEPATOLOGY
   Tsuge M, 2010, J GEN VIROL, V91, P1854, DOI 10.1099/vir.0.019224-0
   van Breugel PC, 2012, HEPATOLOGY, V56, P2116, DOI 10.1002/hep.25928
   Wang J, 2016, J HEPATOL
   Weitzman MD, 2010, ANNU REV MICROBIOL, V64, P61, DOI 10.1146/annurev.micro.112408.134016
   Wieland S, 2004, P NATL ACAD SCI USA, V101, P6669, DOI 10.1073/pnas.0401771101
   Wieland SF, 2005, J VIROL, V79, P9369, DOI 10.1128/JVI.79.15.9369-9380.2005
   Wu N, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-5
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yan N, 2012, NAT IMMUNOL, V13, P214, DOI 10.1038/ni.2229
   Yoneda M, 2016, J IMMUNOL, V197, P630, DOI 10.4049/jimmunol.1502677
   ZOULIM F, 1994, J VIROL, V68, P2026
NR 66
TC 27
Z9 28
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 17
PY 2017
VL 12
IS 1
AR e0169648
DI 10.1371/journal.pone.0169648
PG 32
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EI3EK
UT WOS:000392372300028
PM 28095508
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Qi, YH
   Gao, ZC
   Xu, GW
   Peng, B
   Liu, CX
   Yan, H
   Yao, QY
   Sun, GL
   Liu, Y
   Tang, DB
   Song, ZL
   He, WH
   Sun, YY
   Guo, JT
   Li, WH
AF Qi, Yonghe
   Gao, Zhenchao
   Xu, Guangwei
   Peng, Bo
   Liu, Chenxuan
   Yan, Huan
   Yao, Qiyan
   Sun, Guoliang
   Liu, Yang
   Tang, Dingbin
   Song, Zilin
   He, Wenhui
   Sun, Yinyan
   Guo, Ju-Tao
   Li, Wenhui
TI DNA Polymerase kappa Is a Key Cellular Factor for the Formation of
   Covalently Closed Circular DNA of Hepatitis B Virus
SO PLOS PATHOGENS
LA English
DT Article
ID NUCLEOTIDE-EXCISION-REPAIR; PLUS-STRAND DNA; VIRAL-DNA; IN-VITRO;
   HEPATOCYTE CULTURES; TUPAIA HEPATOCYTES; ENVELOPE PROTEINS; HBV
   REPLICATION; POL-KAPPA; INFECTION
AB Hepatitis B virus (HBV) infection of hepatocytes begins by binding to its cellular receptor sodium taurocholate cotransporting polypeptide (NTCP), followed by the internalization of viral nucleocapsid into the cytoplasm. The viral relaxed circular (rc) DNA genome in nucleocapsid is transported into the nucleus and converted into covalently closed circular (ccc) DNA to serve as a viral persistence reservoir that is refractory to current antiviral therapies. Host DNA repair enzymes have been speculated to catalyze the conversion of rcDNA to cccDNA, however, the DNA polymerase(s) that fills the gap in the plus strand of rcDNA remains to be determined. Here we conducted targeted genetic screening in combination with chemical inhibition to identify the cellular DNA polymerase(s) responsible for cccDNA formation, and exploited recombinant HBV with capsid coding deficiency which infects HepG2-NTCP cells with similar efficiency of wild-type HBV to assure cccDNA synthesis is exclusively from de novo HBV infection. We found that DNA polymerase. (POLK), a Y-family DNA polymerase with maximum activity in non-dividing cells, substantially contributes to cccDNA formation during de novo HBV infection. Depleting gene expression of POLK in HepG2-NTCP cells by either siRNA knockdown or CRISPR/Cas9 knockout inhibited the conversion of rcDNA into cccDNA, while the diminished cccDNA formation in, and hence the viral infection of, the knockout cells could be effectively rescued by ectopic expression of POLK. These studies revealed that POLK is a crucial host factor required for cccDNA formation during a de novo HBV infection and suggest that POLK may be a potential target for developing antivirals against HBV.
C1 [Qi, Yonghe; Gao, Zhenchao; Xu, Guangwei; Peng, Bo; Liu, Chenxuan; Yan, Huan; Yao, Qiyan; Sun, Guoliang; Liu, Yang; Tang, Dingbin; Song, Zilin; He, Wenhui; Sun, Yinyan; Li, Wenhui] Natl Inst Biol Sci, Beijing, Peoples R China.
   [Gao, Zhenchao; Peng, Bo; Tang, Dingbin] Peking Univ, Grad Program Sch Life Sci, Beijing, Peoples R China.
   [Liu, Chenxuan] Beijing Normal Univ, Coll Life Sci, Beijing, Peoples R China.
   [Liu, Yang] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China.
   [Guo, Ju-Tao] Baruch S Blumberg Inst, Doylestown, PA USA.
RP Li, WH (reprint author), Natl Inst Biol Sci, Beijing, Peoples R China.
EM liwenhui@nibs.ac.cn
FU Ministry of Science and Technology [2014CB849600, 2013ZX09509102];
   National Natural Science Foundation of China [81525018]; Science and
   Technology Bureau of Beijing Municipal Government
FX These studies were funded by the Ministry of Science and Technology
   (2014CB849600,2013ZX09509102), National Natural Science Foundation of
   China (81525018), the Science and Technology Bureau of Beijing Municipal
   Government. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Belloni L, 2013, HEPATOLOGY
   Bock CT, 2001, J MOL BIOL, V307, P183, DOI 10.1006/jmbi.2001.4481
   BOCK CT, 1994, VIRUS GENES, V8, P215, DOI 10.1007/BF01703079
   Bourne C, 2008, J VIROL, V82, P10262, DOI 10.1128/JVI.01360-08
   Cai Dawei, 2013, Methods Mol Biol, V1030, P151, DOI 10.1007/978-1-62703-484-5_13
   Campagna MR, 2013, J VIROL, V87, P6931, DOI 10.1128/JVI.00582-13
   Cho MH, 2014, J VIRAL HEPATITIS, V21, P843, DOI 10.1111/jvh.12214
   Cortes L. F., 2009, NATURE, V461, P674, DOI [10.1038/nature08444, DOI 10.1038/NATURE08444]
   Cui XJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128401
   Delmas J, 2002, ANTIMICROB AGENTS CH, V46, P425, DOI 10.1128/AAC.46.2.425-433.2002
   Deres K, 2003, SCIENCE, V299, P893, DOI 10.1126/science.1077215
   Feld JJ, 2007, ANTIVIR RES, V76, P168, DOI 10.1016/j.antiviral.2007.06.014
   FOUREL I, 1994, J VIROL, V68, P1059
   Gao WF, 2007, J VIROL, V81, P6164, DOI 10.1128/JVI.02721-06
   Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200
   Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   Guo HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043270
   Guo JT, 2015, ANTIVIR RES, V122, P91, DOI 10.1016/j.antiviral.2015.08.005
   Guo YH, 2011, EPIGENETICS-US, V6, P720, DOI 10.4161/eip.6.6.15815
   Hantz O, 2009, J GEN VIROL, V90, P127, DOI 10.1099/vir.0.004861-0
   Iwamoto M, 2014, BIOCHEM BIOPH RES CO, V443, P808, DOI 10.1016/j.bbrc.2013.12.052
   Jones SA, 2013, J VIROL, V87, P2563, DOI 10.1128/JVI.02786-12
   Jones SA, 2012, J VIROL, V86, P5134, DOI 10.1128/JVI.07137-11
   KOCK J, 1993, J VIROL, V67, P4867
   Kock J, 2003, HEPATOLOGY, V38, P1410, DOI 10.1016/j.hep.2003.09.009
   Kock J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001082
   Konig A, 2014, J HEPATOL, V61, P867, DOI 10.1016/j.jhep.2014.05.018
   Koniger C, 2014, P NATL ACAD SCI USA, V111, pE4244, DOI 10.1073/pnas.1409986111
   Lentz TB, 2011, J VIROL, V85, P11916, DOI 10.1128/JVI.05373-11
   Liaw YF, 2013, LIVER INT, V33, P111, DOI 10.1111/liv.12057
   Lucifora J, 2014, SCIENCE, V343, P1221, DOI 10.1126/science.1243462
   Mejlvang J, 2014, J CELL BIOL, V204, P29, DOI 10.1083/jcb.201305017
   Moraleda G, 1997, J VIROL, V71, P9392
   Moser J, 2007, MOL CELL, V27, P311, DOI 10.1016/j.molcel.2007.06.014
   Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809
   NEWBOLD JE, 1995, J VIROL, V69, P3350
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Ogi T, 2006, NAT CELL BIOL, V8, P640, DOI 10.1038/ncb1417
   Ogi T, 2010, MOL CELL, V37, P714, DOI 10.1016/j.molcel.2010.02.009
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Perez-Cameo C, 2014, LIVER INT, V34, P146, DOI 10.1111/liv.12398
   Schultz U, 1999, J VIROL, V73, P5459
   Schulze-Bergkamen H, 2003, J HEPATOL, V38, P736, DOI 10.1016/S0168-8278(03)00120-X
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Seeger C, 2015, VIROLOGY, V479, P672, DOI 10.1016/j.virol.2015.02.031
   SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005
   Sohn JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008093
   STAPRANS S, 1991, J VIROL, V65, P1255
   SUMMERS J, 1990, J VIROL, V64, P2819
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   SUMMERS J, 1975, P NATL ACAD SCI USA, V72, P4597, DOI 10.1073/pnas.72.11.4597
   Sun YY, 2014, J VIROL, V88, P237, DOI 10.1128/JVI.02141-13
   TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1
   VONWEIZSACKER F, 1995, J VIROL, V69, P2704
   Wang XY, 2012, ANTIVIR THER, V17, P793, DOI 10.3851/IMP2152
   Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018
   WU TT, 1990, VIROLOGY, V175, P255, DOI 10.1016/0042-6822(90)90206-7
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   YANG WG, 1995, J VIROL, V69, P4029
   Yeh CT, 1998, J MED VIROL, V55, P42, DOI 10.1002/(SICI)1096-9071(199805)55:1<42::AID-JMV8>3.0.CO;2-O
   Zeisel MB, 2015, GUT, V64, P1314, DOI 10.1136/gutjnl-2014-308943
   Zhang XL, 2013, DNA REPAIR, V12, P377, DOI 10.1016/j.dnarep.2013.02.008
   Zhong GC, 2013, J VIROL, V87, P7176, DOI 10.1128/JVI.03533-12
   Zoulim F, 2005, J HEPATOL, V42, P302, DOI 10.1016/j.jhep.2004.12.015
NR 65
TC 35
Z9 37
U1 1
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2016
VL 12
IS 10
AR e1005893
DI 10.1371/journal.ppat.1005893
PG 26
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA EB8UO
UT WOS:000387666900014
PM 27783675
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Ren, S
   Wang, J
   Chen, TL
   Li, HY
   Wan, YS
   Peng, NF
   Gui, XE
   Zhu, Y
AF Ren, Sheng
   Wang, Jun
   Chen, Tie-Long
   Li, Hao-Yu
   Wan, Yu-Shun
   Peng, Nan-Fang
   Gui, Xi-En
   Zhu, Ying
TI Hepatitis B Virus Stimulated Fibronectin Facilitates Viral Maintenance
   and Replication through Two Distinct Mechanisms
SO PLOS ONE
LA English
DT Article
ID MAST-CELL TRYPTASE; IN-VITRO; EXPRESSION; INFECTION; DISEASE; PROTEIN;
   LIVER; HEPATOCYTES; SEQUENCE; SURFACE
AB Fibronectin (FN) is a high molecular weight extracellular matrix protein that functions in cell adhesion, growth, migration, and embryonic development. However, little is known about the role of FN during viral infection. In the present study, we found significantly higher levels of FN in sera, and liver tissues from hepatitis B virus (HBV) patients relative to healthy individuals. HBV expression enhanced FN mRNA and protein levels in the hepatic cell lines Huh7 and HepG2. HBV infection of susceptible HepG2-sodium taurocholate co-transporting polypeptide cells also increased FN expression. We also found that transcriptional factor specificity protein 1 was involved in the induction of FN by HBV. Knockdown of FN expression significantly inhibited HBV DNA replication and protein synthesis through activating endogenous IFN-alpha production. In addition, FN interacted with the transforming growth factor beta-activated protein kinase 1 (TAK1) and TAK1-binding protein complex and attenuated interferon signaling by inhibiting TAK1 phosphorylation. Furthermore, the nuclear translocation of NF-kappa B/p65 was found to be inhibited by FN. We also observed that FN promoted HBV enhancers to support HBV expression. These results suggest novel functions of endogenous FN involved in immune evasion and maintenance of HBV replication.
C1 [Ren, Sheng; Li, Hao-Yu; Wan, Yu-Shun; Peng, Nan-Fang; Zhu, Ying] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Wang, Jun] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Chen, Tie-Long; Gui, Xi-En] Wuhan Univ, Dept Infect Dis, Zhongnan Hosp, Wuhan 430072, Peoples R China.
RP Zhu, Y (reprint author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
EM yingzhu@whu.edu.cn
FU Major State Basic Research Development Program of China [2013CB911102];
   National Natural Science Foundation of China [81461130019, 81271821,
   31570870]; National Mega Project on Major Infectious Diseases Prevention
   [2012ZX10004503-004]
FX This work was supported by research grants from the Major State Basic
   Research Development Program of China (2013CB911102), National Natural
   Science Foundation of China (81461130019, 81271821 and 31570870),
   National Mega Project on Major Infectious Diseases Prevention
   (2012ZX10004503-004). The funding agencies had no role in study design,
   data collection, or analysis, decision to publish, or preparation of the
   manuscript.
CR Bearzotti M, 1999, J VIROL, V73, P7703
   Beer C, 2007, J VIROL, V81, P8247, DOI 10.1128/JVI.00312-07
   Breous E, 2009, HEPATOLOGY, V50, P612, DOI 10.1002/hep.23043
   BUDKOWSKA A, 1995, J VIROL, V69, P840
   Chang ML, 2014, J HEPATOL, V61, P1407, DOI 10.1016/j.jhep.2014.08.033
   Chung HY, 2014, J VIROL, V88, P11022, DOI 10.1128/JVI.01582-14
   Cobbs SL, 2007, BIOCHEM BIOPH RES CO, V362, P288, DOI 10.1016/j.bbre.2007.07.186
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Fu J, 2011, HEPATOLOGY, V53, P181, DOI 10.1002/hep.24015
   Fukai K, 1997, VIROLOGY, V236, P279, DOI 10.1006/viro.1997.8750
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   Goubau D, 2013, IMMUNITY, V38, P855, DOI 10.1016/j.immuni.2013.05.007
   HAUGEN PK, 1992, J NEUROSCI, V12, P2597
   He WH, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004840
   Henderson B, 2011, FEMS MICROBIOL REV, V35, P147, DOI 10.1111/j.1574-6976.2010.00243.x
   Hoshino K, 2006, NATURE, V440, P949, DOI 10.1038/nature04641
   Jackson NE, 2008, J BIOL CHEM, V283, P34178, DOI 10.1074/jbc.M807553200
   Kaminska R, 1999, J INVEST DERMATOL, V113, P567, DOI 10.1046/j.1523-1747.1999.00738.x
   Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118
   Kay A, 2014, J VIRAL HEPATITIS, V21, P921, DOI 10.1111/jvh.12267
   Kim YJ, 2011, LIVER INT, V31, P819, DOI 10.1111/j.1478-3231.2011.02516.x
   Kornblihtt AR, 1996, FASEB J, V10, P248
   Lau DTY, 2003, J VIRAL HEPATITIS, V10, P331, DOI 10.1046/j.1365-2893.2003.00418.x
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x
   Leung HSY, 2012, J VIROL, V86, P10704, DOI 10.1128/JVI.01166-12
   Li H, 2014, CELL MOL IMMUNOL, V11, P175, DOI 10.1038/cmi.2013.66
   Li YK, 2013, J BIOL CHEM, V288, P20927, DOI 10.1074/jbc.M112.440115
   Liaw YF, 2011, LIVER INT, V31, P117, DOI 10.1111/j.1478-3231.2010.02388.x
   LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402
   Luangsay S, 2015, J HEPATOL, V63, P1314, DOI 10.1016/j.jhep.2015.07.014
   Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008
   Marcellin P, 2009, J HEPATOL, V50, P227, DOI 10.1016/j.jhep.2008.10.001
   MOSESSON MW, 1980, BLOOD, V56, P145
   Norton PA, 2004, J VIRAL HEPATITIS, V11, P332, DOI 10.1111/j.1365-2893.2004.00555.x
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Reese V, 2011, INT J BIOCHEM CELL B, V43, P230, DOI 10.1016/j.biocel.2009.11.016
   Samal J, 2012, CLIN MICROBIOL REV, V25, P142, DOI 10.1128/CMR.00018-11
   SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005
   Seo Y, 2014, WORLD J GASTROENTERO, V20, P13284, DOI 10.3748/wjg.v20.i37.13284
   Shang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10066
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Tseng L, 2003, DNA CELL BIOL, V22, P633, DOI 10.1089/104454903770238102
   van der Straaten HM, 2004, J INVEST DERMATOL, V123, P1057, DOI 10.1111/j.0022-202X.2004.23474.x
   VARTIO T, 1987, J CELL SCI, V88, P419
   Villiers MB, 2015, J CLIN MICROBIOL, V53, P1164, DOI 10.1128/JCM.03002-14
   Wang F, 2012, MOL MED REP, V6, P1145, DOI 10.3892/mmr.2012.1029
   Wang Xue-Qing, 2008, BMC Biochemistry, V9, P30, DOI 10.1186/1471-2091-9-30
   Wei CW, 2010, J IMMUNOL, V185, P1158, DOI 10.4049/jimmunol.0903874
   Williams CM, 2008, CANCER RES, V68, P3185, DOI 10.1158/0008-5472.CAN-07-2673
   Wu J, 2009, HEPATOLOGY, V49, P1132, DOI 10.1002/hep.22751
   YAMADA KM, 1978, NATURE, V275, P179, DOI 10.1038/275179a0
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yang J, 2006, BIOCHEM BIOPH RES CO, V344, P757, DOI 10.1016/j.bbrc.2006.03.204
   Yang J, 2010, ARCH VIROL, V155, P881, DOI 10.1007/s00705-010-0657-5
   Yu SY, 2010, J GEN VIROL, V91, P2080, DOI 10.1099/vir.0.020552-0
   Yue X, 2012, J IMMUNOL, V189, P279, DOI 10.4049/jimmunol.1103405
   Zhao FP, 2014, J BIOL CHEM, V289, P35029, DOI 10.1074/jbc.M114.589978
NR 57
TC 2
Z9 2
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 29
PY 2016
VL 11
IS 3
AR e0152721
DI 10.1371/journal.pone.0152721
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DH9KB
UT WOS:000373113900091
PM 27023403
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Yan, L
   Qu, S
   Liu, G
   Liu, L
   Yu, Y
   Ding, GH
   Zhao, YF
   Li, YX
   Xie, YH
   Zhang, JQ
   Qu, D
AF Yan, Liang
   Qu, Su
   Liu, Gang
   Liu, Lei
   Yu, Yao
   Ding, Guohui
   Zhao, Yanfeng
   Li, Yixue
   Xie, Youhua
   Zhang, Junqi
   Qu, Di
TI Comparative Transcriptomic Analysis of Primary Duck Hepatocytes Provides
   Insight into Differential Susceptibility to DHBV Infection
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-B-VIRUS; ENTRY; DIMETHYLSULFOXIDE; REPLICATION
AB Primary duck hepatocytes (PDH) displays differential susceptibility to duck hepatitis B virus when maintained in the media supplemented with fetal bovine serum or dimethyl sulfoxide (DMSO) which has been widely used for the maintenance of hepatocytes, and prolonging susceptibility to hepadnavirus. However the mechanism underlying maintenance of susceptibility to hepadnavirus by DMSO treatment remains unclear. In this study, a global transcriptome analysis of PDHs under different culture conditions was conducted for investigating the effects of DMSO on maintenance of susceptibility of PDH to DHBV in vitro. The 384 differential expressed genes (DEGs) were identified by comparisons between each library pair (PDHs cultured with or without DMSO or fresh isolated PDH). We analyzed canonical pathways in which the DEGs were enriched in Hepatic Fibrosis / Hepatic Stellate Cell Activation, Bile Acid Biosynthesis and Tight Junction signaling. After re-annotation against human genome data, the 384 DEGs were pooled together with proteins belonging to hepatitis B pathway to construct a protein-protein interaction network. The combination of decreased expression of liver-specific genes (CYP3A4, CYP1E1, CFI, RELN and GSTA1 et al) with increased expression of hepatocyte-dedifferentiation-associated genes (PLA2G4A and PLCG1) suggested that in vitro culture conditions results in the fading of hepatocyte phenotype in PDHs. The expression of seven DEGs associated with tight junction formation (JAM3, PPP2R2B, PRKAR1B, PPP2R2C, MAGI2, ACTA2 and ACTG2) was up-regulated after short-term culture in vitro, which was attenuated in the presence of DMSO. Those results could shed light on DHBV infection associated molecular events affected by DMSO.
C1 [Yan, Liang; Qu, Su; Xie, Youhua; Zhang, Junqi; Qu, Di] Fudan Univ, Key Lab Med Mol Virol, Minist Educ & Hlth, Sch Basic Med Sci, Shanghai 200433, Peoples R China.
   [Qu, Su] Fudan Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Shanghai 200433, Peoples R China.
   [Liu, Gang; Liu, Lei; Yu, Yao; Ding, Guohui; Li, Yixue] Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Syst Biol, Shanghai, Peoples R China.
   [Zhao, Yanfeng] Nanjing Med Univ, Affiliated Hosp 2, Dept Lab Med, Nanjing, Jiangsu, Peoples R China.
RP Xie, YH; Zhang, JQ; Qu, D (reprint author), Fudan Univ, Key Lab Med Mol Virol, Minist Educ & Hlth, Sch Basic Med Sci, Shanghai 200433, Peoples R China.
EM yhxie@fudan.edu.cn; junqizhang@fudan.edu.cn; dqu@shmu.edu.cn
FU National Key Project for Infectious Diseases [2012ZX10002002,
   2012ZX10003008-010, 2012ZX10002-006, 2012ZX10002012-003]; National Basic
   Research Program [2012CB519002]; Key Project Supported by Medical
   Science and Technology Development Foundation, Nanjing Department of
   Health [YKK12198]
FX This work was supported by grants from the National Key Project for
   Infectious Diseases (2012ZX10002002; 2012ZX10003008-010,
   2012ZX10002-006, 2012ZX10002012-003, http://www.nmp.gov.cn), National
   Basic Research Program (2012CB519002) and Key Project Supported by
   Medical Science and Technology Development Foundation, Nanjing
   Department of Health (YKK12198).
CR CONDREAY LD, 1990, J VIROL, V64, P3249
   EZZELL RM, 1993, EXP CELL RES, V208, P442, DOI 10.1006/excr.1993.1266
   Funk A, 2004, J VIROL, V78, P8289, DOI 10.1128/jvi.78.15.8289-8300.2004
   Funk A, 2006, HEPATOLOGY, V44, P685, DOI 10.1002/hep.21297
   GRIPON P, 1988, J VIROL, V62, P4136
   KOST DP, 1991, J CELL PHYSIOL, V147, P274, DOI 10.1002/jcp.1041470212
   Lavanchy D, 2005, J CLIN VIROL, V34, pS1, DOI 10.1016/S1386-6532(05)00384-7
   Li J, 2004, J VIROL, V78, P1873, DOI 10.1128/JVI.78.4.1873-1881.2004
   Li JS, 1999, J BIOL CHEM, V274, P27658, DOI 10.1074/jbc.274.39.27658
   Locarnini S, 2013, HEPATOLOGY
   LUSTBADER ED, 1983, SCIENCE, V220, P423, DOI 10.1126/science.6301008
   PUGH JC, 1995, J VIROL, V69, P4814
   PUGH JC, 1989, VIROLOGY, V172, P564, DOI 10.1016/0042-6822(89)90199-2
   Qiao M, 1999, J GEN VIROL, V80, P2127, DOI 10.1099/0022-1317-80-8-2127
   Schulze A, 2012, HEPATOLOGY, V55, P373, DOI 10.1002/hep.24707
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   Tohidi-Esfahani R, 2010, J GEN VIROL, V91, P509, DOI 10.1099/vir.0.015529-0
   Tong YP, 2010, J VIROL, V84, P4569, DOI 10.1128/JVI.02281-09
   TUTTLEMAN JS, 1986, J VIROL, V58, P17
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zhao YF, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-28
NR 21
TC 2
Z9 2
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 22
PY 2016
VL 11
IS 2
AR e0149702
DI 10.1371/journal.pone.0149702
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF3VL
UT WOS:000371276100130
PM 26900848
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Petropolis, DB
   Faust, DM
   Tolle, M
   Riviere, L
   Valentin, T
   Neuveut, C
   Hernandez-Cuevas, N
   Dufour, A
   Olivo-Marin, JC
   Guillen, N
AF Petropolis, Debora B.
   Faust, Daniela M.
   Tolle, Matthieu
   Riviere, Lise
   Valentin, Tanguy
   Neuveut, Christine
   Hernandez-Cuevas, Nora
   Dufour, Alexandre
   Olivo-Marin, Jean-Christophe
   Guillen, Nancy
TI Human Liver Infection in a Dish: Easy-To-Build 3D Liver Models for
   Studying Microbial Infection
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-B; ENTAMOEBA-HISTOLYTICA; IN-VITRO; VIRUS-REPLICATION;
   X-PROTEIN; CELLS; CULTURE; SYSTEM; ENTRY; NTCP
AB Human liver infection is a major cause of death worldwide, but fundamental studies on infectious diseases affecting humans have been hampered by the lack of robust experimental models that accurately reproduce pathogen-host interactions in an environment relevant for the human disease. In the case of liver infection, one consequence of this absence of relevant models is a lack of understanding of how pathogens cross the sinusoidal endothelial barrier and parenchyma. To fill that gap we elaborated human 3D liver in vitro models, composed of human liver sinusoidal endothelial cells (LSEC) and Huh-7 hepatoma cells as hepatocyte model, layered in a structure mimicking the hepatic sinusoid, which enable studies of key features of early steps of hepatic infection. Built with established cell lines and scaffold, these models provide a reproducible and easy-to-build cell culture approach of reduced complexity compared to animal models, while preserving higher physiological relevance compared to standard 2D systems. For proof-of-principle we challenged the models with two hepatotropic pathogens: the parasitic amoeba Entamoeba histolytica and hepatitis B virus (HBV). We constructed four distinct setups dedicated to investigating specific aspects of hepatic invasion: 1) pathogen 3D migration towards hepatocytes, 2) hepatocyte barrier crossing, 3) LSEC and subsequent hepatocyte crossing, and 4) quantification of human hepatic virus replication (HBV). Our methods comprise automated quantification of E. histolytica migration and hepatic cells layer crossing in the 3D liver models. Moreover, replication of HBV virus occurs in our virus infection 3D liver model, indicating that routine in vitro assays using HBV or others viruses can be performed in this easy-to-build but more physiological hepatic environment. These results illustrate that our new 3D liver infection models are simple but effective, enabling new investigations on infectious disease mechanisms. The better understanding of these mechanisms in a human-relevant environment could aid the discovery of drugs against pathogenic liver infection.
C1 [Petropolis, Debora B.; Faust, Daniela M.; Tolle, Matthieu; Valentin, Tanguy; Hernandez-Cuevas, Nora; Guillen, Nancy] Inst Pasteur, INSERM, U786, Cell Biol Parasitism Unit,BCI, F-75724 Paris, France.
   [Riviere, Lise; Neuveut, Christine] Inst Pasteur, Dept Virol, Hepaciviruses & Innate Immun Unit, Paris, France.
   [Petropolis, Debora B.; Dufour, Alexandre; Olivo-Marin, Jean-Christophe; Guillen, Nancy] Inst Pasteur, BCI, Quantitat Image Anal, Paris, France.
RP Petropolis, DB (reprint author), Inst Pasteur, INSERM, U786, Cell Biol Parasitism Unit,BCI, F-75724 Paris, France.; Petropolis, DB (reprint author), Inst Pasteur, BCI, Quantitat Image Anal, Paris, France.
EM petropolis.debora@gmail.com
FU National French Research Agency [ANR-2010-GENM-0011-01]; French
   Parasitology consortium Labex ParaFrap [ANR-11-LABX0024]; DIM Ile de
   France
FX The work was funded by the National French Research Agency
   (ANR-2010-GENM-0011-01, GENAMIBE), the French Parasitology consortium
   Labex ParaFrap (grant ANR-11-LABX0024). The authors wanted to
   acknowledge the generous support of "DIM Ile de France" for the
   Two-photon microscope acquirement and for the fellowship to D.
   Petropolis. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Bale SS, 2015, TISSUE ENG PART C-ME, V21, P413, DOI [10.1089/ten.tec.2014.0152, 10.1089/ten.TEC.2014.0152]
   Bale SS, 2014, EXP BIOL MED, V239, P1180, DOI 10.1177/1535370214531872
   Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989
   CHEN HS, 1993, J VIROL, V67, P1218
   de Chaumont F, 2012, NAT METHODS, V9, P690, DOI [10.1038/NMETH.2075, 10.1038/nmeth.2075]
   DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X
   Faust DM, 2012, MICROBES INFECT, V14, P1428, DOI 10.1016/j.micinf.2012.05.013
   Faust DM, 2011, CELL MICROBIOL, V13, P1091, DOI 10.1111/j.1462-5822.2011.01604.x
   Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699
   Gunness P, 2013, TOXICOL SCI, V133, P67, DOI 10.1093/toxsci/kft021
   Jenne CN, 2013, NAT IMMUNOL, V14, P996, DOI 10.1038/ni.2691
   Keasler VV, 2007, J VIROL, V81, P2656, DOI 10.1128/JVI.02020-06
   Kim Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015456
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Lucifora J, 2011, J HEPATOL, V55, P996, DOI 10.1016/j.jhep.2011.02.015
   Mathur A, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt375
   Ng S, 2015, STEM CELL REP, V4, P1
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Nkongolo S, 2014, J HEPATOL, V60, P723, DOI 10.1016/j.jhep.2013.11.022
   Petropolis DB, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004381
   Petropolis DB, 2014, PEERJ, V2, DOI 10.7717/peerj.317
   Protzer U, 2012, NAT REV IMMUNOL, V12, P201, DOI 10.1038/nri3169
   Sainz B, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-103
   Salmon P, 2000, MOL THER, V2, P404, DOI 10.1006/mthe.2000.0141
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Watashi K, 2014, INT J MOL SCI, V15, P2892, DOI 10.3390/ijms15022892
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
NR 27
TC 6
Z9 6
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 10
PY 2016
VL 11
IS 2
AR e0148667
DI 10.1371/journal.pone.0148667
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DD6PR
UT WOS:000370046600095
PM 26863526
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Zhang, YY
AF Zhang, Yong-Yuan
TI Duck Hepatitis B Virus cccDNA Amplification Efficiency in Natural
   Infection Is Regulated by Virus Secretion Efficiency
SO PLOS ONE
LA English
DT Article
ID CLOSED CIRCULAR DNA; AVIAN HEPADNAVIRUS; ENVELOPE PROTEINS; VIRAL-DNA;
   GENOME; REPLICATION; LIVER; HEPATOCYTES; THERAPY; INTERMEDIATE
AB Previous mutation based studies showed that ablating synthesis of viral envelope proteins led to elevated hepadnaviral covalently closed circular DNA (cccDNA) amplification, but it remains unknown how cccDNA amplification is regulated in natural hepadnaviral infection because of a lack of research system. In this study we report a simple procedure to prepare two identical duck hepatitis B virus inocula, but they possess 10-100-fold difference in cccDNA amplification in infected cell culture. We demonstrate that the infected cells with higher cccDNA amplification significantly reduce the virus secretion efficiency that results in higher accumulation of relaxed circular DNA (rcDNA) and DHBsAg in the cells. The infected cells with lower cccDNA amplification significantly increase the virus secretion efficiency that leads to lower intracellular rcDNA and DHBsAg accumulation. In contrast with the findings generated in the mutation based experimental system, the regulation of cccDNA amplification in natural hepadnaviral infection bypasses direct regulation of the cellular envelope proteins concentration, instead it modulates virus secretion efficiency that ultimately impacts the intracellular rcDNA concentration, an important factor determining the destination of the synthesized rcDNA in infected cells.
C1 [Zhang, Yong-Yuan] HBVtech, Germantown, MD 20874 USA.
RP Zhang, YY (reprint author), HBVtech, Germantown, MD 20874 USA.
EM yongyuanzhang50@gmail.com
CR BARTENSCHLAGER R, 1990, J VIROL, V64, P5324
   Bourne EJ, 2007, J VIRAL HEPATITIS, V14, P55, DOI 10.1111/j.1365-2893.2006.00775.x
   Funk A, 2004, J VIROL, V78, P8289, DOI 10.1128/jvi.78.15.8289-8300.2004
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   Gao WF, 2007, J VIROL, V81, P6164, DOI 10.1128/JVI.02721-06
   Gerlich WH, 2007, J VIRAL HEPATITIS, V14, P16, DOI 10.1111/j.1365-2893.2007.00912.x
   Ghany MG, 2012, ALIMENT PHARM THER, V35, P1027, DOI 10.1111/j.1365-2036.2012.05059.x
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   HADZIYANNIS S, 1973, ARCH PATHOL, V96, P327
   HEERMANN KH, 1984, J VIROL, V52, P396
   Kwon H, 2011, NAT REV GASTRO HEPAT, V8, P275, DOI 10.1038/nrgastro.2011.33
   Lee JM, 2011, HEPATOLOGY, V53, P1486, DOI 10.1002/hep.24221
   Lenhoff RJ, 1999, HEPATOLOGY, V29, P563, DOI 10.1002/hep.510290236
   LENHOFF RJ, 1994, J VIROL, V68, P5706
   Lenhoff RJ, 1998, VIROLOGY, V251, P85, DOI 10.1006/viro.1998.9394
   LENHOFF RJ, 1994, J VIROL, V68, P4565
   Lentz TB, 2011, J VIROL, V85, P11916, DOI 10.1128/JVI.05373-11
   MANDART E, 1984, J VIROL, V49, P782
   MASON WS, 1983, VIROLOGY, V131, P375, DOI 10.1016/0042-6822(83)90505-6
   Miller Darren S, 2004, Methods Mol Med, V96, P3
   MILLER RH, 1989, HEPATOLOGY, V9, P322, DOI 10.1002/hep.1840090226
   MILLER RH, 1984, VIROLOGY, V137, P390, DOI 10.1016/0042-6822(84)90231-9
   PUGH JC, 1995, J VIROL, V69, P4814
   SEEGER C, 1986, SCIENCE, V232, P477, DOI 10.1126/science.3961490
   SUMMERS J, 1981, HEPATOLOGY, V1, P179, DOI 10.1002/hep.1840010215
   SUMMERS J, 1990, J VIROL, V64, P2819
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   SUMMERS J, 1991, J VIROL, V65, P1310
   SUMMERS J, 1975, P NATL ACAD SCI USA, V72, P4597, DOI 10.1073/pnas.72.11.4597
   TUTTLEMAN JS, 1986, J VIROL, V58, P17
   TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1
   Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018
   WU TT, 1990, VIROLOGY, V175, P255, DOI 10.1016/0042-6822(90)90206-7
   Wursthorn K, 2006, HEPATOLOGY, V44, P675, DOI 10.1002/hep.21282
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zhang YY, 2000, J VIROL, V74, P5257, DOI 10.1128/JVI.74.11.5257-5265.2000
   Zhang YY, 2005, J VIROL, V79, P9896, DOI 10.1128/JVI.79.15.9896-9903.2005
   Zhang YY, 1999, J VIROL, V73, P3616
   Zhang YZ, 2003, P NATL ACAD SCI USA, V100, P12372, DOI 10.1073/pnas.2033898100
   Zhu Y, 2001, J VIROL, V75, P311, DOI 10.1128/JVI.75.1.311-322.2001
NR 40
TC 0
Z9 0
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 29
PY 2015
VL 10
IS 12
AR e0145465
DI 10.1371/journal.pone.0145465
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DA0IX
UT WOS:000367481900045
PM 26713436
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Cheng, X
   Guan, WW
   Sun, S
   Li, BS
   Li, HJ
   Kang, FB
   Kang, JW
   Yang, DL
   Nassal, M
   Sun, DX
AF Cheng, Xin
   Guan, Weiwei
   Sun, Shuo
   Li, Baosheng
   Li, Haijun
   Kang, Fubiao
   Kang, Jiwen
   Yang, Dongliang
   Nassal, Michael
   Sun, Dianxing
TI Stable Human Hepatoma Cell Lines for Efficient Regulated Expression of
   Nucleoside/Nucleotide Analog Resistant and Vaccine Escape Hepatitis B
   Virus Variants and Woolly Monkey Hepatitis B Virus
SO PLOS ONE
LA English
DT Article
ID PRIMARY TUPAIA HEPATOCYTES; SURFACE-ANTIGEN VARIANTS; CIRCULAR DNA
   FORMATION; ARGININE-RICH DOMAIN; DRUG-RESISTANT; HEPG2 CELLS; P-PROTEIN;
   RECOMBINANT BACULOVIRUS; REVERSE-TRANSCRIPTASE; COMMON STRUCTURE
AB Hepatitis B virus (HBV) causes acute and chronic hepatitis B (CHB). Due to its error-prone replication via reverse transcription, HBV can rapidly evolve variants that escape vaccination and/or become resistant to CHB treatment with nucleoside/nucleotide analogs (NAs). This is particularly problematic for the first generation NAs lamivudine and adefovir. Though now superseded by more potent NAs, both are still widely used. Furthermore, resistance against the older NAs can contribute to cross-resistance against more advanced NAs. For lack of feasible HBV infection systems, the biology of such variants is not well understood. From the recent discovery of Na+-taurocholate cotransporting polypeptide (NTCP) as an HBV receptor new in vitro infection systems are emerging, yet access to the required large amounts of virions, in particular variants, remains a limiting factor. Stably HBV producing cell lines address both issues by allowing to study intracellular viral replication and as a permanent source of defined virions. Accordingly, we generated a panel of new tetracycline regulated TetOFF HepG2 hepatoma cell lines which produce six lamivudine and adefovir resistance-associated and two vaccine escape variants of HBV as well as the model virus woolly monkey HBV (WMHBV). The cell line-borne viruses reproduced the expected NA resistance profiles and all were equally sensitive against a non-NA drug. The new cell lines should be valuable to investigate under standardized conditions HBV resistance and cross-resistance. With titers of secreted virions reaching >3x10(7) viral genome equivalents per ml they should also facilitate exploitation of the new in vitro infection systems.
C1 [Cheng, Xin; Guan, Weiwei; Sun, Shuo; Li, Baosheng; Li, Haijun; Kang, Fubiao; Kang, Jiwen; Sun, Dianxing] Bethune Int Peace Hosp, Liver Dis Diag & Treatment Ctr PLA, Shijiazhuang, Peoples R China.
   [Sun, Shuo] Troop 66220 PLA, Xingtai, Xingtai Of Hebe, Peoples R China.
   [Yang, Dongliang] Huazhong Univ Sci & Technol, Dept Infect Dis, Union Hosp, Tongji Med Coll, Wuhan 430074, Peoples R China.
   [Nassal, Michael] Univ Hosp Freiburg, Dept Internal Med Mol Biol 2, Freiburg, Germany.
RP Nassal, M (reprint author), Univ Hosp Freiburg, Dept Internal Med Mol Biol 2, Freiburg, Germany.
EM nassal2@ukl.uni-freiburg.de; sundianxing@hotmail.com
OI Nassal, Michael/0000-0003-2204-9158
FU National Major Science and Technology Special Project for Infectious
   Diseases of China [2012ZX10004503-012, 2008ZX10002-011]; European
   Commission
FX This work was supported by the National Major Science and Technology
   Special Project for Infectious Diseases of China (2012ZX10004503-012,
   2008ZX10002-011). Initial experiments were supported by the European
   Commission through project HepBvar. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amini-Bavil-Olyaee S, 2010, J VIROL, V84, P1026, DOI 10.1128/JVI.01796-09
   Bartholomeusz A, 2004, ANTIVIR THER, V9, P149
   Beck J, 2002, NUCLEIC ACIDS RES, V30, P1679, DOI 10.1093/nar/30.7.1679
   Beck J, 2007, WORLD J GASTROENTERO, V13, P48, DOI 10.3748/wjg.v13.i1.48
   Beck J, 2011, J VIROL, V85, P7742, DOI 10.1128/JVI.00482-11
   Bellecave P, 2009, HEPATOLOGY, V50, P46, DOI 10.1002/hep.22951
   BIRNBAUM F, 1990, J VIROL, V64, P3319
   Brezillon N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025096
   Brunelle MN, 2005, HEPATOLOGY, V41, P1391, DOI 10.1002/hep20723
   Carman WF, 1999, J HEPATOL, V31, P195, DOI 10.1016/S0168-8278(99)80213-X
   Carman WF, 1997, J VIRAL HEPATITIS, V4, P11, DOI 10.1111/j.1365-2893.1997.tb00155.x
   Chevaliez S, 2013, J HEPATOL, V58, P676, DOI 10.1016/j.jhep.2012.11.039
   Chotiyaputta W, 2009, NAT REV GASTRO HEPAT, V6, P453, DOI 10.1038/nrgastro.2009.107
   Christen V, 2007, J VIROL, V81, P159, DOI 10.1128/JVI.01292-06
   Dallmeier K, 2008, ADV INFECT DIS
   Das K, 2001, J VIROL, V75, P4771, DOI 10.1128/JVI.75.10.4771-4779.2001
   Delaney WE, 1998, HEPATOLOGY, V28, P1134, DOI 10.1002/hep.510280432
   Deres K, 2003, SCIENCE, V299, P893, DOI 10.1126/science.1077215
   Gehring AJ, 2007, J VIROL, V81, P2940, DOI 10.1128/JVI.02415-06
   Glebe D, 2005, GASTROENTEROLOGY, V129, P234, DOI 10.1053/j.gastro.2005.03.090
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   Ireland JH, 2000, HEPATOLOGY, V31, P1176, DOI 10.1053/he.2000.6407
   Iwamoto M, 2014, BIOCHEM BIOPH RES CO, V443, P808, DOI 10.1016/j.bbrc.2013.12.052
   Kamili S, 2009, HEPATOLOGY, V49, P1483, DOI 10.1002/hep.22796
   Kock J, 2001, J VIROL, V75, P5084, DOI 10.1128/JVI.75.11.5084-5089.2001
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Ladner SK, 1998, ANTIVIR CHEM CHEMOTH, V9, P65
   Lanford RE, 2003, J VIROL, V77, P7814, DOI 10.1128/JVI.77.14.7814-7819.2003
   Le Pogam S, 2005, J VIROL, V79, P1871, DOI 10.1128/JVI.79.3.1871-1887.2005
   Liu JX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053392
   Lo AOS, 2014, EXPERT REV GASTROENT, V8, P607, DOI 10.1586/17474124.2014.909724
   Locarnini SA, 2010, ANTIVIR THER, V15, P451, DOI 10.3851/IMP1499
   Lucifora J, 2008, J GEN VIROL, V89, P1819, DOI 10.1099/vir.0.83659-0
   Lucifora J, 2010, HEPATOLOGY, V51, P63, DOI 10.1002/hep.23230
   Marion MJ, 2010, METHODS MOL BIOL, V640, P261, DOI 10.1007/978-1-60761-688-7_13
   NASSAL M, 1992, J VIROL, V66, P4107
   Nassal M, 2008, VIRUS RES, V134, P235, DOI 10.1016/j.virusres.2007.12.024
   Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809
   Nassal M, 2009, FUTURE VIROL, V4, P55, DOI 10.2217/17460794.4.1.55
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Papatheodoridis G, 2012, J HEPATOL, V57, P167, DOI 10.1016/j.jhep.2012.02.010
   PASEK M, 1979, NATURE, V282, P575, DOI 10.1038/282575a0
   Petersen J, 2008, NAT BIOTECHNOL, V26, P335, DOI 10.1038/nbt1389
   Prange R, 2012, MED MICROBIOL IMMUN, V201, P449, DOI 10.1007/s00430-012-0267-9
   Protzer-Knolle U, 1998, HEPATOLOGY, V27, P254, DOI 10.1002/hep.510270138
   Qi XP, 2007, ANTIVIR THER, V12, P355
   Ren ST, 2001, J VIROL, V75, P1104, DOI 10.1128/JVI.75.3.1104-1116.2001
   Rodgers MA, 2009, J AM CHEM SOC, V131, P5030, DOI 10.1021/ja809949r
   Schonig K, 2010, METHOD ENZYMOL, V477, P429, DOI 10.1016/S0076-6879(10)77022-1
   Seigneres B, 2002, HEPATOLOGY, V36, P710, DOI 10.1053/jhep.2002.35070
   SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005
   SERWER P, 1995, J CHROMATOGR A, V698, P251, DOI 10.1016/0021-9673(94)01259-H
   Stray SJ, 2006, J MOL RECOGNIT, V19, P542, DOI 10.1002/jmr.801
   Stuyver LJ, 2001, HEPATOLOGY, V33, P751, DOI 10.1053/jhep.2000.22166
   Sun DX, 2006, J HEPATOL, V45, P636, DOI 10.1016/j.jhep.2006.05.019
   Sun DX, 2010, J HEPATOL, V52, P817, DOI 10.1016/j.jhep.2009.10.038
   Sureau C, 2013, HEPATOLOGY, V57, P985, DOI 10.1002/hep.26125
   Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8
   Villet S, 2008, J HEPATOL, V48, P747, DOI 10.1016/j.jhep.2008.01.027
   Walker A, 2011, SCI REP-UK, V1, DOI 10.1038/srep00005
   Wang TZ, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-231
   Wang YX, 2012, J VIROL, V86, P6394, DOI 10.1128/JVI.00011-12
   Wang ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060306
   Warner N, 2008, HEPATOLOGY, V48, P88, DOI 10.1002/hep.22295
   Weinberger KM, 2000, J VIROL METHODS, V85, P75, DOI 10.1016/S0166-0934(99)00154-8
   Xu CX, 2010, J VIROL, V84, P9332, DOI 10.1128/JVI.00918-10
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zeisel MB, 2015, GUT
   Zhang MS, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-292
   Zhao R, 2011, WORLD J GASTROENTERO, V17, P1152, DOI 10.3748/wjg.v17.i9.1152
   Zhong GC, 2013, J VIROL, V87, P7176, DOI 10.1128/JVI.03533-12
   Zhu Y, 2007, J CLIN MICROBIOL, V45, P3335, DOI 10.1128/JCM.00272-07
   Zidek Zdenek, 2005, Biomedical Papers (Olomouc), V149, P315
   Zoulim F, 2015, COLD SPRING HARB PER, V5
   Zoulim F, 2009, GASTROENTEROLOGY, V137, P1593, DOI 10.1053/j.gastro.2009.08.063
NR 75
TC 1
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 23
PY 2015
VL 10
IS 12
AR e0145746
DI 10.1371/journal.pone.0145746
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ4SI
UT WOS:000367092600127
PM 26699621
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Cui, XJ
   McAllister, R
   Boregowda, R
   Sohn, JA
   Ledesma, FC
   Caldecott, KW
   Seeger, C
   Hu, JM
AF Cui, Xiuji
   McAllister, Rebecca
   Boregowda, Rajeev
   Sohn, Ji A.
   Cortes Ledesma, Felipe
   Caldecott, Keith W.
   Seeger, Christoph
   Hu, Jianming
TI Does Tyrosyl DNA Phosphodiesterase-2 Play a Role in Hepatitis B Virus
   Genome Repair?
SO PLOS ONE
LA English
DT Article
ID CLOSED CIRCULAR DNA; HEPADNAVIRUS REVERSE-TRANSCRIPTASE; ENVELOPE
   PROTEINS; COVALENT COMPLEXES; VIRAL-DNA; IN-VITRO; CELLS; TDP2;
   REPLICATION; POLYMERASE
AB Hepatitis B virus (HBV) replication and persistence are sustained by a nuclear episome, the covalently closed circular (CCC) DNA, which serves as the transcriptional template for all viral RNAs. CCC DNA is converted from a relaxed circular (RC) DNA in the virion early during infection as well as from RC DNA in intracellular progeny nucleocapsids via an intracellular amplification pathway. Current antiviral therapies suppress viral replication but cannot eliminate CCC DNA. Thus, persistence of CCC DNA remains an obstacle toward curing chronic HBV infection. Unfortunately, very little is known about how CCC DNA is formed. CCC DNA formation requires removal of the virally encoded reverse transcriptase (RT) protein from the 5' end of the minus strand of RC DNA. Tyrosyl DNA phosphodiesterase-2 (Tdp2) was recently identified as the enzyme responsible for cleavage of tyrosyl-5' DNA linkages formed between topoisomerase II and cellular DNA. Because the RT-DNA linkage is also a 5' DNA-phosphotyrosyl bond, it has been hypothesized that Tdp2 might be one of several elusive host factors required for CCC DNA formation. Therefore, we examined the role of Tdp2 in RC DNA deproteination and CCC DNA formation. We demonstrated Tdp2 can cleave the tyrosyl-minus strand DNA linkage using authentic HBV RC DNA isolated from nucleocapsids and using RT covalently linked to short minus strand DNA produced in vitro. On the other hand, our results showed that Tdp2 gene knockout did not block CCC DNA formation during HBV infection of permissive human hepatoma cells and did not prevent intracellular amplification of duck hepatitis B virus CCC DNA. These results indicate that although Tdp2 can remove the RT covalently linked to the 5' end of the HBV minus strand DNA in vitro, this protein might not be required for CCC DNA formation in vivo.
C1 [Cui, Xiuji; McAllister, Rebecca; Boregowda, Rajeev; Hu, Jianming] Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.
   [Sohn, Ji A.; Seeger, Christoph] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   [Cortes Ledesma, Felipe] CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Seville 41092, Spain.
   [Caldecott, Keith W.] Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.
RP Hu, JM (reprint author), Penn State Univ, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.
EM juh13@psu.edu
RI Cortes Ledesma, Felipe/F-4803-2014; Caldecott, Keith/S-4245-2019
OI Cortes Ledesma, Felipe/0000-0002-0440-6783; 
FU National Institutes of Health [R01 AI074982, R21 AI101558, T32
   CA060395]; Cancer Research UK [16771]
FX Funding for this work came from the National Institutes of Health,
   http://www.nih.gov, R01 AI074982 to JH, R21 AI101558 to CS, and T32
   CA060395 to RM. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Boregowda RK, 2011, J VIROL, V85, P7754, DOI 10.1128/JVI.00483-11
   Gao R, 2014, J BIOL CHEM, V289, P17960, DOI 10.1074/jbc.M114.565374
   Gao WF, 2007, J VIROL, V81, P6164, DOI 10.1128/JVI.02721-06
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   Hantz O, 2009, J GEN VIROL, V90, P127, DOI 10.1099/vir.0.004861-0
   Hu J, 2015, COLD SPRING HARB PER
   Jones SA, 2013, J VIROL, V87, P2563, DOI 10.1128/JVI.02786-12
   Jones SA, 2012, J VIROL, V86, P5134, DOI 10.1128/JVI.07137-11
   Kock J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001082
   Koniger C, 2014, P NATL ACAD SCI USA, V111, pE4244, DOI 10.1073/pnas.1409986111
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Ledesma FC, 2009, NATURE, V461, P674, DOI 10.1038/nature08444
   Lentz TB, 2011, J VIROL, V85, P11916, DOI 10.1128/JVI.05373-11
   Lin CP, 2009, J BIOL CHEM, V284, P28084, DOI 10.1074/jbc.M109.030601
   Lin L, 2008, J VIROL, V82, P2305, DOI 10.1128/JVI.02147-07
   Litwin S, 2005, J CLIN VIROL, V34, pS96, DOI 10.1016/S1386-6532(05)80018-6
   Nguyen DH, 2007, J VIROL, V81, P4465, DOI 10.1128/JVI.02510-06
   Ning XJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002255
   Pommier Y, 2014, DNA REPAIR, V19, P114, DOI 10.1016/j.dnarep.2014.03.020
   Raney AK, 2001, J VIROL, V75, P2900, DOI 10.1128/JVI.75.6.2900-2911.2001
   Schellenberg MJ, 2012, NAT STRUCT MOL BIOL, V19, P1363, DOI 10.1038/nsmb.2418
   Seeger C., 2013, FIELDS VIROLOGY, P2185
   Seeger C, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.68
   Shi K, 2012, NAT STRUCT MOL BIOL, V19, P1372, DOI 10.1038/nsmb.2423
   Sohn JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008093
   SUMMERS J, 1990, J VIROL, V64, P2819
   SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X
   SUMMERS J, 1991, J VIROL, V65, P1310
   Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8
   TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1
   WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8
   Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831
   Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981
   Wang XT, 2003, J VIROL, V77, P4471, DOI 10.1128/JVI.77.8.4471-4480.2003
   WEBER M, 1994, J VIROL, V68, P2994
   WU TT, 1990, VIROLOGY, V175, P255, DOI 10.1016/0042-6822(90)90206-7
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zeng ZH, 2011, J BIOL CHEM, V286, P403, DOI 10.1074/jbc.M110.181016
   Zhang AL, 2006, J BIOL CHEM, V281, P35997, DOI 10.1074/jbc.M604149200
   Zhang YZ, 2003, P NATL ACAD SCI USA, V100, P12372, DOI 10.1073/pnas.2033898100
   ZOULIM F, 1994, J VIROL, V68, P6
NR 41
TC 30
Z9 31
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 16
PY 2015
VL 10
IS 6
AR e0128401
DI 10.1371/journal.pone.0128401
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK9EB
UT WOS:000356542300010
PM 26079492
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Ye, L
   Yu, HS
   Li, CW
   Hirsch, ML
   Zhang, LG
   Samulski, RJ
   Li, WP
   Liu, Z
AF Ye, Lei
   Yu, Haisheng
   Li, Chengwen
   Hirsch, Matthew L.
   Zhang, Liguo
   Samulski, R. Jude
   Li, Wuping
   Liu, Zhong
TI Adeno-Associated Virus Vector Mediated Delivery of the HBV Genome
   Induces Chronic Hepatitis B Virus Infection and Liver Fibrosis in Mice
SO PLOS ONE
LA English
DT Article
ID TAUROCHOLATE COTRANSPORTING POLYPEPTIDE; CHRONIC VIRAL-HEPATITIS;
   TRANSGENIC MICE; SURFACE-ANTIGEN; MOUSE MODEL; TUPAIA HEPATOCYTES;
   CARRIER STATE; T-LYMPHOCYTE; IN-VITRO; EXPRESSION
AB Liver cirrhosis and hepatocellular carcinomas are major health problems of chronic hepatitis B virus (HBV) infection. To date, rare model has reproduced liver fibrosis associated with long-term HBV infection which in turn has hindered both the understanding of HBV biology and the development of new treatment options. Here, using adeno-associated virus serotype 8 (AAV8) mediated delivery of a 1.2-kb HBV genome, we successfully generated a chronic HBV infectious mouse model that presents the associated liver fibrosis observed following human infection. After AAV8/HBV1.2 vector administration, mice demonstrated effective HBV replication and transcription which resulted in HBV antigen expression and viremia over 6 months. Although no obvious acute inflammatory response was noted, these mice still developed chronic liver disease and hepatic fibrogenesis as demonstrated by increased ground glass-like hepatocytes, an increasing trend of collagen deposition and upregulated fibrosis markers, including type I collagen, type III collagen, tissue inhibitor of metalloproteinase (TIMP), and transforming growth factor-beta 1(TGF-beta 1). Taken together, AAV-mediated HBV gene delivery to the mouse liver, induced HBV persistent infection accompanied by liver fibrosis which can serve as a model for investigating the precise mechanisms underlying liver fibrosis following chronic HBV infection as well as for the potential development of novel therapeutics.
C1 [Ye, Lei; Li, Wuping; Liu, Zhong] Chinese Acad Med Sci, Inst Blood Transfus, Chengdu, Peoples R China.
   [Ye, Lei; Li, Wuping; Liu, Zhong] Peking Union Med Coll, Chengdu, Peoples R China.
   [Yu, Haisheng; Zhang, Liguo] Chinese Acad Sci, Inst Biophys, Key Lab Immun & Infect, Beijing 100080, Peoples R China.
   [Li, Chengwen; Hirsch, Matthew L.; Samulski, R. Jude] Univ N Carolina, Dept Pharmacol, Gene Therapy Ctr, Chapel Hill, NC USA.
   [Li, Wuping] Chinese Acad Med Sci, Inst Pathogen Biol, MOH Key Lab Syst Biol Pathogens, Chengdu, Peoples R China.
RP Li, WP (reprint author), Chinese Acad Med Sci, Inst Blood Transfus, Chengdu, Peoples R China.
EM lwpzhr@sina.com
OI zhang, li guo/0000-0002-9795-0314
FU Peking Union Medical College graduated student innovation fund
   [2011-1001-033]; Institute of Pathogen Biology, Chinese Academy of
   Medical Sciences [2011IPB106]
FX Peking Union Medical College graduated student innovation fund,
   2011-1001-033, LY. The basic grant of Institute of Pathogen Biology,
   Chinese Academy of Medical Sciences, 2011IPB106, WPL.
CR ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207
   ARTHUR MJP, 1995, J HEPATOL, V22, P43
   BARKER LF, 1973, J INFECT DIS, V127, P648, DOI 10.1093/infdis/127.6.648
   Barrera A, 2005, J VIROL, V79, P9786, DOI 10.1128/JVI.79.15.9786-9798.2005
   Baumert TF, 2005, HEPATOLOGY, V41, P247, DOI 10.1002/hep.20553
   Bedossa P, 2003, J PATHOL, V200, P504, DOI 10.1002/path.1397
   Bertoni R, 1998, J IMMUNOL, V161, P4447
   Bility MT, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004032
   BRATTIG NW, 1983, HEPATOLOGY, V3, P638
   Brunetto MR, 2013, J HEPATOL, V59, P1153, DOI [10.1016/j.jhep.2013.07.017, 10.1016/j.jhep.2013.09.005]
   CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369
   CHISARI FV, 1995, HEPATOLOGY, V22, P1316, DOI 10.1016/0270-9139(95)90645-2
   CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909
   Constandinou C, 2005, METH MOLEC MED, V117, P237
   Dion S, 2013, J VIROL, V87, P5554, DOI 10.1128/JVI.03134-12
   Dong QM, 2009, J VIROL METHODS, V159, P135, DOI 10.1016/j.jviromet.2009.03.012
   DUSHEIKO GM, 1983, J CLIN INVEST, V71, P1104, DOI 10.1172/JCI110860
   Eng FJ, 2000, AM J PHYSIOL-GASTR L, V279, pG7
   FERNAN A, 1989, CLIN EXP IMMUNOL, V76, P222
   GERBER MA, 1974, AM J PATHOL, V75, P489
   GERBER MA, 1974, P SOC EXP BIOL MED, V145, P863
   GUIDOTTI LG, 1995, J VIROL, V69, P6158
   Gutierrez-Reyes G, 2007, ARCH MED RES, V38, P644, DOI 10.1016/j.arcmed.2006.10.001
   HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424
   Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507
   Huang LR, 2006, P NATL ACAD SCI USA, V103, P17862, DOI 10.1073/pnas.0608578103
   Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542
   Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1053/jhep.1996.v24.pm0008707259
   Isogawa M, 2005, VIROLOGY, V333, P293, DOI 10.1016/j.virol.2005.01.004
   Ke L, 2011, TRANSFUSION, V51, P1909, DOI 10.1111/j.1537-2995.2011.03067.x
   KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0
   Kim H, 2008, RADIOLOGY, V247, P696, DOI 10.1148/radiol.2473070605
   KNITTEL T, 1992, GASTROENTEROLOGY, V102, P1724, DOI 10.1016/0016-5085(92)91736-N
   Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201
   Lalazar A, 1997, GENE, V195, P235, DOI 10.1016/S0378-1119(97)00159-5
   Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   MABIT H, 1994, J GEN VIROL, V75, P2681, DOI 10.1099/0022-1317-75-10-2681
   McMahon BJ, 2001, ANN INTERN MED, V135, P759, DOI 10.7326/0003-4819-135-9-200111060-00006
   Nebbia G, 2012, QJM-INT J MED, V105, P109, DOI 10.1093/qjmed/hcr270
   NOWICKI MJ, 1986, HEPATOLOGY, V6, P180, DOI 10.1002/hep.1840060205
   Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013
   PETERS M, 1991, HEPATOLOGY, V13, P977, DOI 10.1002/hep.1840130529
   Sprinzl MF, 2001, J VIROL, V75, P5108, DOI 10.1128/JVI.75.11.5108-5118.2001
   TSUKAMOTO H, 1990, SEMIN LIVER DIS, V10, P56, DOI 10.1055/s-2008-1040457
   World Health Organization, 2015, GLOB ACT PLAN ANT RE, P19
   Wu EX, 2007, MAGN RESON MED, V58, P687, DOI 10.1002/mrm.21350
   Xiao X, 1998, J VIROL, V72, P2224
   YAMADA G, 1993, INTERNAL MED, V32, P911, DOI 10.2169/internalmedicine.32.911
   Yan H, 2013, J VIROL, V87, P7977, DOI 10.1128/JVI.03540-12
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yang D, 2014, CELL MOL IMMUNOL, V11, P71, DOI 10.1038/cmi.2013.43
   Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599
   Zhang Q, 2014, J VIRAL HEPATITIS, V21, P525, DOI 10.1111/jvh.12177
   Zhong GC, 2013, J VIROL, V87, P7176, DOI 10.1128/JVI.03533-12
NR 55
TC 13
Z9 14
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 15
PY 2015
VL 10
IS 6
AR e0130052
DI 10.1371/journal.pone.0130052
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK6HU
UT WOS:000356329900129
PM 26075890
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Yan, R
   Zhang, YM
   Cai, DW
   Liu, YJ
   Cuconati, A
   Guo, HT
AF Yan, Ran
   Zhang, Yongmei
   Cai, Dawei
   Liu, Yuanjie
   Cuconati, Andrea
   Guo, Haitao
TI Spinoculation Enhances HBV Infection in NTCP-Reconstituted Hepatocytes
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-B-VIRUS; CLOSED CIRCULAR DNA; TAUROCHOLATE COTRANSPORTING
   POLYPEPTIDE; MEDIATED GENE-TRANSFER; CENTRIFUGAL ENHANCEMENT; MEMBRANE
   TRANSPORTER; CYCLOSPORINE-A; ENTRY; CELLS; IDENTIFICATION
AB Hepatitis B virus (HBV) infection and its sequelae remain a major public health burden, but both HBV basic research and the development of antiviral therapeutics have been hindered by the lack of an efficient in vitro infection system. Recently, sodium taurocholate cotransporting polypeptide (NTCP) has been identified as the HBV receptor. We herein report that we established a NTCP-complemented HepG2 cell line (HepG2-NTCP12) that supports HBV infection, albeit at a low infectivity level following the reported infection procedures. In our attempts to optimize the infection conditions, we found that the centrifugation of HepG2-NTCP12 cells during HBV inoculation (termed "spinoculation") significantly enhanced the virus infectivity. Moreover, the infection level gradually increased with accelerated speed of spinoculation up to 1,000g tested. However, the enhancement of HBV infection was not significantly dependent upon the duration of centrifugation. Furthermore, covalently closed circular (ccc) DNA was detected in infected cells under optimized infection condition by conventional Southern blot, suggesting a successful establishment of HBV infection after spinoculation. Finally, the parental HepG2 cells remained uninfected under HBV spinoculation, and HBV entry inhibitors targeting NTCP blocked HBV infection when cells were spinoculated, suggesting the authentic virus entry mechanism is unaltered under centrifugal inoculation. Our data suggest that spinoculation could serve as a standard protocol for enhancing the efficiency of HBV infection in vitro.
C1 [Yan, Ran; Cai, Dawei; Liu, Yuanjie; Guo, Haitao] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.
   [Zhang, Yongmei] Fudan Univ, Huashan Hosp, Dept Infect Dis, Shanghai 200040, Peoples R China.
   [Cuconati, Andrea] Hepatitis B Fdn, Baruch S Blumberg Inst, Doylestown, PA 18902 USA.
RP Guo, HT (reprint author), Indiana Univ Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM haitguo@iupui.edu
FU National Institutes of Health [R01AI094474, R21AI103838]
FX This study was supported by National Institutes of Health (grant numbers
   R01AI094474 and R21AI103838, http://nih.gov/). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Asabe S, 2009, J VIROL, V83, P9652, DOI 10.1128/JVI.00867-09
   BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S
   Bardens A, 2011, CELL MICROBIOL, V13, P602, DOI 10.1111/j.1462-5822.2010.01557.x
   Block Timothy M, 2007, Clin Liver Dis, V11, P685, DOI 10.1016/j.cld.2007.08.002
   BUNNELL BA, 1995, P NATL ACAD SCI USA, V92, P7739, DOI 10.1073/pnas.92.17.7739
   Cai Dawei, 2013, Methods Mol Biol, V1030, P151, DOI 10.1007/978-1-62703-484-5_13
   Cai DW, 2012, ANTIMICROB AGENTS CH, V56, P4277, DOI 10.1128/AAC.00473-12
   Chai N, 2008, J VIROL, V82, P7812, DOI 10.1128/JVI.00561-08
   Gao WF, 2007, J VIROL, V81, P6164, DOI 10.1128/JVI.02721-06
   Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   Guo HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043270
   Guo HT, 2011, ANTIMICROB AGENTS CH, V55, P478, DOI 10.1128/AAC.00989-10
   Guo HT, 2010, J VIROL, V84, P387, DOI 10.1128/JVI.01921-09
   Guo J, 2011, J VIROL, V85, P9824, DOI 10.1128/JVI.05170-11
   HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091
   HO WZ, 1993, J LEUKOCYTE BIOL, V53, P208
   Huang HC, 2012, J VIROL, V86, P9443, DOI 10.1128/JVI.00873-12
   HUDSON JB, 1976, VIROLOGY, V72, P235, DOI 10.1016/0042-6822(76)90326-3
   Iwamoto M, 2014, BIOCHEM BIOPH RES CO, V443, P808, DOI 10.1016/j.bbrc.2013.12.052
   Kotani N, 2012, MOL PHARMACEUT, V9, P3434, DOI 10.1021/mp300171p
   Lindenbach BD, 2013, NAT REV MICROBIOL, V11, P688, DOI 10.1038/nrmicro3098
   Mao RC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003494
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Ning XJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002255
   Nkongolo S, 2014, J HEPATOL, V60, P723, DOI 10.1016/j.jhep.2013.11.022
   NybergHoffman C, 1997, NAT MED, V3, P808, DOI 10.1038/nm0797-808
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000
   OSBORN JE, 1968, J VIROL, V2, P853
   PADGETT BL, 1962, P SOC EXP BIOL MED, V111, P364
   Park IH, 2014, ANTIVIR RES, V104, P118, DOI 10.1016/j.antiviral.2014.01.021
   Reading SA, 2001, J VIROL METHODS, V98, P167, DOI 10.1016/S0166-0934(01)00368-8
   Scanlan PM, 2005, J VIROL METHODS, V128, P104, DOI 10.1016/j.jviromet.2005.04.008
   Schulze A, 2007, HEPATOLOGY, V46, P1759, DOI 10.1002/hep.21896
   Schulze-Bergkamen H, 2003, J HEPATOL, V38, P736, DOI 10.1016/S0168-8278(03)00120-X
   Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000
   Seeger C, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.68
   Seeger C, 2013, GUT, V62, P1093, DOI 10.1136/gutjnl-2013-304594
   SUNDIN DR, 1989, J CLIN MICROBIOL, V27, P1659
   TENSER RB, 1978, INFECT IMMUN, V21, P281
   Tong SP, 2014, GASTROENTEROLOGY, V146, P902, DOI 10.1053/j.gastro.2014.02.024
   Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8
   Watashi K, 2014, HEPATOLOGY, V59, P1726, DOI 10.1002/hep.26982
   Yan H, 2014, J VIROL, V88, P3273, DOI 10.1128/JVI.03478-13
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Ye L, 2008, J VIROL METHODS, V148, P161, DOI 10.1016/j.jviromet.2007.11.002
   Zhang YM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110442
NR 47
TC 19
Z9 21
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 12
PY 2015
VL 10
IS 6
AR e0129889
DI 10.1371/journal.pone.0129889
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK6GR
UT WOS:000356327000119
PM 26070202
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Tan, YW
   Ye, Y
   Zhou, XB
   Chen, L
   Wen, DF
AF Tan, Youwen
   Ye, Yun
   Zhou, Xinbei
   Chen, Li
   Wen, Danfeng
TI Age as a Predictor of Significant Fibrosis Features in HBeAg-Negative
   Chronic Hepatitis B Virus Infection with Persistently Normal Alanine
   Aminotransferase
SO PLOS ONE
LA English
DT Article
ID HBV-DNA LEVELS; NORMAL ALT; PEGINTERFERON ALPHA-2A; LAMIVUDINE
   TREATMENT; LIVER-DISEASE; C PATIENTS; FOLLOW-UP; CARRIERS; COMBINATION;
   HISTOLOGY
AB Background
   Although alanine aminotransferase (ALT) levels reflect the degree of liver damage, not all patients with chronic hepatitis B virus (HBV) infection exhibit persistently elevated ALT levels. In the present study, we aimed to comprehensively evaluate the characteristics of histological abnormalities in a large population of Chinese patients with chronic HBV and persistently normal ALT levels.
   Methods
   In total, 2303 consecutive patients who underwent liver biopsy were screened. Of these patients, 273 were categorized as having persistently normal ALT levels (PNALT), whereas 618 were categorized as having persistently or intermittently elevated ALT levels (PIALT). All these patients had at least three ALT values recorded in the year prior to the baseline liver biopsy.
   Results
   Significant necroinflammation was observed in 9.7% (11/113) patients with PNALT, 23.3% (42/180) patients with PIALT (ALT 1-2x upper limit of normal [ULN]), and 27.8%(42/151) patients with PIALT (ALT > 2x ULN), whereas significant fibrosis was observed in 8.8% (10/113) patients with PNALT, 27.8% (42/151) patients with PIALT (ALT 1-2x ULN), and 21.2% (32/151) patients with PIALT (ALT > 2x ULN). Multiple logistic regression analysis indicated that age parameters were associated with significant histological abnormalities in patients with PNALT. The area under the curve showed that age was associated with significant fibrosis characteristics in patients with hepatitis B extracellular antigen (HBeAg)-negative PNALT.
   Conclusion
   Significant histological abnormalities are not often observed in Chinese patients with PNALT. Interestingly, age appears to be a predictor of significant fibrosis in patients with HBeAg-negative PNALT.
C1 [Tan, Youwen] Soochow Univ, Dept Infect Dis, Affiliated Hosp 1, Suzhou, Peoples R China.
   [Tan, Youwen; Ye, Yun; Zhou, Xinbei; Chen, Li; Wen, Danfeng] Jiangsu Univ, Dept Hepatosis, Hosp Zhenjiang Affiliated 3, Zhenjiang, Peoples R China.
RP Tan, YW (reprint author), Soochow Univ, Dept Infect Dis, Affiliated Hosp 1, Suzhou, Peoples R China.
EM tyw915@sina.com
FU Natural Science Foundation of Jiangsu Province, China [BK2011515];
   Medical Project of Health Department, Jiangsu Province [H201248];
   Preventive medicine research projects, Jiangsu Province [Y2012016];
   Social Development Project of Zhenjiang City [SH2013056]
FX This work was supported by the Natural Science Foundation of Jiangsu
   Province, China (BK2011515) (http://www.jstd.gov.cn/), Medical Project
   of Health Department, Jiangsu Province (H201248)
   (http://www.jswst.gov.cn/), Preventive medicine research projects,
   Jiangsu Province (Y2012016) (http://www.jswst.gov.cn/), and the Social
   Development Project of Zhenjiang City (SH2013056)
   (http://kjj.zhenjiang.gov.cn/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Andreani T, 2007, CLIN GASTROENTEROL H, V5, P636, DOI 10.1016/j.cgh.2007.01.005
   Arora S, 2006, J GASTROEN HEPATOL, V21, P406, DOI 10.1111/j.1440-1746.2005.04059.x
   Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57
   Chan WK, 2014, J GASTROEN HEPATOL, V29, P1470, DOI 10.1111/jgh.12557
   Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65
   Dai CY, 2009, HEPATOLOGY, V49, P704, DOI 10.1002/hep.22723
   Hui CK, 2007, ALIMENT PHARM THER, V25, P1283, DOI 10.1111/j.1365-2036.2007.03318.x
   Kim WR, 2008, HEPATOLOGY, V47, P1363, DOI 10.1002/hep.22109
   Kirschberg O, 2004, J CLIN VIROL, V29, P39, DOI 10.1016/S1386-6532(03)00084-2
   KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511
   Kumar M, 2008, GASTROENTEROLOGY, V134, P1376, DOI 10.1053/j.gastro.2008.02.075
   Lai M, 2007, J HEPATOL, V47, P760, DOI 10.1016/j.jhep.2007.07.022
   Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470
   Lesmana CRA, 2011, J DIGEST DIS, V12, P476, DOI 10.1111/j.1751-2980.2011.00540.x
   Liao BL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078672
   Lin CL, 2007, HEPATOLOGY, V45, P1193, DOI 10.1002/hep.21585
   Lok ASF, 2009, HEPATOLOGY, V50, P661, DOI 10.1002/hep.23190
   Manesis EK, 2002, GASTROENTEROLOGY, V122, P2092, DOI 10.1053/gast.2002.34021
   Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140-6736(12)61425-1
   Martinot-Peignoux M, 2002, J HEPATOL, V36, P543, DOI 10.1016/S0168-8278(02)00004-1
   McMahon BJ, 2004, SEMIN LIVER DIS, V24, P17, DOI 10.1055/s-2004-828674
   Papatheodoridis G, 2012, J HEPATOL, V57, P167, DOI 10.1016/j.jhep.2012.02.010
   Papatheodoridis GV, 2008, HEPATOLOGY, V48, P1451, DOI 10.1002/hep.22518
   Papatheodoridis GV, 2012, J HEPATOL, V57, P196, DOI 10.1016/j.jhep.2011.11.030
   Park JY, 2008, J VIRAL HEPATITIS, V15, P615, DOI 10.1111/j.1365-2893.2008.00989.x
   Perrillo RP, 2002, HEPATOLOGY, V36, P186, DOI 10.1053/jhep.2002.34294
   Seto WK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032622
   ter Borg F, 2000, J CLIN PATHOL, V53, P541, DOI 10.1136/jcp.53.7.541
   Tseng KC, 2014, ANTIVIR THER, V19, P755, DOI 10.3851/IMP2754
   Wang H, 2013, J VIRAL HEPATITIS, V20, pe3, DOI 10.1111/jvh.12010
   Wang H, 2013, PROTEIN CELL, V4, P643, DOI 10.1007/s13238-013-3048-3
   Wong GLH, 2009, CLIN GASTROENTEROL H, V7, P227, DOI 10.1016/j.cgh.2008.10.023
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yuen MF, 2007, HEPATOLOGY, V46, P1695, DOI 10.1002/hep.21939
   Yuen MF, 2005, GUT, V54, P1610, DOI 10.1136/gut.2005.065136
   Zacharakis G, 2008, J HEPATOL, V49, P884, DOI 10.1016/j.jhep.2008.06.009
   Zoulim F, 2012, GUT, V61, P333, DOI 10.1136/gutjnl-2011-300937
NR 37
TC 8
Z9 10
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 17
PY 2015
VL 10
IS 4
AR e0123452
DI 10.1371/journal.pone.0123452
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CG1EX
UT WOS:000353017000067
PM 25885705
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU He, WH
   Ren, BJ
   Mao, FF
   Jing, ZY
   Li, YF
   Liu, Y
   Peng, B
   Yan, H
   Qi, YH
   Sun, YY
   Guo, JT
   Sui, JH
   Wang, FC
   Li, WH
AF He, Wenhui
   Ren, Bijie
   Mao, Fengfeng
   Jing, Zhiyi
   Li, Yunfei
   Liu, Yang
   Peng, Bo
   Yan, Huan
   Qi, Yonghe
   Sun, Yinyan
   Guo, Ju-Tao
   Sui, Jianhua
   Wang, Fengchao
   Li, Wenhui
TI Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate
   Co-transporting Polypeptide
SO PLOS PATHOGENS
LA English
DT Article
ID DELTA VIRUS; RNA; REPLICATION; GENOME; LIVER; SUSCEPTIBILITY;
   TRANSMISSION; INTERFERONS; ADENOSINE; IMMUNITY
AB Hepatitis D virus (HDV) is the smallest virus known to infect human. About 15 million people worldwide are infected by HDV among those 240 million infected by its helper hepatitis B virus (HBV). Viral hepatitis D is considered as one of the most severe forms of human viral hepatitis. No specific antivirals are currently available to treat HDV infection and antivirals against HBV do not ameliorate hepatitis D. Liver sodium taurocholate co-transporting polypeptide (NTCP) was recently identified as a common entry receptor for HDV and HBV in cell cultures. Here we show HDV can infect mice expressing human NTCP (hNTCP-Tg). Antibodies against critical regions of HBV envelope proteins blocked HDV infection in the hNTCP-Tg mice. The infection was acute yet HDV genome replication occurred efficiently, evident by the presence of antigenome RNA and edited RNA species specifying large delta antigen in the livers of infected mice. The resolution of HDV infection appears not dependent on adaptive immune response, but might be facilitated by innate immunity. Liver RNA-seq analyses of HDV infected hNTCP-Tg and type I interferon receptor 1 (IFN alpha/beta R1) null hNTCP-Tg mice indicated that in addition to induction of type I IFN response, HDV infection was also associated with up-regulation of novel cellular genes that may modulate HDV infection. Our work has thus proved the concept that NTCP is a functional receptor for HDV infection in vivo and established a convenient small animal model for investigation of HDV pathogenesis and evaluation of antiviral therapeutics against the early steps of infection for this important human pathogen.
C1 [He, Wenhui; Li, Wenhui] Chinese Acad Med Sci, Grad Program, Beijing 100730, Peoples R China.
   [He, Wenhui; Li, Wenhui] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [He, Wenhui; Ren, Bijie; Mao, Fengfeng; Jing, Zhiyi; Li, Yunfei; Liu, Yang; Peng, Bo; Yan, Huan; Qi, Yonghe; Sun, Yinyan; Sui, Jianhua; Wang, Fengchao; Li, Wenhui] Natl Inst Biol Sci, Beijing, Peoples R China.
   [Qi, Yonghe] Beijing Normal Univ, Grad Sch, Beijing 100875, Peoples R China.
   [Guo, Ju-Tao] Drexel Univ, Coll Med, Drexel Inst Biotechnol & Virol Res, Doylestown, PA USA.
RP Li, WH (reprint author), Chinese Acad Med Sci, Grad Program, Beijing 100730, Peoples R China.
EM liwenhui@nibs.ac.cn
OI Li, Wenhui/0000-0003-1305-7404; SUI, JIANHUA/0000-0002-1272-9662
FU National Science and Technology Major Project, China [2013ZX09509102];
   Ministry of Science and Technology, China [2010CB530101, 2011CB812501];
   Science and Technology Bureau of Beijing Municipal Government
FX This work was funded by the National Science and Technology Major
   Project, China (2013ZX09509102), the Ministry of Science and Technology,
   China (2010CB530101,2011CB812501), and the Science and Technology Bureau
   of Beijing Municipal Government. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BONINO F, 1986, J VIROL, V58, P945
   CASEY JL, 1995, J VIROL, V69, P7593
   Casey JL, 2012, CURR TOP MICROBIOL, V353, P123, DOI 10.1007/82_2011_146
   Chang JH, 2001, J VIROL, V75, P3469, DOI 10.1128/JVI.75.7.3469-3473.2001
   CHAO M, 1990, J VIROL, V64, P5066
   CHEN PJ, 1986, P NATL ACAD SCI USA, V83, P8774, DOI 10.1073/pnas.83.22.8774
   Christianson SW, 1996, CELL IMMUNOL, V171, P186, DOI 10.1006/cimm.1996.0193
   Ciancio A, 2014, NAT REV GASTRO HEPAT, V11, P68, DOI 10.1038/nrgastro.2013.164
   CUSTER RP, 1985, AM J PATHOL, V120, P464
   Dakic A, 2004, J IMMUNOL, V172, P1018, DOI 10.4049/jimmunol.172.2.1018
   George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621
   Giersch K, 2014, J HEPATOL, V60, P538, DOI 10.1016/j.jhep.2013.11.010
   GUIDOTTI LG, 1995, J VIROL, V69, P6158
   GUILHOT S, 1994, J VIROL, V68, P1052
   HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091
   Hartwig D, 2006, J VIRAL HEPATITIS, V13, P150, DOI 10.1111/j.1365-2893.2005.00663.x
   LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355
   Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075
   Li H, 2014, CELL MOL IMMUNOL, V11, P175, DOI 10.1038/cmi.2013.66
   Liu SY, 2012, P NATL ACAD SCI USA, V109, P4239, DOI 10.1073/pnas.1114981109
   Lutgehetmann M, 2012, HEPATOLOGY, V55, P685, DOI 10.1002/hep.24758
   Meier A, 2013, HEPATOLOGY, V58, P31, DOI 10.1002/hep.26181
   MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221
   NETTER HJ, 1993, J VIROL, V67, P3357
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   POLO JM, 1995, J VIROL, V69, P4880
   PONZETTO A, 1987, J INFECT DIS, V155, P72, DOI 10.1093/infdis/155.1.72
   PONZETTO A, 1984, P NATL ACAD SCI-BIOL, V81, P2208, DOI 10.1073/pnas.81.7.2208
   Publicover J, 2013, J CLIN INVEST, V123, P3728, DOI 10.1172/JCI68182
   Publicover J, 2011, J CLIN INVEST, V121, P1154, DOI 10.1172/JCI44198
   Raney AK, 2001, J VIROL, V75, P2900, DOI 10.1128/JVI.75.6.2900-2911.2001
   Schieck A, 2013, HEPATOLOGY, V58, P43, DOI 10.1002/hep.26211
   Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907
   Sellers RS, 2012, VET PATHOL, V49, P5, DOI 10.1177/0300985811421324
   Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255
   SHULTZ LD, 1995, J IMMUNOL, V154, P180
   SIGEL MM, 1952, ANNU REV MICROBIOL, V6, P247, DOI 10.1146/annurev.mi.06.100152.001335
   Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007
   Stieger B, 2011, HANDB EXP PHARMACOL, V201, P205, DOI 10.1007/978-3-642-14541-4_5
   Sureau C, 2013, HEPATOLOGY, V57, P985, DOI 10.1002/hep.26125
   Taylor JM, 2006, VIROLOGY, V344, P71, DOI 10.1016/j.virol.2005.09.033
   Tregoning JS, 2010, J IMMUNOL, V185, P5384, DOI 10.4049/jimmunol.1001594
   Wedemeyer H, 2010, NAT REV GASTRO HEPAT, V7, P31, DOI 10.1038/nrgastro.2009.205
   Yan H, 2013, J VIROL, V87, P7977, DOI 10.1128/JVI.03540-12
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
NR 45
TC 49
Z9 53
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2015
VL 11
IS 4
AR e1004840
DI 10.1371/journal.ppat.1004840
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA CI7XE
UT WOS:000354978000045
PM 25902143
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Hamada-Tsutsumi, S
   Iio, E
   Watanabe, T
   Murakami, S
   Isogawa, M
   Iijima, S
   Inoue, T
   Matsunami, K
   Tajiri, K
   Ozawa, T
   Kishi, H
   Muraguchi, A
   Joh, T
   Tanaka, Y
AF Hamada-Tsutsumi, Susumu
   Iio, Etsuko
   Watanabe, Tsunamasa
   Murakami, Shuko
   Isogawa, Masanori
   Iijima, Sayuki
   Inoue, Takako
   Matsunami, Kayoko
   Tajiri, Kazuto
   Ozawa, Tatsuhiko
   Kishi, Hiroyuki
   Muraguchi, Atsushi
   Joh, Takashi
   Tanaka, Yasuhito
TI Validation of Cross-Genotype Neutralization by Hepatitis B
   Virus-Specific Monoclonal Antibodies by In Vitro and In Vivo Infection
SO PLOS ONE
LA English
DT Article
ID SURFACE-ANTIGEN; CELL-LINE; VACCINE; DNA; DIVERSITY; MUTATION; EPITOPE;
   BLOOD
AB Vaccines based on hepatitis B virus (HBV) genotype A have been used worldwide for immunoprophylaxis and are thought to prevent infections by non-A HBV strains effectively, whereas, vaccines generated from genotype C have been used in several Asian countries, including Japan and Korea, where HBV genotype C is prevalent. However, acute hepatitis B caused by HBV genotype A infection has been increasing in Japan and little is known about the efficacy of immunization with genotype C-based vaccines against non-C infection. We have isolated human monoclonal antibodies (mAbs) from individuals who were immunized with the genotype C-based vaccine. In this study, the efficacies of these two mAbs, HB0116 and HB0478, were analyzed using in vivo and in vitro models of HBV infection. Intravenous inoculation of HBV genotype C into chimeric mice with human hepatocytes resulted in the establishment of HBV infection after five weeks, whereas preincubation of the inocula with HB0116 or HB0478 protected chimeric mice from genotype C infection completely. Interestingly, both HB0116 and HB0478 were found to block completely genotype A infection. Moreover, infection by a genotype C strain with an immune escape substitution of amino acid 145 in the hepatitis B surface protein was also completely inhibited by incubation with HB0478. Finally, in vitro analysis of dose dependency revealed that the amounts of HB0478 required for complete protection against genotype C and genotype A infection were 5.5 mIU and 55 mIU, respectively. These results suggested that genotype C-based vaccines have ability to induce cross-genotype immunity against HBV infection.
C1 [Hamada-Tsutsumi, Susumu; Iio, Etsuko; Watanabe, Tsunamasa; Murakami, Shuko; Isogawa, Masanori; Iijima, Sayuki; Inoue, Takako; Matsunami, Kayoko; Tanaka, Yasuhito] Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Aichi, Japan.
   [Hamada-Tsutsumi, Susumu; Iio, Etsuko; Watanabe, Tsunamasa; Murakami, Shuko; Isogawa, Masanori; Iijima, Sayuki; Inoue, Takako; Matsunami, Kayoko; Tanaka, Yasuhito] Nagoya City Univ, Grad Sch Med Sci, Liver Unit, Nagoya, Aichi, Japan.
   [Iio, Etsuko; Matsunami, Kayoko; Joh, Takashi] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan.
   [Tajiri, Kazuto] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Internal Med 3, Toyama 930, Japan.
   [Tajiri, Kazuto; Ozawa, Tatsuhiko; Kishi, Hiroyuki; Muraguchi, Atsushi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Immunol, Toyama 930, Japan.
RP Tanaka, Y (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Virol, Nagoya, Aichi, Japan.
EM ytanaka@med.nagoya-cu.ac.jp
OI Ozawa, Tatsuhiko/0000-0002-3112-452X
FU Ministry of Health, Labour, and Welfare of Japan [009, 011, 013];
   Ministry of Education, Culture, Sports, Science and Technology, Japan
   [25293176]
FX This study was supported by grants from the Ministry of Health, Labour,
   and Welfare of Japan (009, 011, and 013), and a grant-in-aid from the
   Ministry of Education, Culture, Sports, Science and Technology, Japan
   (25293176). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abe A, 1999, J CLIN MICROBIOL, V37, P2899
   Allweiss L, 2014, J HEPATOL, V60, P500, DOI 10.1016/j.jhep.2013.10.021
   Avazova D, 2008, J MED VIROL, V80, P217, DOI 10.1002/jmv.21035
   Cassidy A, 2011, EXPERT REV VACCINES, V10, P1709, DOI [10.1586/ERV.11.151, 10.1586/erv.11.151]
   Cerec V, 2007, HEPATOLOGY, V45, P957, DOI 10.1002/hep.21536
   Cooreman MP, 2001, J BIOMED SCI, V8, P237, DOI 10.1159/000054039
   Fujiwara K, 2005, J VIROL, V79, P14404, DOI 10.1128/JVI.79.22.14404-14410.2005
   Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699
   ITOH Y, 1986, P NATL ACAD SCI USA, V83, P9174, DOI 10.1073/pnas.83.23.9174
   IWARSON S, 1985, J MED VIROL, V16, P89, DOI 10.1002/jmv.1890160112
   Jin A, 2009, NAT MED, V15, P1088, DOI 10.1038/nm.1966
   Kim BK, 2011, ANTIVIR THER, V16, P1169, DOI 10.3851/IMP1982
   Komatsu Haruki, 2012, BMC Res Notes, V5, P22, DOI 10.1186/1756-0500-5-22
   Kurbanov F, 2010, HEPATOL RES, V40, P14, DOI 10.1111/j.1872-034X.2009.00601.x
   Laras A, 2006, HEPATOLOGY, V44, P694, DOI 10.1002/hep.21299
   Lee PI, 1997, J INFECT DIS, V176, P427, DOI 10.1086/514060
   Matsuura K, 2009, J CLIN MICROBIOL, V47, P1476, DOI 10.1128/JCM.02081-08
   Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968
   Miyakawa Y, 2003, INTERVIROLOGY, V46, P329, DOI 10.1159/000074988
   Ogata Norio, 2009, Rinsho Byori, V57, P954
   Qiu XX, 1996, J IMMUNOL, V156, P3350
   Shokrgozar MA, 2002, VACCINE, V20, P2215, DOI 10.1016/S0264-410X(02)00116-0
   Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644
   Sugiyama M, 2009, GASTROENTEROLOGY, V136, P652, DOI 10.1053/j.gastro.2008.10.048
   Tajiri K, 2007, CYTOM PART A, V71A, P961, DOI 10.1002/cyto.a.20471
   Tajiri K, 2010, ANTIVIR RES, V87, P40, DOI 10.1016/j.antiviral.2010.04.006
   Tokilmitsu Y, 2007, CYTOM PART A, V71A, P1003, DOI 10.1002/cyto.a.20478
   Wu CC, 2012, J VIROL, V86, P4658, DOI 10.1128/JVI.06353-11
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zanetti AR, 2008, VACCINE, V26, P6266, DOI 10.1016/j.vaccine.2008.09.056
NR 30
TC 5
Z9 6
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2015
VL 10
IS 2
AR e0118062
DI 10.1371/journal.pone.0118062
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC0WZ
UT WOS:000350061500093
PM 25693196
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Pereira, IVA
   Buchmann, B
   Sandmann, L
   Sprinzl, K
   Schlaphoff, V
   Dohner, K
   Vondran, F
   Sarrazin, C
   Manns, MP
   de Oliveira, CPMS
   Sodeik, B
   Ciesek, S
   von Hahn, T
AF Alves Pereira, Isabel Veloso
   Buchmann, Bettina
   Sandmann, Lisa
   Sprinzl, Kathrin
   Schlaphoff, Verena
   Doehner, Katinka
   Vondran, Florian
   Sarrazin, Christoph
   Manns, Michael P.
   Marques Souza de Oliveira, Claudia Pinto
   Sodeik, Beate
   Ciesek, Sandra
   von Hahn, Thomas
TI Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human
   Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting
   Polypeptide (NTCP)
SO PLOS ONE
LA English
DT Article
ID SERUM BILE-ACIDS; CHENODEOXYCHOLIC ACID; DELTA VIRUS; INTRAHEPATIC
   CHOLESTASIS; URSODEOXYCHOLIC ACID; CYCLOSPORINE-A; HEPATOCYTES;
   INFECTION; THERAPY; CHOLESTEROL
AB Background
   The sodium-taurocholate cotransporting polypeptide (NTCP) is both a key bile acid (BA) transporter mediating uptake of BA into hepatocytes and an essential receptor for hepatitis B virus (HBV) and hepatitis D virus (HDV). In this study we aimed to characterize to what extent and through what mechanism BA affect HDV cell entry.
   Methods
   HuH-7 cells stably expressing NTCP (HuH-7/NTCP) and primary human hepatocytes (PHH) were infected with in vitro generated HDV particles. Infectivity in the absence or presence of compounds was assessed using immunofluorescence staining for HDV antigen, standard 50% tissue culture infectious dose (TCID50) assays and quantitative PCR.
   Results
   Addition of primary conjugated and unconjugated BA resulted in a dose dependent reduction in the number of infected cells while secondary, tertiary and synthetic BA had a lesser effect. This effect was observed both in HuH-7/NTCP and in PHH. Other replication cycle steps such as replication and particle assembly and release were unaffected. Moreover, inhibitory BA competed with a fragment from the large HBV envelope protein for binding to NTCP-expressing cells. Conversely, the sodium/BA-cotransporter function of NTCP seemed not to be required for HDV infection since infection was similar in the presence or absence of a sodium gradient across the plasma membrane. When chenodeoxycolic acid (15 mg per kg body weight) was administered to three chronically HDV infected individuals over a period of up to 16 days there was no change in serum HDV RNA.
   Conclusions
   Primary BA inhibit NTCP-mediated HDV entry into hepatocytes suggesting that modulation of the BA pool may affect HDV infection of hepatocytes.
C1 [Alves Pereira, Isabel Veloso; Buchmann, Bettina; von Hahn, Thomas] Hannover Med Sch, Inst Mol Biol, Hannover, Germany.
   [Alves Pereira, Isabel Veloso; Marques Souza de Oliveira, Claudia Pinto] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Clin Div,Hepatol Branch,LIM 07, Sao Paulo, Brazil.
   [Alves Pereira, Isabel Veloso; Sandmann, Lisa; Schlaphoff, Verena; Manns, Michael P.; Ciesek, Sandra; von Hahn, Thomas] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany.
   [Sprinzl, Kathrin; Sarrazin, Christoph] Univ Frankfurt Klinikum, Med Klin 1, Frankfurt, Germany.
   [Doehner, Katinka; Sodeik, Beate] Hannover Med Sch, Inst Virol, Hannover, Germany.
   [Vondran, Florian] Hannover Med Sch, Klin Allgemein Viszeral & Transplantationschirurg, Hannover, Germany.
RP Ciesek, S (reprint author), Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany.
EM Ciesek.sandra@mh-hannover.de; vonhahn.thomas@mh-hannover.de
RI Veloso Alves Pereira, Isabel/N-4616-2014
OI Veloso Alves Pereira, Isabel/0000-0002-3439-1658
FU Deutsche Forschungsgemeinschaft through collaborative research center
   [900]; 'Emmy Noether' grant [HA4394/2-1]; Brazilian research-funding
   agency CNPq; 'Ciencias sem Fronteiras' program
FX This work was supported by Deutsche Forschungsgemeinschaft through
   collaborative research center 900 (Chronic infections) to BS, SC and TVH
   and an 'Emmy Noether' grant (HA4394/2-1) to TVH. IVAP was the recipient
   of a doctoral grant from Brazilian research-funding agency CNPq and the
   'Ciencias sem Fronteiras' program to IVAP. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ambros-Rudolph CM, 2007, ARCH DERMATOL, V143, P757, DOI 10.1001/archderm.143.6.757
   Boyer JL, 2013, COMPR PHYSIOL, V3, P1035, DOI 10.1002/cphy.c120027
   Chen W, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003181.pub2
   DANZINGER RG, 1972, NEW ENGL J MED, V286, P1, DOI 10.1056/NEJM197201062860101
   Gehring G, 2014, J ANTIMICROB CHEMOTH, V69, P2123, DOI 10.1093/jac/dku091
   Heidrich B, 2014, HEPATOLOGY, V60, P87, DOI 10.1002/hep.27102
   Heidrich B, 2013, CURR INFECT DIS REP, V15, P31, DOI 10.1007/s11908-012-0307-z
   Hughes SA, 2011, LANCET, V378, P73, DOI 10.1016/S0140-6736(10)61931-9
   Jansen PLM, 2012, ZAKIM BOYERS HEPATOL, P47
   Karber G, 1931, ARCH EXP PATHOL PH, p[162, 480], DOI DOI 10.1007/BF01863914
   Konig A, 2014, J HEPATOL, V61, P867, DOI 10.1016/j.jhep.2014.05.018
   KullakUblick GA, 1997, GASTROENTEROLOGY, V113, P1295, DOI 10.1053/gast.1997.v113.pm9322525
   KUO MYP, 1989, J VIROL, V63, P1945
   Mederacke I, 2010, J CLIN MICROBIOL, V48, P2022, DOI 10.1128/JCM.00084-10
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   NEALE G, 1971, GUT, V12, P145, DOI 10.1136/gut.12.2.145
   Ni Y, 2014, GASTROENTEROLOGY, V146, P1070, DOI 10.1053/j.gastro.2013.12.024
   Nkongolo S, 2014, J HEPATOL, V60, P723, DOI 10.1016/j.jhep.2013.11.022
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Petersen J, 2008, NAT BIOTECHNOL, V26, P335, DOI 10.1038/nbt1389
   Schukfeh N, 2012, J PEDIATR SURG, V47, P501, DOI 10.1016/j.jpedsurg.2011.08.010
   Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x
   Sulkowski MS, 2014, J INFECT DIS, V209, P658, DOI 10.1093/infdis/jit503
   Sureau C, 2010, METHODS MOL BIOL, V640, P463, DOI 10.1007/978-1-60761-688-7_25
   THISTLE JL, 1973, NEW ENGL J MED, V289, P655, DOI 10.1056/NEJM197309272891303
   TINT GS, 1986, GASTROENTEROLOGY, V91, P1007, DOI 10.1016/0016-5085(86)90708-0
   Triolo M, 2014, LIVER INT, V34, P139, DOI 10.1111/liv.12394
   von Hahn T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024142
   Watashi K, 2014, HEPATOLOGY, V59, P1726, DOI 10.1002/hep.26982
   Wedemeyer H, 2011, NEW ENGL J MED, V364, P322, DOI 10.1056/NEJMoa0912696
   Yan H, 2014, J VIROL, V88, P3273, DOI 10.1128/JVI.03478-13
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
NR 32
TC 15
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 3
PY 2015
VL 10
IS 2
AR e0117152
DI 10.1371/journal.pone.0117152
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA3QZ
UT WOS:000348822600058
PM 25646622
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Zhao, F
   Guo, XL
   Wang, YJ
   Liu, J
   Lee, WH
   Zhang, Y
AF Zhao, Feng
   Guo, Xiaolong
   Wang, Yanjie
   Liu, Jie
   Lee, Wen-hui
   Zhang, Yun
TI Drug Target Mining and Analysis of the Chinese Tree Shrew for
   Pharmacological Testing
SO PLOS ONE
LA English
DT Article
ID IMMUNE-SYSTEM; RNA-SEQ; MODEL; INFECTION; QUANTIFICATION; ACTIVATION;
   DATABASE; GENOMES; VIRUS
AB The discovery of new drugs requires the development of improved animal models for drug testing. The Chinese tree shrew is considered to be a realistic candidate model. To assess the potential of the Chinese tree shrew for pharmacological testing, we performed drug target prediction and analysis on genomic and transcriptomic scales. Using our pipeline, 3,482 proteins were predicted to be drug targets. Of these predicted targets, 446 and 1,049 proteins with the highest rank and total scores, respectively, included homologs of targets for cancer chemotherapy, depression, age-related decline and cardiovascular disease. Based on comparative analyses, more than half of drug target proteins identified from the tree shrew genome were shown to be higher similarity to human targets than in the mouse. Target validation also demonstrated that the constitutive expression of the proteinase-activated receptors of tree shrew platelets is similar to that of human platelets but differs from that of mouse platelets. We developed an effective pipeline and search strategy for drug target prediction and the evaluation of model-based target identification for drug testing. This work provides useful information for future studies of the Chinese tree shrew as a source of novel targets for drug discovery research.
C1 [Zhao, Feng; Guo, Xiaolong; Wang, Yanjie; Liu, Jie; Lee, Wen-hui; Zhang, Yun] Chinese Acad Sci, Kunming Inst Zool, Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China.
   [Zhao, Feng; Guo, Xiaolong; Liu, Jie] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming, Yunnan, Peoples R China.
RP Zhang, Y (reprint author), Chinese Acad Sci, Kunming Inst Zool, Chinese Acad Sci & Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming, Yunnan, Peoples R China.
EM zhangy@mail.kiz.ac.cn
OI Zhao, Feng/0000-0002-8309-0536
FU Chinese Academy of Sciences [KSCX2-EW-R-11, KSCX2-EW-J-23, KJZD-EW-L03];
   National 863 project of China [2012AA021801, 2012AA022402]
FX This work was supported by grants from the Chinese Academy of Sciences
   (KSCX2-EW-R-11 and KSCX2-EW-J-23), the National 863 project of China
   (No. 2012AA021801, 2012AA022402), and the Key Research Program of the
   Chinese Academy of Sciences (KJZD-EW-L03). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Cheng AC, 2007, NAT BIOTECHNOL, V25, P71, DOI 10.1038/nbt1273
   Chu XY, 2013, EXPERT OPIN DRUG MET, V9, P237, DOI 10.1517/17425255.2013.741589
   Chua HN, 2011, J BIOL CHEM, V286, P23653, DOI 10.1074/jbc.R110.174797
   Coppe A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-635
   Fan Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2416
   Fuchs E, 2005, CNS SPECTRUMS, V10, P182, DOI 10.1017/S1092852900010038
   Horn F, 2001, NUCLEIC ACIDS RES, V29, P346, DOI 10.1093/nar/29.1.346
   Kahn ML, 1998, NATURE, V394, P690
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Kim DD, 2008, BLOOD, V112, P1109, DOI 10.1182/blood-2008-01-134304
   Kim Y, 2011, BIOINFORMATICS, V27, P2772, DOI 10.1093/bioinformatics/btr445
   Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503
   Li Sheng-An, 2012, Zoological Research, V33, P1, DOI 10.3724/SP.J.1141.2012.01001
   Michelson AD, 2010, NAT REV DRUG DISCOV, V9, P154, DOI 10.1038/nrd2957
   Norton TT, 2006, INVEST OPHTH VIS SCI, V47, P4700, DOI 10.1167/iovs.05-1641
   Ortutay C, 2007, IMMUNOGENETICS, V59, P333, DOI 10.1007/s00251-007-0191-0
   Peng Y. Z., 1991, BIOL CHINESE TREE SH
   Pertea G, 2003, BIOINFORMATICS, V19, P651, DOI 10.1093/bioinformatics/btg034
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ramachandran R, 2012, NAT REV DRUG DISCOV, V11, P69, DOI 10.1038/nrd3615
   Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Tsai IJ, 2013, NATURE, V496, P57, DOI 10.1038/nature12031
   Turgeon VL, 1999, J NEUROPATH EXP NEUR, V58, P499, DOI 10.1097/00005072-199905000-00009
   Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849
   Ward SG, 2003, CURR OPIN PHARMACOL, V3, P391, DOI 10.1016/S1471-4892(03)00086-7
   Yamanishi Y, 2008, BIOINFORMATICS, V24
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Yan RQ, 1996, J CANCER RES CLIN, V122, P283, DOI 10.1007/BF01261404
   Zhang A, 2012, BMC SYST BIOL, V6, P1752
   Zhang Y, 2012, J THROMB HAEMOST, V10, P411, DOI 10.1111/j.1538-7836.2011.04607.x
   Zhao F, 2014, DNA RES, V21, P1, DOI 10.1093/dnares/dst035
   Zhao SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011764
   Zhao XP, 2002, J CLIN INVEST, V109, P221, DOI 10.1172/JCI200213011
NR 36
TC 11
Z9 12
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 8
PY 2014
VL 9
IS 8
AR e104191
DI 10.1371/journal.pone.0104191
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AR0CG
UT WOS:000343231900040
PM 25105297
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Xiao, F
   Fofana, I
   Heydmann, L
   Barth, H
   Soulier, E
   Habersetzer, F
   Doffoel, M
   Bukh, J
   Patel, AH
   Zeisel, MB
   Baumert, TF
AF Xiao, Fei
   Fofana, Isabel
   Heydmann, Laura
   Barth, Heidi
   Soulier, Eric
   Habersetzer, Francois
   Doffoel, Michel
   Bukh, Jens
   Patel, Arvind H.
   Zeisel, Mirjam B.
   Baumert, Thomas F.
TI Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting
   Antiviral Agents
SO PLOS PATHOGENS
LA English
DT Article
ID B TYPE-I; NS5A INHIBITORS; ENTRY FACTORS; INFECTION; HCV; COMBINATION;
   PROTEASE; THERAPY; CD81; PERSPECTIVES
AB Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes. Viral cell-cell transmission has been shown to play an important role in viral persistence allowing evasion from neutralizing antibodies. In contrast, the role of HCV cell-cell transmission for antiviral resistance is unknown. Aiming to address this question we investigated the phenotype of HCV strains exhibiting resistance to directacting antivirals (DAAs) in state-of-the-art model systems for cell-cell transmission and spread. Using HCV genotype 2 as a model virus, we show that cell-cell transmission is the main route of viral spread of DAA-resistant HCV. Cell-cell transmission of DAA-resistant viruses results in viral persistence and thus hampers viral eradication. We also show that blocking cell-cell transmission using host-targeting entry inhibitors (HTEIs) was highly effective in inhibiting viral dissemination of resistant genotype 2 viruses. Combining HTEIs with DAAs prevented antiviral resistance and led to rapid elimination of the virus in cell culture model. In conclusion, our work provides evidence that cell-cell transmission plays an important role in dissemination and maintenance of resistant variants in cell culture models. Blocking virus cell-cell transmission prevents emergence of drug resistance in persistent viral infection including resistance to HCV DAAs.
C1 [Xiao, Fei; Fofana, Isabel; Heydmann, Laura; Barth, Heidi; Soulier, Eric; Habersetzer, Francois; Doffoel, Michel; Zeisel, Mirjam B.; Baumert, Thomas F.] INSERM, U1110, Strasbourg, France.
   [Xiao, Fei; Fofana, Isabel; Heydmann, Laura; Barth, Heidi; Soulier, Eric; Habersetzer, Francois; Doffoel, Michel; Zeisel, Mirjam B.; Baumert, Thomas F.] Univ Strasbourg, Strasbourg, France.
   [Barth, Heidi] Hop Univ Strasbourg, Lab Virol, Strasbourg, France.
   [Habersetzer, Francois; Doffoel, Michel; Baumert, Thomas F.] Hop Univ Strasbourg, Strasbourg, France.
   [Bukh, Jens] Univ Copenhagen, Dept Infect Dis, Copenhagen Hepatitis Program CO HEP C, Copenhagen, Denmark.
   [Bukh, Jens] Univ Copenhagen, Hvidovre Hosp, Clin Res Ctr, Copenhagen, Denmark.
   [Bukh, Jens] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Patel, Arvind H.] Univ Glasgow, Ctr Virus Res, MRC, Glasgow, Lanark, Scotland.
   [Baumert, Thomas F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA USA.
RP Xiao, F (reprint author), INSERM, U1110, Strasbourg, France.
EM Thomas.Baumert@unistra.fr
RI ; Xiao, Fei/E-7133-2013
OI Bukh, Jens/0000-0002-7815-4806; Xiao, Fei/0000-0001-7353-2700
FU Inserm; University of Strasbourg; European Union
   [ERC-2008-AdG-233130-HEPCENT]; ANRS [2011/132, 2012/239, 2012/318,
   2013/108]; Laboratoire d'excellence LabEx HEPSYS (Investissement
   d'Avenir) [ANR-10-LAB-28]; Direction Generale de l'Offre de Soins
   [A12027MS]; Medical Research Council [MC_UU_12014/2, MC_U130184144];
   Novo Nordisk Fonden [NNF12OC0002037]
FX This work was supported by Inserm, University of Strasbourg, the
   European Union (ERC-2008-AdG-233130-HEPCENT, INTERREG-IV-Rhin
   Superieur-FEDER-Hepato-Regio-Net 2009 and 2012), ANRS (2011/132,
   2012/239, 2012/318, 2013/108), Laboratoire d'excellence LabEx HEPSYS
   (Investissement d'Avenir; ANR-10-LAB-28), the Direction Generale de
   l'Offre de Soins (A12027MS). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abela IA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002634
   Bartolini B, 2013, VIRUS RES, V177, P205, DOI 10.1016/j.virusres.2013.08.001
   Bauhofer O, 2012, GASTROENTEROLOGY, V143, P429, DOI 10.1053/j.gastro.2012.04.018
   Brimacombe CL, 2011, J VIROL, V85, P596, DOI 10.1128/JVI.01592-10
   Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960
   Catanese MT, 2013, J VIROL, V87, P8282, DOI 10.1128/JVI.01102-13
   Fofana I, 2014, ANTIVIR RES, V104, P136, DOI 10.1016/j.antiviral.2014.02.001
   Fofana I, 2013, J VIROL, V87, P10405, DOI 10.1128/JVI.01691-13
   Fofana I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064221
   Fofana I, 2012, GASTROENTEROLOGY, V143, P223, DOI 10.1053/j.gastro.2012.04.006
   Fofana I, 2010, GASTROENTEROLOGY, V139, P953, DOI 10.1053/j.gastro.2010.05.073
   Gane EJ, 2013, NEW ENGL J MED, V368, P34, DOI 10.1056/NEJMoa1208953
   Gottwein JM, 2013, ANTIMICROB AGENTS CH, V57, P1291, DOI 10.1128/AAC.02164-12
   Gottwein JM, 2009, HEPATOLOGY, V49, P364, DOI 10.1002/hep.22673
   Grove J, 2008, J VIROL, V82, P12020, DOI 10.1128/JVI.01569-08
   Haid S, 2014, HEPATOLOGY, V59, P24, DOI 10.1002/hep.26567
   Hezode C, 2013, J HEPATOL, V59, P434, DOI 10.1016/j.jhep.2013.04.035
   Jacobson IM, 2013, NEW ENGL J MED, V368, P1867, DOI 10.1056/NEJMoa1214854
   Jones CT, 2010, NAT BIOTECHNOL, V28, P167, DOI 10.1038/nbt.1604
   Keck ZY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002653
   Koutsoudakis G, 2006, J VIROL, V80, P5308, DOI 10.1128/JVI.02460-05
   Kuonen F, 2010, CYTOM PART A, V77A, P1082, DOI 10.1002/cyto.a.20969
   Kwon H, 2011, NAT REV GASTRO HEPAT, V8, P275, DOI 10.1038/nrgastro.2011.33
   Lange CM, 2013, J HEPATOL, V58, P583, DOI 10.1016/j.jhep.2012.10.019
   Lee C, 2011, VIROLOGY, V414, P10, DOI 10.1016/j.virol.2011.03.026
   Lenz O, 2010, ANTIMICROB AGENTS CH, V54, P1878, DOI 10.1128/AAC.01452-09
   Liang TJ, 2013, NEW ENGL J MED, V368, P1907, DOI 10.1056/NEJMra1213651
   Lok AS, 2012, NEW ENGL J MED, V366, P216, DOI 10.1056/NEJMoa1104430
   Lupberger J, 2011, NAT MED, V17, P589, DOI 10.1038/nm.2341
   Masson D, 2009, ARTERIOSCL THROM VAS, V29, P2054, DOI 10.1161/ATVBAHA.109.191320
   McHutchison JG, 2010, NEW ENGL J MED, V362, P1292, DOI 10.1056/NEJMoa0908014
   Meredith LW, 2013, J HEPATOL, V58, P1074, DOI 10.1016/j.jhep.2013.01.019
   Nathan C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003081
   Owsianka A, 2005, J VIROL, V79, P11095, DOI 10.1128/JVI.79.17.11095-11104.2005
   Pawlotsky JM, 2013, J HEPATOL, V59, P375, DOI 10.1016/j.jhep.2013.03.030
   Pawlotsky JM, 2013, CURR TOP MICROBIOL, V369, P321, DOI 10.1007/978-3-642-27340-7_13
   Pawlotsky JM, 2011, HEPATOLOGY, V53, P1742, DOI 10.1002/hep.24262
   Pietschmann T, 2006, P NATL ACAD SCI USA, V103, P7408, DOI 10.1073/pnas.0504877103
   Pietschmann T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000475
   Poordad F, 2013, NEW ENGL J MED, V368, P45, DOI 10.1056/NEJMoa1208809
   Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494
   Rong LB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000544
   Sainz B, 2006, J VIROL, V80, P10253, DOI 10.1128/JVI.01059-06
   Sarrazin C, 2012, J HEPATOL, V56, pS88, DOI 10.1016/S0168-8278(12)60010-5
   Sattentau Q, 2008, NAT REV MICROBIOL, V6, P815, DOI 10.1038/nrmicro1972
   Scheel TKH, 2011, GASTROENTEROLOGY, V140, P1032, DOI 10.1053/j.gastro.2010.11.036
   Shi N, 2013, GUT, V62, P1055, DOI 10.1136/gutjnl-2012-302600
   Sigal A, 2011, NATURE, V477, P95, DOI 10.1038/nature10347
   Soriano V, 2012, EXPERT OPIN PHARMACO, V13, P313, DOI 10.1517/14656566.2012.653341
   Sulkowski MS, 2014, J INFECT DIS, V209, P658, DOI 10.1093/infdis/jit503
   Tarr AW, 2013, HEPATOLOGY, V58, P932, DOI 10.1002/hep.26430
   Timpe JM, 2008, HEPATOLOGY, V47, P17, DOI 10.1002/hep.21959
   Trembling PM, 2013, NAT REV GASTRO HEPAT, V10, P713, DOI 10.1038/nrgastro.2013.163
   Trono D, 2010, SCIENCE, V329, P174, DOI 10.1126/science.1191047
   Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268
   Witteveldt J, 2009, J GEN VIROL, V90, P48, DOI [10.1099/vir.0.2008/006700-0, 10.1099/vir.0.006700-0]
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zahid MN, 2013, HEPATOLOGY, V57, P492, DOI 10.1002/hep.26097
   Zeisel MB, 2007, HEPATOLOGY, V46, P1722, DOI 10.1002/hep.21994
   Zeisel MB, 2013, J HEPATOL, V58, P375, DOI 10.1016/j.jhep.2012.09.022
   Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102
   Zhong P, 2013, CURR OPIN VIROL, V3, P44, DOI 10.1016/j.coviro.2012.11.004
   Zhu HH, 2012, J INFECT DIS, V205, P656, DOI 10.1093/infdis/jir802
   Zona L, 2013, CELL HOST MICROBE, V13, P302, DOI 10.1016/j.chom.2013.02.006
NR 64
TC 48
Z9 49
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2014
VL 10
IS 5
AR e1004128
DI 10.1371/journal.ppat.1004128
PG 15
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA AJ5NX
UT WOS:000337732300037
PM 24830295
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Liu, F
   Campagna, M
   Qi, Y
   Zhao, XS
   Guo, F
   Xu, CX
   Li, SC
   Li, WH
   Block, TM
   Chang, JH
   Guo, JT
AF Liu, Fei
   Campagna, Matthew
   Qi, Yonghe
   Zhao, Xuesen
   Guo, Fang
   Xu, Chunxiao
   Li, Sichen
   Li, Wenhui
   Block, Timothy M.
   Chang, Jinhong
   Guo, Ju-Tao
TI Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering
   Epigenetic Modification of cccDNA Minichromosomes
SO PLOS PATHOGENS
LA English
DT Article
ID HEPATITIS-B-VIRUS; CLOSED CIRCULAR DNA; GENE-EXPRESSION; INFECTED-CELLS;
   VIRAL-DNA; PEGINTERFERON ALPHA-2A; REVERSE TRANSCRIPTION; REPLICATIVE
   ACTIVITY; DEACETYLASE ACTIVITY; POLYMERASE-ACTIVITY
AB Covalently closed circular DNA (cccDNA) of hepadnaviruses exists as an episomal minichromosome in the nucleus of infected hepatocyte and serves as the transcriptional template for viral mRNA synthesis. Elimination of cccDNA is the prerequisite for either a therapeutic cure or immunological resolution of HBV infection. Although accumulating evidence suggests that inflammatory cytokines-mediated cure of virally infected hepatocytes does occur and plays an essential role in the resolution of an acute HBV infection, the molecular mechanism by which the cytokines eliminate cccDNA and/or suppress its transcription remains elusive. This is largely due to the lack of convenient cell culture systems supporting efficient HBV infection and cccDNA formation to allow detailed molecular analyses. In this study, we took the advantage of a chicken hepatoma cell line that supports tetracycline-inducible duck hepatitis B virus (DHBV) replication and established an experimental condition mimicking the virally infected hepatocytes in which DHBV pregenomic (pg) RNA transcription and DNA replication are solely dependent on cccDNA. This cell culture system allowed us to demonstrate that cccDNA transcription required histone deacetylase activity and IFN-alpha induced a profound and long-lasting suppression of cccDNA transcription, which required protein synthesis and was associated with the reduction of acetylated histone H3 lysine 9 (H3K9) and 27 (H3K27) in cccDNA minichromosomes. Moreover, IFN-alpha treatment also induced a delayed response that appeared to accelerate the decay of cccDNA. Our studies have thus shed light on the molecular mechanism by which IFN-alpha noncytolytically controls hepadnavirus infection.
C1 [Liu, Fei; Campagna, Matthew; Zhao, Xuesen; Guo, Fang; Xu, Chunxiao; Block, Timothy M.; Chang, Jinhong; Guo, Ju-Tao] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Drexel Inst Biotechnol & Virol Res, Doylestown, PA USA.
   [Campagna, Matthew; Block, Timothy M.] Hepatitis B Fdn, Inst Hepatitis & Virol Res, Doylestown, PA USA.
   [Qi, Yonghe; Li, Wenhui] Natl Inst Biol Sci, Beijing, Peoples R China.
   [Li, Sichen] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
RP Liu, F (reprint author), Drexel Univ, Coll Med, Dept Microbiol & Immunol, Drexel Inst Biotechnol & Virol Res, Doylestown, PA USA.
EM Ju-Tao.Guo@drexelmed.edu
RI LIU, FEI/H-2783-2013
OI Li, Wenhui/0000-0003-1305-7404
FU Hepatitis B Foundation
FX The study was supported by Hepatitis B Foundation and appropriation from
   the Commonwealth of Pennsylvania. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alcantara FF, 2002, NUCLEIC ACIDS RES, V30, P2068, DOI 10.1093/nar/30.9.2068
   Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Beck J, 2007, WORLD J GASTROENTERO, V13, P48, DOI 10.3748/wjg.v13.i1.48
   BeckelMitchener A, 1997, J VIROL, V71, P7917
   Belloni L, 2012, J CLIN INVEST, V122, P529, DOI 10.1172/JCI58847
   Belloni L, 2009, P NATL ACAD SCI USA, V106, P19975, DOI 10.1073/pnas.0908365106
   Bertoletti A., 2011, GUT, V61, P1754, DOI DOI 10.1136/GUTJNL-2011-301073
   Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Fierz B, 2012, NAT CHEM BIOL, V8, P417, DOI [10.1038/NCHEMBIO.938, 10.1038/nchembio.938]
   Gao WF, 2007, J VIROL, V81, P6164, DOI 10.1128/JVI.02721-06
   GERLICH WH, 1980, J VIROL, V36, P787
   Gunther T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000935
   Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825
   Guo H, 2007, J VIROL, V81, P12472, DOI 10.1128/JVI.01123-07
   Guo HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043270
   Guo HT, 2010, J VIROL, V84, P387, DOI 10.1128/JVI.01921-09
   Guo JT, 2000, J VIROL, V74, P1495, DOI 10.1128/JVI.74.3.1495-1505.2000
   Guo JT, 2003, J VIROL, V77, P1885, DOI 10.1128/JVI.77.3.1885-1893.2003
   Guo YH, 2009, J MED VIROL, V81, P1177, DOI 10.1002/jmv.21525
   HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5
   Hosel M, 2009, HEPATOLOGY, V50, P1773, DOI 10.1002/hep.23226
   Huber K, 2011, J BIOL CHEM, V286, P22211, DOI 10.1074/jbc.M110.180224
   Janssen HLA, 2005, LANCET, V365, P123, DOI 10.1016/S0140-6736(05)17701-0
   Jiang D, 2008, J VIROL, V82, P1665, DOI 10.1128/JVI.02113-07
   Jones SA, 2012, J VIROL, V86, P5134, DOI 10.1128/JVI.07137-11
   Kantor B, 2009, P NATL ACAD SCI USA, V106, P18786, DOI 10.1073/pnas.0905859106
   Kim JW, 2011, INTERVIROLOGY, V54, P316, DOI 10.1159/000321450
   Knipe DM, 2008, NAT REV MICROBIOL, V6, P211, DOI 10.1038/nrmicro1794
   KOCK J, 1993, J VIROL, V67, P4867
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kubicek S, 2012, P NATL ACAD SCI USA, V109, P5364, DOI 10.1073/pnas.1201079109
   Lai CL, 2002, GASTROENTEROLOGY, V123, P1831, DOI 10.1053/gast.2002.37058
   Laras A, 2006, HEPATOLOGY, V44, P694, DOI 10.1002/hep.21299
   Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051
   Liaw YF, 2000, GASTROENTEROLOGY, V119, P172, DOI 10.1053/gast.2000.8559
   LOFGREN B, 1989, ANTIVIR RES, V12, P301, DOI 10.1016/0166-3542(89)90057-0
   Lucifora J, 2011, J HEPATOL, V55, P996, DOI 10.1016/j.jhep.2011.02.015
   Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681
   MOLNARKIMBER KL, 1983, J VIROL, V45, P165
   Moraleda G, 1997, J VIROL, V71, P9392
   NEWBOLD JE, 1995, J VIROL, V69, P3350
   Nguyen DH, 2008, J CELL PHYSIOL, V216, P289, DOI 10.1002/jcp.21416
   Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100
   Perrillo R, 2009, HEPATOLOGY, V49, pS103, DOI 10.1002/hep.22956
   Pollicino T, 2006, GASTROENTEROLOGY, V130, P823, DOI 10.1053/j.gastro.2006.01.001
   Quasdorff M, 2010, J VIRAL HEPATITIS, V17, P527, DOI 10.1111/j.1365-2893.2010.01315.x
   Roizman B, 2011, J VIROL, V85, P7474, DOI 10.1128/JVI.00180-11
   Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314
   Schneider WM, 2012, VIROLOGY, V426, P188, DOI 10.1016/j.virol.2012.01.034
   Schultz U, 1999, J VIROL, V73, P5459
   Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000
   Shi LP, 2012, J VIROL, V86, P10059, DOI 10.1128/JVI.00535-12
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Summers J, 2003, P NATL ACAD SCI USA, V100, P11652, DOI 10.1073/pnas.1635109100
   SUMMERS J, 1975, P NATL ACAD SCI USA, V72, P4597, DOI 10.1073/pnas.72.11.4597
   Szerlong HJ, 2010, J BIOL CHEM, V285, P31954, DOI 10.1074/jbc.M110.148718
   Takkenberg B, 2011, J GASTROEN HEPATOL, V26, P1527, DOI 10.1111/j.1440-1746.2011.06766.x
   TAVIS JE, 1994, J VIROL, V68, P3536
   Tian YJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002159
   Turin F, 1996, J VIROL, V70, P2691
   TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1
   Volz T, 2007, GASTROENTEROLOGY, V133, P843, DOI 10.1053/j.gastro.2007.06.057
   WANG GH, 1993, J VIROL, V67, P6507
   WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8
   Wang SH, 2009, HEPATOLOGY, V50, P1392, DOI 10.1002/hep.23163
   Wieland SF, 2005, P NATL ACAD SCI USA, V102, P9913, DOI 10.1073/pnas.0504273102
   Wieland SF, 2004, P NATL ACAD SCI USA, V101, P2129, DOI 10.1073/pnas.0308478100
   Wong DKH, 2006, ANTIVIR THER, V11, P909
   WU TT, 1990, VIROLOGY, V175, P255, DOI 10.1016/0042-6822(90)90206-7
   Wursthorn K, 2006, HEPATOLOGY, V44, P675, DOI 10.1002/hep.21282
   Xu CX, 2010, J VIROL, V84, P9332, DOI 10.1128/JVI.00918-10
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
   Zhang YZ, 2003, P NATL ACAD SCI USA, V100, P12372, DOI 10.1073/pnas.2033898100
   Zhou TL, 2006, ANTIVIR RES, V72, P116, DOI 10.1016/j.antiviral.2006.05.006
   Zhu Y, 2001, J VIROL, V75, P311, DOI 10.1128/JVI.75.1.311-322.2001
   ZOULIM F, 1994, J VIROL, V68, P2026
NR 80
TC 77
Z9 82
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2013
VL 9
IS 9
AR e1003613
DI 10.1371/journal.ppat.1003613
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 224WM
UT WOS:000324922300031
PM 24068929
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Longarela, OL
   Schmidt, TT
   Schoeneweis, K
   Romeo, R
   Wedemeyer, H
   Urban, S
   Schulze, A
AF Longarela, Oscar Lamas
   Schmidt, Tobias T.
   Schoeneweis, Katrin
   Romeo, Raffaella
   Wedemeyer, Heiner
   Urban, Stephan
   Schulze, Andreas
TI Proteoglycans Act as Cellular Hepatitis Delta Virus Attachment Receptors
SO PLOS ONE
LA English
DT Article
ID HEPARAN-SULFATE PROTEOGLYCANS; LARGE ENVELOPE PROTEIN; LARGE SURFACE
   PROTEIN; INFECTION IN-VIVO; B-VIRUS; PRE-S1 DOMAIN; SURAMIN; CELLS;
   REPLICATION; BINDING
AB The hepatitis delta virus (HDV) is a small, defective RNA virus that requires the presence of the hepatitis B virus (HBV) for its life cycle. Worldwide more than 15 million people are co-infected with HBV and HDV. Although much effort has been made, the early steps of the HBV/HDV entry process, including hepatocyte attachment and receptor interaction are still not fully understood. Numerous possible cellular HBV/HDV binding partners have been described over the last years; however, so far only heparan sulfate proteoglycans have been functionally confirmed as cell-associated HBV attachment factors. Recently, it has been suggested that ionotrophic purinergic receptors (P2XR) participate as receptors in HBV/HDV entry. Using the HBV/HDV susceptible HepaRG cell line and primary human hepatocytes (PHH), we here demonstrate that HDV entry into hepatocytes depends on the interaction with the glycosaminoglycan (GAG) side chains of cellular heparan sulfate proteoglycans. We furthermore provide evidence that P2XR are not involved in HBV/HDV entry and that effects observed with inhibitors for these receptors are a consequence of their negative charge. HDV infection was abrogated by soluble GAGs and other highly sulfated compounds. Enzymatic removal of defined carbohydrate structures from the cell surface using heparinase III or the obstruction of GAG synthesis by sodium chlorate inhibited HDV infection of HepaRG cells. Highly sulfated P2XR antagonists blocked HBV/HDV infection of HepaRG cells and PHH. In contrast, no effect on HBV/HDV infection was found when uncharged P2XR antagonists or agonists were applied. In summary, HDV infection, comparable to HBV infection, requires binding to the carbohydrate side chains of hepatocyte-associated heparan sulfate proteoglycans as attachment receptors, while P2XR are not actively involved.
C1 [Longarela, Oscar Lamas; Schmidt, Tobias T.; Schoeneweis, Katrin; Urban, Stephan; Schulze, Andreas] Univ Heidelberg Hosp, Dept Infect Dis Mol Virol, Heidelberg, Germany.
   [Romeo, Raffaella] Univ Milan, Fdn IRCCS Cagranda Osped Maggiore Policlin, Div Gastroenterol 1, Milan, Italy.
   [Wedemeyer, Heiner] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany.
RP Urban, S (reprint author), Univ Heidelberg Hosp, Dept Infect Dis Mol Virol, Heidelberg, Germany.
EM stephan.urban@med.uni-heidelberg.de
OI Romeo, Raffaella/0000-0002-7858-4670; Schmidt,
   Tobias/0000-0002-9064-6192
FU Sheila Dame Postdoctoral Grant; European Association for the Study of
   the Liver (EASL)
FX Oscar Lamas was supported by a Sheila Dame Postdoctoral Grant awarded by
   the European Association for the Study of the Liver (EASL)
   (www.easl.eu). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Abou Jaoude G, 2005, J VIROL, V79, P10460, DOI 10.1128/JVI.79.16.10460-10644.2005
   Aguilar JS, 1999, VIROLOGY, V258, P141, DOI 10.1006/viro.1999.9723
   BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4
   BALZARINI J, 1986, INT J CANCER, V37, P451, DOI 10.1002/ijc.2910370318
   Barrera A, 2005, J VIROL, V79, P9786, DOI 10.1128/JVI.79.15.9786-9798.2005
   Blanchet M, 2007, J VIROL, V81, P5841, DOI 10.1128/JVI.00096-07
   Bradley HJ, 2010, FEBS LETT, V584, P4740, DOI 10.1016/j.febslet.2010.11.007
   Browne LE, 2010, TRENDS PHARMACOL SCI, V31, P229, DOI 10.1016/j.tips.2010.02.004
   Croon J J, 1982, Acta Leiden, V48, P5
   De CE, 1987, ANTIVIR RES, V7, P1
   Emmett DS, 2008, HEPATOLOGY, V47, P698, DOI 10.1002/hep.22035
   Engelke M, 2006, HEPATOLOGY, V43, P750, DOI 10.1002/hep.21112
   Fleck SL, 2003, J BIOL CHEM, V278, P47670, DOI 10.1074/jbc.M306603200
   Funk A, 2004, J VIROL, V78, P3977, DOI 10.1128/JVI.78.8.3977-3983.2004
   Germi R, 2002, J MED VIROL, V68, P206, DOI 10.1002/jmv.10196
   Glebe D, 2007, WORLD J GASTROENTERO, V13, P22, DOI 10.3748/wjg.v13.i1.22
   Gripon P, 2005, J VIROL, V79, P1613, DOI 10.1128/JVI.79.3.1616-1622.2005
   Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699
   GRIPON P, 1995, VIROLOGY, V213, P292, DOI 10.1006/viro.1995.0002
   Honke K, 2002, MED RES REV, V22, P637, DOI 10.1002/med.10020
   Hughes SA, 2011, LANCET, V378, P73, DOI 10.1016/S0140-6736(10)61931-9
   Ladner SK, 1997, ANTIMICROB AGENTS CH, V41, P1715, DOI 10.1128/AAC.41.8.1715
   Le DY, 2009, J VIROL, V83, P12443, DOI [10.1128/JVI.01594-09, DOI 10.1128/JVI.01594-09]
   Le Seyec J, 1999, J VIROL, V73, P2052
   Leistner CM, 2008, CELL MICROBIOL, V10, P122, DOI 10.1111/j.1462-5822.2007.01023.x
   Lutgehetmann M, 2012, HEPATOLOGY, V55, P685, DOI 10.1002/hep.24758
   LYON M, 1994, J BIOL CHEM, V269, P11208
   McGeary RP, 2008, MINI-REV MED CHEM, V8, P1384, DOI 10.2174/138955708786369573
   OFFENSPERGER WB, 1993, ANTIMICROB AGENTS CH, V37, P1539, DOI 10.1128/AAC.37.7.1539
   PETCU DJ, 1988, VIROLOGY, V167, P385, DOI 10.1016/S0042-6822(88)90099-2
   Petersen J, 2008, NAT BIOTECHNOL, V26, P335, DOI 10.1038/nbt1389
   Rizzetto M, 2009, J HEPATOL, V50, P1043, DOI 10.1016/j.jhep.2009.01.004
   Salisse J, 2009, J VIROL, V83, P9321, DOI 10.1128/JVI.00678-09
   Schulze A, 2007, HEPATOLOGY, V46, P1759, DOI 10.1002/hep.21896
   Schulze A, 2010, J VIROL, V84, P1989, DOI 10.1128/JVI.01902-09
   Stokes L, 2006, BRIT J PHARMACOL, V149, P880, DOI 10.1038/sj.bjp.0706933
   STOW JL, 1985, J CELL BIOL, V100, P975, DOI 10.1083/jcb.100.3.975
   Sureau C, 2006, CURR TOP MICROBIOL, V307, P113
   Sureau C, 2013, HEPATOLOGY, V57, P985, DOI 10.1002/hep.26125
   Taylor JM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015784
   TSIQUAYE K, 1985, J HEPATOL, V1, P663, DOI 10.1016/S0168-8278(85)80009-X
   Vongchan P, 2005, BBA-GEN SUBJECTS, V1721, P1, DOI 10.1016/j.bbagen.2004.09.007
   VOOGD TE, 1993, PHARMACOL REV, V45, P177
   Wedemeyer H, 2011, LIVER INT, V31, P140, DOI 10.1111/j.1478-3231.2010.02408.x
   Wilson HL, 2007, BRIT J PHARMACOL, V151, P96, DOI 10.1038/sj.bjp.0707213
   Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049
NR 46
TC 33
Z9 33
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2013
VL 8
IS 3
AR e58340
DI 10.1371/journal.pone.0058340
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136BN
UT WOS:000318334500070
PM 23505490
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

EF